WO2006033633A1

WO2006033633A1 - Compounds, compositions containing them, preparations thereof and uses thereof ii

Info

Publication number: WO2006033633A1
Application number: PCT/SE2005/001405
Authority: WO
Inventors: John Wei; Claire Milburn; Helene Desfosses; Daniel PAGÈ; Sanjay Srivastava; Christopher Walpole; Hua Yang
Original assignee: Astrazeneca Ab
Priority date: 2004-09-24
Filing date: 2005-09-22
Publication date: 2006-03-30
Also published as: AU2005287429A1; EP1797070A1; CA2582512A1; JP2008514595A

Abstract

Compounds of Formulae I, or pharmaceutically acceptable salts thereof: (I) wherein R1, R2, R3, R4 and G are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.

Description

COMPOUNDS. COMPOSITIONS CONTAINING THEM. PREPARATION THEREOF AND USES THEREOF H

BACKGROUND OF THE INVENTION

1. Field of the invention

The invention is related to therapeutic compounds, pharmaceutical compositions containing these compounds, manufacturing processes thereof and uses thereof. Particularly, the present invention is related to compounds that may be effective in treating pain, cancer, multiple sclerosis, Parkinson's disease, Huntington's chorea, Alzheimer's disease, anxiety disorders, gastrointestinal disorders and/or cardiovascular disorders.

2. Discussion of Relevant Technology Pain management has been studied for many years. It is known that cannabinoid receptor (e.g., CB₁ receptor, CB₂ receptor) ligands including agonists, antagonists and inverse agonists produce relief of pain in a variety of animal models by interacting with CB₁ and/or CB₂ receptors. Generally, CB₁ receptors are located predominately in the central nervous system, whereas CB₂ receptors are located primarily in the periphery and are primarily restricted to the cells and tissues derived from the immune system.

While CB₁ receptor agonists, such as Δ⁹-tetrahydrocannabinol (Δ⁹-THC) and anadamide, are useful in anti-nociception models in animals, they tend to exert undesired CNS side-effects, e.g., psychoactive side effects, the abuse potential, drug dependence and tolerance, etc. These undesired side effects are known to be mediated by the CBi receptors located in CNS. There are lines of evidence, however, suggesting that CB₁ agonists acting at peripheral sites or with limited CNS exposure can manage pain in humans or animals with much improved overall in vivo profile. Therefore, there is a need for new CB₁ receptor ligands such as agonists that may be useful in managing pain or treating other related symptoms or diseases with reduced or minimal undesirable CNS side-effects. DESCRIPTION OF THE EMBODIMENTS

The present invention provides CB₁ receptor ligands which may be useful in treating pain and/or other related symptoms or diseases.

The term "C_m-n" or "C_m._n group" used alone or as a prefix, refers to any group having m to n carbon atoms.

The term "alkyl" refers to a saturated monovalent straight or branched chain hydrocarbon radical comprising 1 to about 12 carbon atoms. Illustrative examples of alkyls include, but are not limited to, Ci_-4alkyl groups, such as methyl, ethyl, propyl, isopropyl, 2-methyl-l -propyl, 2-methyl-2-propyl, butyl, isobutyl, t-butyl. The term "cycloalkyl" refers to a saturated monovalent ring-containing hydrocarbon radical comprising at least 3 up to about 12 carbon atoms. Examples of cycloalkyls include, but are not limited to, C_3-7cycloalkyl groups, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl, and saturated cyclic and bicyclic terpenes. A cycloalkyl can be unsubstiruted or substituted by one or two suitable substituents. Preferably, the cycloalkyl is a monocyclic ring or bicyclic ring.

The term "alkoxy" refers to radicals of the general formula -O-R, wherein R is an alkyl. Exemplary alkoxy includes methoxy, ethoxy, propoxy, isopropoxy, butoxy, t-butoxy, and isobutoxy.

The term "heterocycle" used alone or as a suffix or prefix, refers to a ring- containing structure or molecule having one or more multivalent heteroatoms, independently selected from N, O, P and S, as apart of the ring structure and including at least 3 and up to about 20 atoms in the ring(s). Heterocycle may be saturated or unsaturated, containing one or more double bonds, and heterocycle may contain more than one ring. When a heterocycle contains more than one ring, the rings may be fused or unfused. Fused rings generally refer to at least two rings sharing two atoms therebetween. Heterocycle may have aromatic character or may not have aromatic character.

Heterocycle includes, for example, monocyclic heterocycles such as: aziridine, oxirane, thiirane, azetidine, oxetane, thietane, pyrrolidine, pyrroline, imidazolidine, pyrazolidine, pyrazoline, dioxolane, sulfolane 2,3-dihydrofuran, 2,5- dihydrofuran tetrahydrofuran, thiophane, piperidine, 1,2,3,6-tetrahydro-pyridine, piperazine, morpholine, thiomorpholine, pyran, thiopyran, 2,3-dihydropyran, tetrahydropyran, 1,4-dihydropyridine, 1,4-dioxane, 1,3-dioxane, dioxane, homopiperidine, 2,3,4,7-tetrahydro-li/^:-azepme homopiperazine, 1,3-dioxepane, 4,7- dihydro-l,3-dioxepin, and hexamethylene oxide.

In addition, heterocycle includes aromatic heterocycles, for example, pyridine, pyrazine, pyrimidine, pyridazine, thiophene, furan, furazan, pyrrole, imidazole, thiazole, oxazole, pyrazole, isothiazole, isoxazole, 1,2,3-triazole, tetrazole, 1,2,3- thiadiazole, 1,2,3-oxadiazole, 1,2,4-triazole, 1,2,4-thiadiazole, 1,2,4-oxadiazole, 1,3,4- triazole, 1,3,4-thiadiazole, and 1,3,4- oxadiazole.

Additionally, heterocycle encompass polycyclic heterocycles, for example, indole, indoline, isoindoline, quinoline, tetrahydroquinoline, isoquinoline, tetrahydroisoquinoline, 1,4-benzodioxan, coumarin, dihydrocoumarin, benzofuran,

2,3-dihydrobenzofuran, isobenzofuran, chromene, chroman, isochroman, xanthene, phenoxathiin, thianthrene, indolizine, isoindole, indazole, purine, phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline, pteridine, phenanthridine, perimidine, phenanthroline, phenazine, phenothiazine, phenoxazine, 1,2- benzisoxazole, benzothiophene, benzoxazole, benzthiazole, benzimidazole, benztriazole, thioxanthine, carbazole, carboline, acridine, pyrolizidine, and quinolizidine.

In addition to the polycyclic heterocycles described above, heterocycle includes polycyclic heterocycles wherein the ring fusion between two or more rings includes more than one bond common to both rings and more than two atoms common to both rings. Examples of such bridged heterocycles include quinuclidine, diazabicyclo[2.2.1]heptane and 7-oxabicyclo[2.2.1]heptane.

Preferably, the heterocycle is a monocyclic or bicyclic ring, more preferably, a monocyclic ring, wherein the ring comprises from 2 to 6 carbon atoms and from 1 to 3 heteroatoms, referred to herein as C₂.₆heterocycle.

The term "heterocylcoalkyl" used alone or as a suffix or prefix, refers to a monocyclic or polycyclic ring comprising carbon and hydrogen atoms and at least one heteroatom, preferably, 1 to 3 heteroatoms selected from nitrogen, oxygen, and sulfur, and having no unsaruration. Examples of heterocycloalkyl groups include pyrrolidinyl, pyrrolidino, piperidinyl, piperidino, piperazinyl, piperazino, morpholinyl, morpholino, thiomorpholinyl, thiomorpholino, and pyranyl. A heterocycloalkyl group can be unsubstituted or substituted with one or two suitable substituents. Preferably, the heterocycloalkyl group is a monocyclic or bicyclic ring, more preferably, a monocyclic ring, wherein the ring comprises from 2 to 5 carbon atoms and from 1 to 3 heteroatoms, referred to herein as C_2-5heterocycloalkyl.

The term "heterocyclyl" refers a monovalent radical derived from a heterocycle by removing one hydrogen therefrom. Halogen includes fluorine, chlorine, bromine and iodine.

"RT" or "rt" means room temperature.

" Acyl" refers to -C(=O)-R, wherein R is an alkyl. C_2-5ACyI groups include, for example, acetyl, propionyl, 2,2-dimethylpropionyl, and methyl-propionyl.

"Link," "linked," or "linking," unless otherwise specified, means covalently linked or bonded.

In one aspect, an embodiment of the invention provides a compound of Formula I, a pharmaceutically acceptable salt thereof, diastereomers, enantiomers, or mixtures thereof:

I wherein

G is selected from -O-, -CHF-, and -CF₂-;

R¹ is a C_2-6heterocyclyl, wherein said C_2-6heterocyclyl includes at least one nitrogen on said C_2-6heterocyclyl ring, one of said at least one nitrogen is directly linked to the sulfonyl group of formula I, and said C_2-6heterocyclyl is optionally substituted with one or more groups selected from halogen, hydroxy, R⁵-C(=O)-₅ R⁵- C(=O)-NH-, R⁵R⁶-NH-C(=O)-, R⁵R⁶-NH-C(=O)-NH-, R⁵-O-C(=O)-, R⁵-O-C(=O)- NH-, C_1-6alkoxy, and C^alkylamino, wherein said R⁵, R⁶ are independently selected from -H, C_1-6alkyl, C_6-i₀aryl, C_2-6alkenyl, C_3-6cycloalkyl, C₂.₆heterocyclyl, halogenated C_1-6alkyl, and hydroxy-C_1-6alkyl; and

R², R³ and R⁴ are independently selected from fluoro and methyl. In another embodiment, the compounds are those of formula I, wherein

G is selected from -O- and -CF₂-; R¹ is a C_2-6heterocycloalkyl, wherein said C2-6heterocycloalkyl includes at least one nitrogen on said C_2-6heterocycloalkyl ring, one of said at least one nitrogen is directly linked to the sulfonyl group of formula I, and said Ca-βheterocycloalkyl is optionally substituted with one or more groups selected from halogen, hydroxy, R⁵- C(=O)-, R⁵-C(=O)-NH-, R⁵R⁶-NH-C(=O)-, R⁵R⁶-NH-C(=O)-NH-, R⁵-O-C(=O)-, R⁵- O-C(=O)-NH-, C_1-6alkoxy, and C_1-6alkylamino, wherein said R⁵, R⁶ are independently selected from -H, C₁^aIkVl, C_2-6alkenyl, C₃,₆cycloalkyl, C_2-5heterocycloalkyl, halogenated Ci_-6alkyl, and hydroxy-C_1-6alkyl; and

R², R³ and R⁴ are independently selected from fluoro and methyl. Another embodiment of the invention provides a compound of formula I, wherein

G is selected from -O- and -CF₂-;

R¹ is selected from Cs-sheterocycloalkyl and C_2-5heteroaryl, wherein said C_3-5heterocycloalkyl or C_2-5heteroaryl includes at least one nitrogen on said C_3-5heterocycloalkyl or C_2-5heteroaryl rings, respectively, one of said at least one nitrogen is directly linked to the sulfonyl group of formula I, and said Cs-sheterocycloalkyl and C_2-5heteroaryl are optionally substituted with one or more groups selected from halogen, C₁.₃alk.oxy, Q.salkylamino and C_2-sacylamino; R², R³ and R⁴ are independently selected from fluoro and methyl. A further embodiment of the invention provides a compound of formula I, wherein

G is selected from -O- and -CF₂-;

R¹ is selected from piperidinyl, imidazolyl, pyrazolyl, morpholinyl, pyrrolidinyl, azetidinyl, and isoxazolidinyl, wherein said piperidinyl, imidazolyl, pyrazolyl, morpholinyl, pyrrolidinyl, azetidinyl, and isoxazolidinyl are optionally substituted with one or more groups selected from fluoro and C_2-5acylamino; R², R³ and R⁴ are selected from fluoro and methyl with a proviso that R², R³ and R⁴ are the same.

An even further embodiment of the invention provides a compound of formula I, wherein

G is selected from -O- and -CF₂-; R¹ is selected from

and wherein said

and are optionally substituted by one or more groups

selected from fluoro,

; and

R², R³ and R⁴ are selected from fluoro and methyl with a proviso that R², R³ and R⁴ are the same.

A further embodiment of the invention provides a compound selected from

pharmaceutically acceptable salts thereof. In another embodiment, the compound of formula I is selected from: N-( 1 - { [ {2-tert-Butyl- 1 - [(4,4-difiuorocyclohexyl)methyl]- 1H-benzimidazol-5- yl}(methyl)amino]sulfonyl}piperidin-4-yl)acetamide;

N-[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-berizimidazol-5-yl]-N- methylisoxazolidine-2-sulfonamide;

N-[2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-N- methylazetidine- 1 -sulfonamide;

Λ^r-[2-ter^-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-l/i-benzimidazol-5-yl]-N- methylpyrrolidine- 1 -sulfonamide; N-[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-N- methylmorpholine-4-sulfonamide;

N- [2-tert-Butyl- 1 -(tetrahydro-2H-pyran-4-ylmethy I)- 1H-benzimidazol-5 -yl] -N- methylpiperidine- 1 -sulfonamide; N-{2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-li^:/-benzimidazol-5-yl}-Λr-. methylpiperidine-1 -sulfonamide;

7V^"-[2-(l,l-difluoroethyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]- N-methylisoxazolidine-2-sulfonamide;

N-(I - { [[2-(1 , 1 -difluoroethyl)- l-(tetrahydro-2H-pyran-4-ylmethyl)- 1H-benzimidazol-

5-yl](methyl)amino]sulfonyl}piperidin-4-yl)acetamide; 1-{[[2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}-N-cyclopropylpiperidine-4-carboxamide;

1 - { [[2-tert-butyl- 1 -(tetrahydro^H-pyran^-ylmethyl)- li-T-benzimidazol-5- yl](methyl)amino]sulfonyl}-N-isopropylpiperidine-4-carboxamide; 1-{[[2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-ljy^r-benzimidazol-5- yl](methyl)amino]sulfonyl}-N-cyclobutylpiperidine-4-carboxamide;

1 - { [[2-tert-butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)- 1H-benzimidazol-5- ylKmethyl)amino]sulfonyl}-N-cyclopentylpiperidine^-carboxamide;

1 - {[[2-tert-Wty\-l -(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}-N-pyrrolidin-1-ylpiperidine-4-carboxamide; 1 - { [[2-tert-butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)- 1H-benzimidazol-5- yl](methyl)amino]sulfonyl}-N-1H-pyrrol-1-ylpiperidine-4-carboxamide; 1-{[[2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}-N-ethylpiperidine-4-carboxamide; N-(tert-butyl)-1-{[[2-tert-butyl4-(tetrahydro-2H-pyran-4-ylmethyl)-1H- benzimidazol-5-yl](methyl)amino]sulfonyl}piperidine-4-carboxamide;

1 - { [[2-tert-butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}-N,N-dimethylpiperidine-4-carboxamide; 1-{[[2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzirQidazol-5- yl](methyl)amino]sulfonyl}-N,N-diethylpiperidine-4-carboxamide;

1 - { [[2-tert-butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}-N-methylpiperidine-4-carboxamide;

1 - { [[2-tert-butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}-N-propylpiperidme-4-carboxamide;

N-butyl-1-{[[2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}piperidine-4-carboxamide;

1 - { [[2-tert-butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}-N-(2,2,2-trifluoroethyl)piperidine-4-carboxamide; N-allyl- 1 - {[[2-tert-butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](metbyl)amino]sulfonyl}piperidine-4-carboxamide;

1 - { [[2-tert-butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)arαino]sulfonyl}-N-isobutylpiperidine-4-carboxamide;

1 - { [[2-tert-butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}-N-(2-hydroxy-1-methylethyl)ρiperidine-4-carboxamide;

1 - {[[2-tert-butyl-l -(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}-N-(2-hydroxyethyl)piperidine-4-carboxamide;

Ethyl 1 - { [[2-tert-butyl- 1 -(tetrahydro-2Η-pyran-4-ylmethyl)-1H-benzimidazol-5- yl] (methy l)amino] sulfony 1} piperidine-4-carboxylate ; N-(1-{[[2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyllazetidin-3-yl)cyclopropanecarboxamide;

N-( 1 - { [[2-tert-butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}azetidin-3-yl)-2-methylpropanamide;

N-(I- { [[2-tert-butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}azetidin-3-yl)cyclobutanecarboxamide;

N-(I- { [[2-tert-butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}azetidin-3-yl)butanamide; N-(1-{[[2-tert-butyl-1-(tetrahydro-2H;-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}azetidin-3-yl)propanamide;

Methyl 1-{[[2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}azetidine-3-carboxylate; N-[2-(l,l-dimethylethyl)-1-[(tetrahydro-2H-pyran-4-yl)methyl]-1H-beiizimidazol-5- yl]hexahydro-N-methyl-1H-azepine- 1 -sulfonamide;

N-[2-(l,l-dimethylethyl)-1-[(tetrahydro-2H-pyran-4-yl)methyl]-1H-benzimidazol-5- yl]-N,4-dimethyl-1-piperidinesulfonamide;

N-[2-(l , 1 -dimethylethyl)-l -[(tetrahydro-2H-pyran-4-yl)methyl]-1H-benzimidazol-5- ylJ-S-^ydroxymethy^-N-methyl-1-piperidinesulfonamide;

N-[2-(l,l-dimethylethyl)-1-[(tetrahydro-2H-pyran-4-yl)methyl]-lF-benzimidazol-5- yl]-4-hydroxy-N-methyl-1-piperidinesulfonamide;

N-[2-(l,l-dimethylethyl)-1-[(tetrahydro-2H-pyran-4-yl)methyl]-1H-benzimidazol-5- yl]-4-methoxy-N-methyl-1-piperidmesulfonamide; N-[2-(l,l-dimethylethyl)-1-[(tetrahydro-2H-pyran-4-yl)methyl]-1H-benzimidazol-5- yl]-3-hydroxy-N-methyl-1-piperidinesulfonamide;

N-[2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-N- methylazetidine- 1 -sulfonamide ;

N-[2-tert-butyl-1-(tetxahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-4,4- difluoro-N-methylpiperidine- 1 -sulfonamide;

N-[2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-3,3- difluoro-N-methylpyrrolidine- 1 -sulfonamide;

Methyl 1 - { [[2-tert-butyl- 1 -(tetrahy dro-2H-pyran-4-ylmethyl)- 1 H-benzimidazol-5- yl](methyl)amino]sulfonyl}piperidine-4-carboxylate; N-[2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-N- methylisoxazolidine-2-sulfonamide;

(4R)-N- [2-tert-butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)- 1 H-benzimidazol-5-yl]-4- hydroxy-N,4-dimethylisoxazolidine-2-sulfonamide;

N-( 1 - { [[2-tert-butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)- lH-benzimidazol-5- yl](memyl)amino]sulfonyl}piperidin-4-yl)acetamide;

N-(1-{[[2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}piperidin-4-yl)-2,2-dimethylpropanamide; tert-Butyl [1 -( {methyl[l -(tetrahydro-2H-pyran-4-ylmethyl)-2-(trifluoromethyl)- IH- benzimidazol-5-yl]amino}sulfonyl)piρeridin-4-yl]carbamate tert-Butyl 4-( {methyl[ 1 -(tetrahydro-2H-pyran-4-ylmethyl)-2-(trifluoromethyl)- IH- benzimidazol-5-yl]amino} sulfonyl)piperazine-l -carboxylate; 4-{[(Cyclopropylamino)carbonyl]amino}-N-methyl-N-[l-(tetrahydro-2H-pyran-4- ylmethyl)-2-(trifluoromethyl)-1H-benzimidazol-5-yl]piperidine-1-sulfonamide; N-cyclopropyl-4-( {methyl[ 1 -(tetrab.ydro-2H-pyran-4-ylmethyl)-2-(trifluoromethyl)- 1H-benzimidazol-5 -yl] amino } sulfonyl)piperazine- 1 -carboxamide ;

4-{[(isopropylamino)carbonyl]amino}-N-methyl-N-[l-(tetrab.ydro-2H-pyran-4- ylmethyl)-2-(trifluoromethyl)-1H-benzimidazol-5-yl]piperidme-1-sulfonamide; N-isopropyl-4-({methyl[l-(tetrahydro-2H-pyran-4-ylmethyl)-2-(trifluoromethyl)-1H- benzimidazol-5-yl]amino}sulfonyl)piperazine-1-carboxamide; N-[l-({methyl[l-(tetrahydro-2H-pyran-4-ylmethyl)-2-(trifluoromethyl)-1H- benzimidazol-5-yl]amino}sulfonyl)piperidin-4-yl]acetamide; 2,2-Dimethyl-N-[l-({methyl[l-(tetrahydro-2H-pyran-4-ylmethyl)-2-(trifluoromethyl)- 1H-benzimidazol-5-yl]amino}sulfonyl)piperidin-4-yl]propanamide;

2-Methyl-N- [ 1 -( {methyl[ 1 -(tetrahy dro-2H-pyran-4-ylmethyl)-2-(trifluoromethyl)- IH- benzimidazol-5-yl]amino}sulfonyl)piperidin-4-yl]propanamide;

4-Acetyl-N-methyl-N-[l-(tetrahydro-2H-pyran-4-ylmethyl)-2-(trifluoromethyl)-1H- benzimidazol-5-yl]piperazine-1-sulfonamide;

4-(2,2-Dimethylpropanoyl)-N-methyl-N-[l-(tetrahydro-2H-pyran-4-ylinethyl)-2-

(trifluoromethyl)-1H-benzimidazol-5-yl]piperazine-1-sulfonamide; N-(1-{[{2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5- yl}(methyl)amino]sulfonyl}piperidin-4-yl)acetamide; N-(1-{[{2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5- yl}(methyl)amino]sulfonyl}piperidin-4-yl)-2,2-dimethylpropanamide; N-{2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl}-N- methylmorpholine-4-sulfonamide; N-{2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl}-N- methylpyrrolidine-1 -sulfonamide; N-{2-tert-Butyl-1-[(4,4-difiuorocyclohexyl)methyl]-1H-benzimidazol-5-yl}-3,3- difluoro-N-methylpyrrolidine- 1 -sulfonamide; N-{2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl}-N- methylisoxazolidine-2-sulfonamide;

N- {2-tert-Butyl- 1 - [(4,4-difluorocyclohexyl)methyl] -1H-benzimidazol-5-yl} -4,4- difmoro-N-methylpiperidine-1-sulfonamide; tert-Butyl 4-{[{2-tert-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5- yl}(methyl)amino]sulfonyl}piperazine-1-carboxylate;

4- { [ {2-tert-Butyl-l -[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5- yl}(methyl)amino]sulfonyl}-N-isopropylpiperazine-1-carboxamide;

4-{[{2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5- yl}(methyl)amino]sulfonyl}-N-methylpiperazine-1-carboxamide;

4-{[{2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5- yl}(methyl)amino]sulfonyl}-N-cyclopropylpiperazine-1-carboxamide;

4-{[{2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5- yl}(methyl)amino]sulfonyl}-N-cyclobutylpiperazine-1-carboxamide; N- {2-tert-Butyl- 1 -[(4,4-difluorocyclohexyl)methyl] -1H-benzimidazol-5-yl} -N- methyl-4-{[(methylamino)carbonyl]amino}piperidine-1-sulfonamide;

N-[2-tert-Butyl-1-(tetrahydro-2Η-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-Ν- methylisoxazolidine-2-sulfonamide;

4-Acetyl-N-[2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]- N-methylpiperazine- 1 -sulfonamide;

N-[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-4-(2,2- dimethylpropanoyl)-N-methylpiperazine- 1 -sulfonamide;

4-Benzoyl-N-[2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl] -N-methylpiperazine- 1 -sulfonamide; N-[2-tert-Butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-N- methyl-4-(3-methylbutanoyl)piperazine-1-sulfonamide;

N-[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-4-

(cyclopropylcarbonyl)-N-methylpiperazine- 1 -sulfonamide;

N-[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-N- methyl-4-propionylpiperazine-1-sulfonamide;

N-[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-4- isobutyryl-N-methylpiperazine- 1 -sulfonamide; N-[2-tert-Butyl-1-(tetrahydro-2/i-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-4-

(cyclobutylcarbonyl)-N-methylρiperazine- 1 -sulfonamide; N-[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-4- butyryl-N-methylpiperazine-1-sulfonamide; 4- { [[2-tert-Butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}-N,N-dimethylpiperazine-1-carboxamide;

4- { [[2-tert-Butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}-N-isopropylpiperazme-1-carboxamide;

4- { [[2-tert-Butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}-N-cyclopentylpiperazme-1-carboxamide;

4-{[[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}-N-methylpiperazine-1-carboxamide;

4-{[[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- ylj^ethyl)amino]sulfonyl}-N-cyclopropylpiperazine-1-carboxamide; 4- { [[2-tert-Butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- ylJ^ethyl)amino]sulfonyll-N-cyclobutylpiperazine-1-carboxamide;

N-(tert-Butyl)-4- { [[2-tert-butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)- IH- benzimidazol-5-yl](methyl)amino]sulfonyl}piperazine-1-carboxamide; N-butyl-4- {[[2-tert-Butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl] (methyl)amino] sulfonyl } piperazine- 1 -carboxamide ; N-Allyl-4-{[[2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}piperazine-1-carboxamide;

4-{[[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl} -N-ethylpiperazine-l -carboxamide; 4- { [[2-tert-Butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}-N-propylpiperazme-1-carboxamide;

4- { [[2-tert-Butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}-N-(cyclopropylmethyl)piperazine-1-carboxainide;

N-[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-4-(1H- imidazol- 1 -ylcarbony^-N-methylpiperazine- 1 -sulfonamide;

Isopropyl 4-{[[2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}piperazine-1-carboxylate; N-(1-{[[2-tert-Butyl4-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl] (methyl) amino] sulfonyl} pyrrolidin-3 -yl)acetamide;

N-( 1 - { [[2-tert-Butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)- 1H-benzimidazol-5- yl](methyl)amino]sulfonyl}pyrrolidin-3-yl)-2,2-dimethylpropanamide; N-(1-{[[2-tert-Butyl-1-(tetrahydro-2/i-pyran-4-ylmethyl)-li/-benzimidazol-5- yl](methyl)amino]sulfonyl}azetidin-3-yl)acetamide;

N-{2-te^Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl}-N- methyl-1H-imidazole-1-sulfonamide; N-{2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl}-N- methyl- IH-1 ,2,4-triazole- 1 -sulfonamide;

N- {2-tert-Butyl-l -[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl} -N- methyl- IH-1 ,2,3-triazole- 1 -sulfonamide;

N-[2-tert-Butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-4- formyl-N-methyl-1H-pyrazole- 1 -sulfonamide; 1 - { [[2-tert-Butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)- 1H-benzimidazol-5- yl](methyl)amino]sulfonyl}-N-cyclopropyl-1H-pyrazole-4-carboxamide;

1 - { [[2-tert-Butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)- 1H-benzimidazol-5- yl](methyl)amino]sulfonyl}-N-ethyl-1H-pyrazole-4-carboxamide;

N-AlIyI- 1 - { [[2-tert-butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)- 1H-benzimidazol-5- yl] (methyl) amino] sulfonyl} -1H-pyrazole-4-carboxamide; 1-{[[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}-N-propyl-1H-pyrazole-4-carboxamide;

1 - { [[2-tert-Butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)- 1H-benzimidazol-5- yl](methyl)amino]sulfonyl}-N_:)N-dimethyl-1H-pyrazole-4-carboxamide; 1-{[[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl] (methyl) amino] sulfonyl} -N-methyl-1H-pyrazole-4-carboxamide;

N-(tert-Butyl)- 1 - { [[2-tert-butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)- IH- benzimidazol-5-yl](methyl)amino]sulfonyl}-1H-pyrazole-4-carboxamide;

N-(I- { [[2-tert-Butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)- 1H-benzimidazol-5- yl](methyl)amino]sulfonyl}-1H-pyrazol-3-yl)acetamide; N-[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-4- formyl-N-methyl-1H-imidazole- 1 -sulfonamide; 1- { [[2-f ert-Butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)- 1H-benzimidazol-5- ylj^ethyl)aminojsulfonyl}-N-cyclopropyl-1H-imidazole^-carboxamide; 1 - { [ [2-fert-Butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)- 1H-benzimidazol-5- ylj^ethyl)amino]sulfonyl}-N-cyclopropyl-1H-pyrazole-S-carboxainide; 1 - { [[2-fert-Butyl- 1 -(tefrahydro-2H-pyran-4-ylmethyl)- 1H-benzimidazol-5- yl](memyl)amino]sulfonyl}-N-isopropyl-1H-pyrazole-3-carboxamide; 1-{[[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-lϋ-^'-benzimidazol-5- ylj^ethyl)aminojsulfonyl}-N-propyl-1H-pyrazole-S-carboxainide; N- Allyl- 1 - { [[2-tert-butyl- 1 -(tetrahy dro-2H-pyran-4-ylmethyl)- 1H-benzimidazol-5- yl] (methyl)amino]sulfonyl} -1H-pyrazole-3-carboxamide;

1 - {[[2-tert-Butyl-l -(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}-N-ethyl-l/i-pyrazole-3-carboxamide; N-[2-^rt-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benziinidazol-5-yl]-N- methyl-4-(morpholm-4-ylcarbonyl)piperazine- 1 -sulfonamide; 4- { [[2-tert-Butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl] (methyl)amino] sulfonyl} -N-(2-hydroxyethyl)piperazine- 1 -carboxamide; N-[2-tert-Butyl-l<tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-N- methyl-4-(l.fir-pyrazol- 1 -ylcarbonyl)piperazine- 1 -sulfonamide; N-[2-tert-Butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-N- methyl-4-(pyrrolidin- 1 -ylcarbonyl)piperazine- 1 -sulfonamide; and pharmaceutically acceptable salts thereof.

It will be understood that when compounds of the present invention contain one or more chiral centers, the compounds of the invention may exist in, and be isolated as, enantiomeric or diastereomeric forms, or as a racemic mixture. The present invention includes any possible enantiomers, diastereomers, racemates or mixtures thereof, of a compound of Formula I. The optically active forms of the compound of the invention may be prepared, for example, by chiral chromatographic separation of a racemate, by synthesis from optically active starting materials or by asymmetric synthesis based on the procedures described thereafter. It will also be appreciated that certain compounds of the present invention may exist as geometrical isomers, for example E and Z isomers of alkenes. The present invention includes any geometrical isomer of a compound of Formula I. It will farther be understood that the present invention encompasses tautomers of the compounds of the Formula I.

It will also be understood that certain compounds of the present invention may exist in solvated, for example hydrated, as well as unsolvated forms. It will further be understood that the present invention encompasses all such solvated forms of the compounds of the Formula I.

Within the scope of the invention are also salts of the compounds of the Formula I. Generally, pharmaceutically acceptable salts of compounds of the present invention may be obtained using standard procedures well known in the art, for example by reacting a sufficiently basic compound, for example an alkyl amine with a suitable acid, for example, HCl or acetic acid, to afford a physiologically acceptable anion. It may also be possible to make a corresponding alkali metal (such as sodium, potassium, or lithium) or an alkaline earth metal (such as a calcium) salt by treating a compound of the present invention having a suitably acidic proton, such as a carboxylic acid or a phenol with one equivalent of an alkali metal or alkaline earth metal hydroxide or alkoxide (such as the ethoxide or methoxide), or a suitably basic organic amine (such as choline or meglumine) in an aqueous medium, followed by conventional purification techniques.

In one embodiment, the compound of Formula I above may be converted to a pharmaceutically acceptable salt or solvate thereof, particularly, an acid addition salt such as a hydrochloride, hydrobromide, phosphate, acetate, fumarate, maleate, tartrate, citrate, methanesulphonate or jσ-toluenesulphonate.

We have now found that the compounds of the invention have activity as pharmaceuticals, in particular as modulators or ligands such as agonists, partial agonists, inverse agonist or antagonists Of CB₁ receptors. More particularly, the compounds of the invention exhibit selective activity as agonist of the CB₁ receptors and are useful in therapy, especially for relief of various pain conditions such as chronic pain, neuropathic pain, acute pain, cancer pain, pain caused by rheumatoid arthritis, migraine, visceral pain etc. This list should however not be interpreted as exhaustive. Additionally, compounds of the present invention are useful in other disease states in which dysfunction Of CB₁ receptors is present or implicated. Furthermore, the compounds of the invention may be used to treat cancer, multiple sclerosis, Parkinson's disease, Huntington's chorea, Alzheimer's disease, anxiety disorders, gastrointestinal disorders and cardiovascular disorders.

Compounds of the invention are useful as immunomodulators, especially for autoimmune diseases, such as arthritis, for skin grafts, organ transplants and similar surgical needs, for collagen diseases, various allergies, for use as anti-tumour agents and anti viral agents.

Compounds of the invention are useful in disease states where degeneration or dysfunction of cannabinoid receptors is present or implicated in that paradigm. This may involve the use of isotopically labelled versions of the compounds of the invention in diagnostic techniques and imaging applications such as positron emission tomography (PET).

Compounds of the invention are useful for the treatment of diarrhoea, depression, anxiety and stress-related disorders such as post-traumatic stress disorders, panic disorder, generalized anxiety disorder, social phobia, and obsessive compulsive disorder, urinary incontinence, premature ejaculation, various mental illnesses, cough, lung oedema, various gastro-intestinal disorders, e.g. constipation, functional gastrointestinal disorders such as Irritable Bowel Syndrome and Functional Dyspepsia, Parkinson's disease and other motor disorders, traumatic brain injury, stroke, cardioprotection following miocardial infarction, spinal injury and drug addiction, including the treatment of alcohol, nicotine, opioid and other drug abuse and for disorders of the sympathetic nervous system for example hypertension.

Compounds of the invention are useful as an analgesic agent for use during general anaesthesia and monitored anaesthesia care. Combinations of agents with different properties are often used to achieve a balance of effects needed to maintain the anaesthetic state (e.g. amnesia, analgesia, muscle relaxation and sedation). Included in this combination are inhaled anaesthetics, hypnotics, anxiolytics, neuromuscular blockers and opioids.

Also within the scope of the invention is the use of any of the compounds according to the Formula I above, for the manufacture of a medicament for the treatment of any of the conditions discussed above.

A further aspect of the invention is a method for the treatment of a subject suffering from any of the conditions discussed above, whereby an effective amount of a compound according to the Formula I above, is administered to a patient in need of such treatment.

Thus, the invention provides a compound of Formula I or pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined for use in therapy. In a further aspect, the present invention provides the use of a compound of

Formula I or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined in the manufacture of a medicament for use in therapy.

In the context of the present specification, the term "therapy" also includes "prophylaxis" unless there are specific indications to the contrary. The term "therapeutic" and "therapeutically" should be contrued accordingly. The term "therapy" within the context of the present invention further encompasses to administer an effective amount of a compound of the present invention, to mitigate either a pre-existing disease state, acute or chronic, or a recurring condition. This definition also encompasses prophylactic therapies for prevention of recurring conditions and continued therapy for chronic disorders.

The compounds of the present invention are useful in therapy, especially for the therapy of various pain conditions including, but not limited to: acute pain, chronic pain, neuropathic pain, back pain, cancer pain, and visceral pain.

In use for therapy in a warm-blooded animal such as a human, the compound of the invention may be administered in the form of a conventional pharmaceutical composition by any route including orally, intramuscularly, subcutaneously, topically, intranasally, intraperitoneally, intrathoracially, intravenously, epidurally, intrathecally, transdermally, intracerebroventricularly and by injection into the joints. In one embodiment of the invention, the route of administration may be oral, intravenous or intramuscular.

The dosage will depend on the route of administration, the severity of the disease, age and weight of the patient and other factors normally considered by the attending physician, when determining the individual regimen and dosage level at the most appropriate for a particular patient. For preparing pharmaceutical compositions from the compounds of this invention, inert, pharmaceutically acceptable carriers can be either solid and liquid. Solid form preparations include powders, tablets, dispersible granules, capsules, cachets, and suppositories. A solid carrier can be one or more substances, which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, or table disintegrating agents; it can also be an encapsulating material.

In powders, the carrier is a finely divided solid, which is in a mixture with the finely divided compound of the invention, or the active component. In tablets, the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.

For preparing suppository compositions, a low-melting wax such as a mixture of fatty acid glycerides and cocoa butter is first melted and the active ingredient is dispersed therein by, for example, stirring. The molten homogeneous mixture in then poured into convenient sized moulds and allowed to cool and solidify.

Suitable carriers are magnesium carbonate, magnesium- stearate, talc, lactose, sugar, pectin, dextrin, starch, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, a low-melting wax, cocoa butter, and the like. The term composition is also intended to include the formulation of the active component with encapsulating material as a carrier providing a capsule in which the active component (with or without other carriers) is surrounded by a carrier which is thus in association with it. Similarly, cachets are included.

Tablets, powders, cachets, and capsules can be used as solid dosage forms suitable for oral administration.

Liquid form compositions include solutions, suspensions, and emulsions. For example, sterile water or water propylene glycol solutions of the active compounds may be liquid preparations suitable for parenteral administration. Liquid compositions can also be formulated in solution in aqueous polyethylene glycol solution.

Aqueous solutions for oral administration can be prepared by dissolving the active component in water and adding suitable colorants, flavoring agents, stabilizers, and thickening agents as desired. Aqueous suspensions for oral use can be made by dispersing the finely divided active component in water together with a viscous material such as natural synthetic gums, resins, methyl cellulose, sodium carboxymethyl cellulose, and other suspending agents known to the pharmaceutical formulation art. Depending on the mode of administration, the pharmaceutical composition will preferably include from 0.05% to 99%w (per cent by weight), more preferably from 0.10 to 50%w, of the compound of the invention, all percentages by weight being based on total composition. A therapeutically effective amount for the practice of the present invention may be determined, by the use of known criteria including the age, weight and response of the individual patient, and interpreted within the context of the disease which is being treated or which is being prevented, by one of ordinary skills in the art.

Within the scope of the invention is the use of any compound of Formula I as defined above for the manufacture of a medicament.

Also within the scope of the invention is the use of any compound of Formula I for the manufacture of a medicament for the therapy of pain.

Additionally provided is the use of any compound according to Formula I for the manufacture of a medicament for the therapy of various pain conditions including, but not limited to: acute pain, chronic pain, neuropathic pain, back pain, cancer pain, and visceral pain.

A further aspect of the invention is a method for therapy of a subject suffering from any of the conditions discussed above, whereby an effective amount of a compound according to the Formula I above, is administered to a patient in need of such therapy.

Additionally, there is provided a pharmaceutical composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier.

Particularly, there is provided a pharmaceutical composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier for therapy, more particularly for therapy of pain.

Further, there is provided a pharmaceutical composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier use in any of the conditions discussed above.

In a further aspect, the present invention provides a method of preparing the compounds of the present invention. In one embodiment, the invention provides a process for preparing a compound of Formula I, comprising:

I reacting a compound of Formula II with a compound of formula III,

followed by treating the reaction product with MeOTf and subsequently with R¹H, wherein R¹, R², R³, R⁴ and G are as defined above. Compounds of the present invention may also be prepared according to the synthetic routes as depicted in Schemes 1-5.

Scheme 1

H₂, Pd

reducing agent base, e.g. DMAP e.g. AIH₃ solvent, e.g. DMF solvent, e.g. THF coupling reagent, e.g. HATU

3) solvent, e.g. AcOH acid, e.g. AcOH microwave oven heating, 100-190⁰C

solvent, e.g. AcCN

base, e.g. (IPr)₂EtN AcCN

base

G, R¹, R², R³ and R⁴ are as defined above.

Scheme 2

cone. HCI °C

G, R¹, R², R³ and R⁴ are as defined above.

Scheme 3

base

G, R², R³ and R⁴ are as defined above.

N ^ is a C₂.₆heterocyc!yl as used in defining the R¹ above

X is Acyl-O- or halogen

Scheme 4

base, e.g. Hunig's base

Re-N=CO solvent, e.g. CH₂CI₂

G, R², R³ and R⁴ are as defined above. R⁴ R.³

is a C₂._βheterocyclyl as used in defining the R¹ above

X is Acyl-O- or halogen Scheme 5

HATU base

G, R², R³ and R⁴ are as defined above. R⁶ is C_1-6 alkyl or C₃.₆ cycloalkyl

N ^"I^" is a C₂.₆heterocyclyl as used in defining the R¹ above

X is Acyl-O- or halogen

Biological Evaluation hCB^ and hCB? receptor binding Human CBi receptor from Receptor Biology (hCBi) or human CB₂ receptor from BioSignal (hCB₂) membranes are thawed at 37 °C, passed 3 times through a 25- gauge blunt-end needle, diluted in the cannabinoid binding buffer (50 mM Tris, 2.5 mM EDTA, 5 mM MgCl₂, and 0.5 mg/mL BSA fatty acid free, pH 7.4) and aliquots containing the appropriate amount of protein are distributed in 96-well plates. The IC₅₀ of the compounds of the invention at hCBi and hCB₂ are evaluated from 10-point dose-response curves done with ³H-CP55,940 at 20000 to 25000 dpm per well (0.17- 0.21 nM) in a final volume of 300 μl. The total and non-specific binding are determined in the absence and presence of 0.2 μM of HU210 respectively. The plates are vortexed and incubated for 60 minutes at room temperature, filtered through Unifilters GF/B (presoaked in 0.1% polyethyleneimine) with the Tomtec or Packard harvester using 3 mL of wash buffer (50 mM Tris, 5 mM MgCl₂, 0.5 mg BSA pH 7.0). The filters are dried for 1 hour at 55 ⁰C. The radioactivity (cpm) is counted in a TopCount (Packard) after adding 65 μl/well of MS-20 scintillation liquid.

hCB, and hCB? GTPYS binding Human CBi receptor from Receptor Biology (!1CB₁) or human CB₂ receptor membranes (BioSignal) are thawed at 37 °C, passed 3 times through a 25-gauge blunt-end needle and diluted in the GTPγS binding buffer (50 rnM Hepes, 20 mM NaOH, 100 mM NaCl, 1 mM EDTA, 5 mM MgCl₂, pH 7.4, 0.1% BSA). The EC₅₀ and E_max of the compounds of the invention are evaluated from 10-point dose- response curves done in 300μl with the appropriate amount of membrane protein and 100000-130000 dpm Of GTPg³⁵S per well (0.11 -0.14 nM). The basal and maximal stimulated binding is determined in absence and presence of 1 μM (hCB₂) or 10 μM (hCBi) Win 55,212-2 respectively. The membranes are pre-incubated for 5 minutes with 56.25 μM (hCB2) or 112.5 μM (!1CB₁) GDP prior to distribution in plates (15 μM (hCB₂) or 30 μM (!1CB₁) GDP final). The plates are vortexed and incubated for 60 minutes at room temperature, filtered on Unifilters GF/B (presoaked in water) with the Tomtec or Packard harvester using 3 ml of wash buffer (50 mM Tris, 5 mM MgCl₂, 50 mM NaCl, pH 7.0). The filters are dried for 1 hour at 55 °C. The radioactivity (cpm) is counted in a TopCount (Packard) after adding 65 μl/well of MS-20 scintillation liquid. Antagonist reversal studies are done in the same way except that (a) an agonist dose-response curve is done in the presence of a constant concentration of antagonist, or (b) an antagonist dose-response curve is done in the presence of a constant concentration of agonist. Based on the above assays, the dissociation constant (Ki) for a particular compound of the invention towards a particular receptor is determined using the following equation:

Ki = IC₅₀/(l+[rad]/Kd),

Wherein IC₅₀ is the concentration of the compound of the invention at which 50% displacement has been observed;

[rad] is a standard or reference radioactive ligand concentration at that moment; and

Kd is the dissociation constant of the radioactive ligand towards the particular receptor. Using the above-mentioned assays, the Ki towards human CB₁ receptors for certain compounds of the invention are in the range of between 1 nM and 2897 nM. EC₅₀ for these compounds are in the range of between 0.58 nM and 7647 nM. Emax for these compounds are in the range of between 72% and 161%. EXAMPLES

The invention will further be described in more detail by the following Examples which describe methods whereby compounds of the present invention may be prepared, purified, analyzed and biologically tested, and which are not to be construed as limiting the invention.

Example 1 N-(1-{[{2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-lJ3^r-benziinidazol-5- yl}(methyl)amino]sulfonyl}piperidin-4-yl)acetamide

Step A: N-(1-{[{2-ter^-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-l_JH-benziraidazol- 5-yl}(methyl)amino]sulfonyl}piperidin-4-yl)acetaraide

Acetic anhydride (2.0 mmol) was added into a solution of triethylamine (2.0 mmol) and 4-amino-N-{2-tert-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5- yl}-N-methylpiperidine-l~sulfonamide (crude product from step J, 0.9 mmol) in CH₂Cl₂ (20 mL). After being stirred at room temperature for 1 hr, the reaction mixture was concentrated under reduced pressure. The residue was then purified by silica gel chromatography (AcOEt to MeOH/AcOEt (1:9)) to give N-(1-{[{2-tert-butyl-1-[(4,4- difluorocyclohexyl)methyl]-1H-benzimidazol-5- yl}(methyl)amino]sulfonyl}piperidin-4-yl)acetamide as a solid (235 mg, 48 % for steps A-D). ¹HNMR (400 MHz, CD₃OD, TFA salt) δ 1.28 (m, 2H), 1.40-1.76 (m, 8H), 1.64 (s, 9H), 1.88 (s, 3H), 2.04 (m, 2H), 2.24 (m, 1H), 2.90 (m, 2H), 3.28 (s, 3H), 3.68 (m, 3H), 4.50 (d, J= 8.0 Hz, 2H), 7.60 (d, J= 8.0 Hz, 1H), 7.77 (s, 1H), 7.86 (d, J= 8.0 Hz, 1H).

Step B. N-(4-Fluoro-3-nitrophenyl)acetamide

4-Fluoro-3-nitro-aniline (45.0 g, 0.288 mol) was added in portions to acetic anhydride (150 mL) at room temperature. The reaction mixture was stirred at room temperature for 2 h. The white solid was collected and dried in vacuo to give the title compound (42.0 g, 70%). ¹H NMR (400 MHz, CDCl₃): δ 2.23 (s, 3 H), 7.26 (m, 1 H), 7.50 (s broad, 1 H), 7.87 (m, 1 H), 8.23 (dd, J=6.44, 2.73 Hz, 1 H).

Step C. N-(4-Fluoro-3-nitrophenyl)-N-methylacetamide

Sodium hydride (2.40 g, 60 mmol) was added in portions to a solution of N-(4-fluoro- 3-nitrophenyl)acetamide (7.93 g, 40 mmol) in THF (120 mL) at 0 ⁰C. Stirring for 20 min, iodomethane (17.0 g, 120 mmol) was added. The reaction mixture was stirred at room temperature for 2 h, quenched with saturaed NaHCO₃ (30 mL) and extracted with EtOAc (3x100 mL). The combined organic phases were washed with saturated NaCl (2x30 mL). After filtration and concentration, 8.73 g (100%) of the title compound was obtained as a brown solid. ¹H NMR (400 MHz, CDCl₃): δ 1.92 (s, 3 H), 3.30 (s, 3 H), 7.38 (s, 1 H), 7.52 (s, 1 H), 7.95 (s, 1 H).

Step D. N-(4-{[(4,4-Difluorocyclohexyl)methyl]ammo}-3-nitrophenyl)-N- methylacetamide

[(4,4-difluorocyclohexyl)methyl]amine TFA salt (780 mg, 2.96 mmol) was added to a mixture of N-(4-fluoro-3-nitrophenyl)-N-methylacetamide (628 mg, 2.96 mmol) and DIPEA (1.29 mL, 7.40 mmol) in EtOH (15 mL) at room temperature. The reaction mixture was heated for 18 hrs at 70 ⁰C. Removal of the solvent, the crude product was purified by MPLC using EtOAc/Heptane 70-100% to give 855 mg (85%) of the title compound as an orange-red solid (84%). MS (ESI) (M+H)⁺: 341.96.

Step E. N-(3-Amino-4-{[(4,4-difluorocyclohexyl)inethyl] amino} pheny I)-N- methylacetamide

N-(4- { [(4,4-Difluorocyclohexyl)methyl] amino } -3 -nitrophenyl)-N-methy lacetamide (855 mg, 2.50 mmol) was hydrogenated in ethyl acetate (50 mL) catalyzed by 10% Pd/C at 50 psi H₂ in Parr shaker for 18 h at room temperature. After filtration through celite and concentration, 716 mg (92%) of a white solid was obtained, which was used in the next step without further purification. MS (ESI) (M+H)⁺: 311.99

Step F. N-{2-te//-ButyI-1-[(4,4-difluorocyclohexyl)methyl]-1H-benziinidazol-5- yl}-N-methylacetamide

Trimethylacetyl chloride (0.29 mL, 2.41 mmol) was dropwise added to a solution of N-(3-amino-4-{[(4,4-difluorocyclohexyl)methyl]atriino}phenyl)-N-methylacetamide (716 mg, 2.30 mmol) and Et₃N (0.38 mL, 2.75 mmol) in dichloromethane (100 mL) at 0 ⁰C. The resulting mixture was stirred for 4h at room temperature. After evaporation of the solvent, the residue was dissolved in acetic acid (16 mL) and then divided to 4 sealed test tubes. The mixture was heated at 150°C in a Personal Chemistry SmithSynthesizer microwave instrument for 3 hrs. The combined reaction mixture was evaporated and then dissolved in EtOAc (200 mL), washed with saturated sodium bicarbonate solution, brine and dried over Na₂SO₄. After filtration and evaporation, the residue was purified by MPLC using MeOH 5% and acetone 10% in DCM as eluent on silica gel to give 570 mg (65%) of the title compound as a white solid. MS (ESI) (M+H)⁺: 378.23.

Step G. 2-fe^-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-N-methyl-lH^r- benzimidazol-5-amine

N-{2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl}-N- methylacetamide (570 mg, 1.51 mmol ) and cone, hydrochloric acid (15 mL) were heated together at 8O⁰C for 18 hrs. Upon cooling down to room temperature, the reaction mixture was poured into ice-water (100 mL), brought the pH tol3 by using cone. NaOH and extracted with EtOAc (3x50 mL). The combined organic layers were washed with brine and dried with Na₂SO₄. After filtration and evaporation, 459 mg (90%) of the title compound was obtained as a white solid. MS (ESI) (M+H)⁺: 336.04.

Step H: 1-{[{2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-lir-benzimidazol-5- yl](methyl)amino]sulfonyl}-3-methyl-1H-imidazol-S-ium triflate

3-(Imidazole-1-sulfonyl)-1-methyl-3H-imidazol-1-ium triflate (508 mg; 1.4 mmol) was added into a solution of 2-fert-butyl-1-[(4,4-difluorocyclohexyl)methyl]-N- methyl-1H-benzimidazol-5-amine (300 mg, 0.9 mmol) in acetonitrile (10 mL). After being stirred at room temperature for 2 hr, the reaction mixture was concentrated under reduced pressure. The residue was then dissolved in AcOEt (60 mL), washed with brine, and dried over Na₂SO₄. Removal of solvents provided a mixture (1 : 1) of N-{2-fert-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl}-N- methyl-1H-imidazole-l -sulfonamide and 1-{[{2-tert-butyl-1-[(4,4- difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl](methyl)aminojsulfonyl}-3- methyl-1H-imidazol-3-ium triflate, which was dissolved in dichloromethane (10 mL). The resulting solution was treated with methyl trifluoromethanesulfonate (0.5 mmol) at 0°C for 2 hr. The reaction mixture was then concentrated under reduced pressure to give 1-{[{2-tert-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5- yl}(methyl)amino]sulfonyl}-3-methyl-1H-imidazol-3-ium triflate as a solid, which was used in the step I without any purification. Step I: tert-Butyl (l-{[{2-terj;-butyl-1-[(4,4-difluorocyclohexyl)methyl]-lJ9^r- benzimidazoi-5-yl}(methyl)amino]sulfonyl}piperidin-4-yl)carbamate

A solution of Hunig's base (1.0 mmol), 1-{[{2-tert-butyl-1-[(4,4- difluorocyclohexy^methyy-1H-benzimidazol-5-yl}(methyl)amino]sulfonyl}-3- methyl-1H-imidazol-3-ium triflate (crude product from Step H, 0.9 mmol) and tert- butyl piperidin-4-ylcarbamate (200 mg, 1.0 mmol) in MeCN (20 mL) was heated for 1 hr at 80°C. The reaction mixture was then concentrated under reduced pressure to give crude tert-hvAyl (1-{[{2-tert-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H- benzimidazol-5-yl}(methyl)amino]sulfonyl}piperidin-4-yl)carbamate as a solid, which was used directly in Step J.

Step J: 4-Amino-N-{2-ter-¹-butyl-1-[(4,4-difluorocyclohexyl)methyl]-lJΪ- benzimidazol-5-yl}-N-methylpiperidine-1-sulfonamide

A solution of tert-butyl (1-{[{2-tert-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H- benzimidazol-5-yl} (methyl)amino]sulfonyl}piperidin-4-yl)carbamate (crude product from Step I, 0.9 mmol) in 10 mL CH₂Cl₂ was treated with 10 mL TFA at room temperature. After being stirred at room temperature for 1 hr, the reaction mixture was concentrated under reduced pressure. The residue was then dissolved in AcOEt (60 mL), washed with Na₂CO₃ solution and brine, and dried over Na₂SO₄. Removal of solvents provided the crude 4-amino-N-{2-tert-butyl-1-[(4,4- difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl} -N-methylpiperidine- 1 - sulfonamide, which was used in Step A without purification.

Example 2 Ν-[2-^r/-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-Ν- methylisoxazolidine-2-sulfbnamide

Step A: N-[2-ter^-ButyI-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl]-N-methylisoxazolidine-2-sulfonamide

Following the procedure in Step I of Example 1, 1-{[[2-teri;-butyl-1-(tetrahydro-2H- pyran-4-ylmethyl)-1H-benzimidazol-5-yl](methyl)amino]sulfonyl}-3-methyl-liir- imidazol-3-ium triflate (crude product from Step G, 1.67 mmol) was reacted with isoxazolidine hydrochloride (220 mg, 2.0 mmol) and Hunig's base (0.72 mL, 4.2 mml), after being purified by silica gel chromatography by using 20-30 % AcOEt in dichloromethane, to provide N-[2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H- benzimidazol-5-yl]-N-methylisoxazolidine-2-sulfonamide (TFA salt, 807 mg, 88 %): ¹H NMR (600 MHz, CD₃OD) δ 1.43-1.56 (m, 4H), 1.60 (s, 9H), 2.22-2.35 (m, 3H), 3.26 (t, J= 11.14Hz, 2H), 3.37 (s, 3H), 3.47 (t, J= 7.17Hz, 2H), 3.85 (dd, J= 11.26, 3.33Hz, 2H), 4.03 (t, J= 7.30Hz, 2H), 4.46 (d, J= 7.17Hz, 2H), 7.63 (dd, J= 8.70, 1.02Hz, 1H), 7.80-7.84 (d, J= 1.28Hz, 1H), 7.88 (d, J= 8.96Hz, 1H).

Step B: Methyl (4-fluoro-3-nitrophenyl)carbamate

Methyl chloroformate (13.2 mL, 170.2 mmol) was added dropwise to a cold (0⁰C) dichloromethane (200 mL) solution of 4-fluoro-3-nitro aniline (24.15 g, 154.7 mmol) and DIPEA (35 mL, 201 mmol). The reaction mixture was stirred at rt overnight. The solution was then diluted with 200 mL of dichloromethane and washed with 2M HCl, brine and dried over anhydrous MgSO₄. The solvent was concentrated and the product was directly used for next step without further purification. Yield: 35.5 g (99%); ¹H NMR (400 MHz, CHLOROFORM-D): δ 3.81 (s, 3H), 7.02 (s, 1H), 7.23 (m, 1H), 7.72 (d, J = 8.59Hz, 1H), 8.17 (dd, J = 6.35, 2.64Hz, 1H).

Step C. Methyl {3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino] phenyl} carbamate

Methyl (4-fluoro-3-nitrophenyl)carbamate (2.0 g, 9.32 mmol) and 4-aminomethyl tetrahydropyran (1.28g, 11.2 mmol) were stirred in 50 mL of EtOH containing TEA (2.0 mL, 14.0 mmol) at 75°C for 48 h. The solvent was evaporated. The residue was dissolved in EtOAc and washed with aqueous 5% KHSO₄, saturated aqueous NaHCO₃ solution, brine and dried over anhydrous MgSO₄. The crude product was purified by silica gel flash chromatography using 1:1 / hexanes : EtOAc as eluent. Yield: 2.53 g (88%); ¹H NMR (400 MHz, CHLOROFORM-D): δ 1.42 (m, 4.49 Hz, 2 H), 1.73 (d, J=W 6 Hz, 1 H), 1.76 (d, J=1.95 Hz, 1 H), 1.88 - 2.01 (m, 1 H), 3.22 (dd, J=6.74, 5.57 Hz, 2 H), 3.42 (m, 2 H), 3.78 (s, 3 H), 4.01 (d, J=4.30 Hz, 1 H), 4.04 (d, J=3.51 Hz, 1 H), 6.48 (br.s, 1 H), 6.85 (d, J=9.37 Hz, 1 H), 7.65 (br.s, 1 H), 8.03 - 8.09 (m, 2 H). Step D. Methyl {3-amino-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl} carbamate

Methyl {3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl} carbamate (2.53 g, 8.18 mmol) was dissolved in 50 mL of EtOAc containing a catalytic amount of 10% Pd/C. The solution was shaken under H₂ atmosphere (40 psi) using a Parr hydrogenation apparatus overnight at it The solution was filtered through Celite and the solvent was evaporated. Yield: 2.29 g (99%); ¹H NMR (400 MHz, CHLOROFORM-D): δ 1.40 (m, 2 H), 1.70 - 1.74 (m, 1 H), 1.74 - 1.77 (m. 1 H), 1.81 - 1.92 (m, 1 H), 2.99 (d, J=6.64 Hz, 2 H), 3.34 (br.s, 2 H)₃ 3.41 (m, 2 H), 3.74 (s, 3 H), 3.99 (d, J=3.51 Hz, 1 H), 4.02 (d, J=3.51 Hz, 1 H), 6.38 (br.s, 1 H), 6.55 - 6.60 (m, 1 H), 6.62 - 6.68 (m, 1 H), 6.95 (br.s, 1 H).

Step E. Methyl [2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H- benzimidazol-5-yl] carbamate

Methyl {3-amino-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}carbamate (2.29 g, 8.20 mmol) and DMAP (0.20 g, 1.64 mmol) were dissolved in 75 mL of DCM. Trimethylacetyl chloride (1.10 mL, 9.02 mmol) was added dropwise and the solution was stirred at rt for 2h. The solution was washed with aqueous NaHCO₃ solution, brine and dried over anhydrous MgSO₄. The residue was dissolved in 25 mL of AcOH and was heated at 125⁰C for Ih using a Personal Chemistry microwave apparatus. The solvent was evaporated. The residue was dissolved in EtOAc and washed with aqueous NaHCO₃ solution, brine and dried over anhydrous MgSO₄. The crude product was purified by silica gel flash chromatography using 4:3 / hexanes : acetone as eluent. Yield: 1.81 g (64%); ¹H NMR (400 MHz, CHLOROFORM-D): δ 1.48 - 1.54 (m, 4 H) 1.56 (s, 9 H) 2.23 - 2.35 (m, 1 H) 3.27 - 3.35 (m, 2 H) 3.78 (s, 3 H) 3.96 (t, J=2.93 Hz, 1 H) 3.99 (t, J=3.03 Hz, 1 H) 4.18 (d, J=7.42 Hz, 2 H) 6.63 (br.s, 1 H) 7.24 - 7.28 (m, 1 H) 7.41 (br.s, 1 H) 7.61 (d, J=I.95 Hz, 1 H).

Step F: 2-tert-Butyl-N-methyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H- benzimidazol-5-amine

Methyl [2-tert-butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)- lH-benzimidazol-5- yljcarbamate (1.8Og, 5.21 mmol) (for preparation, see Steps B to E) was dissolved in 75 mL of THF at O⁰C. IM HCl/ether (7.3 mL, 7.29 mmol) was added dropwise and the solution was stirred at 0⁰C for 15 min. LiAlH₄ (988 mg, 26.1 mmol) was added slowly and the solution was stirred at rt overnight. The reaction was quenched at 0°C by the addition of MeOH (5 mL) followed by water (10 mL) and the solution was left to stir at rt for 30 min. Anhydrous Na₂SO₄ (10 g) was added and the solution was stirred at rt for another 30 min. The solution was filtered and the solvent was evaporated. The residue was dissolved in EtOAc and washed with aqueous NaHCO₃ solution, brine and dried over anhydrous MgSO₄. The solvent was evaporated. Yield: 1.54g (98%); ¹H NMR (400 MHz, CHLOROFORM-D): δ 1.49 - 1.53 (m, 4 H), 1.53 - 1.57 (m, 9 H), 2.22 - 2.32 (m, 1 H), 2.87 (s, 3 H), 3.26 - 3.35 (m, 2 H), 3.95 (t, J=3.03 Hz, 1 H), 3.97 - 4.00 (m, 1 H), 4.13 (d, J=7.42 Hz, 2 H), 6.61 (dd, J=8.59, 2.15 Hz, 1 H), 6.99 (d, J=1.95 Hz, 1 H), 7.11 (d, J=8.59 Hz, 1 H).

Step G: 1-{[[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-ljH-benzimidazol- 5-yl](methyl)amino]sulfonyl}-3-raethyl-1H-imidazol-3-ium triflate.

Following the procedure in Step H of Example 1, 2-tert-butyl-N-methyl-1- (tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-amine (1.51 g, 5.0 mmol) was converted to 1 - { [[2-tert-butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol- 5-yl](methyl)amino]sulfonyl}-3-methyl-1H-imidazol-3-ium triflate, which was used in Step A without any purification.

Example 3

N-[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-N- methylazetidine-1 -sulfonamide

N-[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl) -1H-benzimidazol-5-yl]-N- methylazetidine-1 -sulfonamide

Following the procedure in Step A of Example 2, 1-{[[2-tert-butyl-1-(tetrahydro-2H- pyran-4-ylmethyl)-1H-benzimidazol-5-yl](methyl)amino]sulfonyl}-3-methyl-1H- imidazol-3-ium triflate (3.33 mmol) was reacted with trimethlene amine (4.99 mmol), after being purified by silica gel chromatography by using 20-50 % AcOEt in dichloromethane, to provide N-[2-tert-butyl-1-(tetrahydro-2/-^r-pyran-4-ylmethyl)-1H- benzimidazol-5.-yl]-N-methylazetidine-1-sulfonamide (TFA salt, 675 mg, 38 %). MS (M+l): 421.01. ¹H NMR (600 MHz, CD₃OD) δ 1.40-1.53 (m, 4H)₃ 1.57 (s, 9H), 2.14 (quint, J= 7.68Hz, 2H), 2.23-2.33 (m, 1H), 3.22 (s, 3H), 3.25 (m, 2H), 3.80 (t, J= 7.68Hz, 4H), 3.84 (m, 2H), 4.41 (d, J= 7.42Hz, 2H), 7.51 (d, J= 8.70Hz, 1H), 7.67 (d, J= 1.79Hz, 1H), 7.80 (d, J= 8.45Hz, 1H).

Example 4 N-[2-tert-Butyl-1-(tetrahydro-2_JH^r-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-A'- methylpyrrolidine-1 -sulfonamide

Step A: N-[2-tert-Butyl-1-(tetrahydro-2_Jδ^r-pyran-4-ylmethyl)-l_JH-benzimidazol-5- yl]-N-methylpyrrolidine-1-sulfonamide

N-[2-tert-Butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)- 1 H-benzimidazol-5-yl]-N- methylsulfamide (for preparation see the following steps B to H) (45 mg, 0.118 mmol) was dissolved in 5 mL of DMF at 0°C. NaH (60% dispersion in oil) (14 mg, 0.354 mmol) was added and the solution was stirred at 0°C for 10 min. 1,4- Dibromobutane (0.014 mL, 0.118 mmol) was added and the solution was stirred at rt for 3h. Another 0.118 mmol of 1,4-dibrombutane was added and the solution was stirred at rt for another 3h. The reaction was quenched by the addition of saturated aqueous NaHCO₃ solution and the solvent was evaporated. The residue was dissolved in EtOAc and washed with saturated aqueous NaHCO₃ solution, brine and dried over anhydrous MgSO₄. The product was purified by reversed-phase HPLC using 10-60% CH₃CN/H₂O and lyophilized affording the title compound as the corresponding TFA salt. Yield: 53 mg (82%). ¹HNMR (400 MHz, METHANOL- D₄) δ 1.52 - 1.58 (m, 2 H), 1.59 - 1.67 (m, 2 H), 1.69 (s, 9 H), 1.87 - 1.92 (m, 4 H), 2.35 - 2.43 (m, 1 H), 3.29 - 3.32 (m, 7 H), 3.35 (m, 2 H), 3.93 (d, J=3.12 Hz, 1 H), 3.96 (d, J=3.71 Hz, 1 H), 4.55 (d, J=7.42 Hz, 2 H), 7.67 (dd, J=8.98, 1.95 Hz, 1 H), 7.81 (d, J=2.15 Hz, 1 H), 7.97 (d, J=8.98 Hz, 1 H); MS (ESI) (M+H)⁺ 435.0; Anal. Calcd(%) for C₂₂H₃₄N₄O₃S + 2.4 TFA + 0.2 H₂O: C, 45.22; H, 5.21; N, 7.87. Found: C, 45.20; H, 5.27; N, 7.90.

Step B : (tert-Butoxy carb onyl) { [4-(dimethyKminio)pyridin-l (4H)- yl] sulf onyl} azanide

Chlorosulfonyl isocyanate (1.2 mL, 13.8 mmol) was added dropwise to a stirring DCM solution (10 mL) of t-butanol (1.3 mL, 13.8 mmol). DMAP (3.45g, 27.6 mmol) was added slowly and the solution was stirred at rt for 2h. The solution was diluted with DCM and washed with water (3X), brine and dried over anhydrous MgSO₄. The solvent was evaporated. The product was recrystallized from acetonitrile. Yield (1.68g (40%). ¹H NMR (400 MHz, DMSO-D₆) δ 1.25 (s, 9 H), 3.21 (s, 6 H), 6.96 (d, J=8.20 Hz, 2 H), 8.45 (d, J=8.01 Hz, 2 H).

Step C : N-[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl]-N-methylsulfamide

2-tert-Butyl-N-methyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-amine (60 mg, 0.199mmol) (for preparation, see Example 2, Steps B to F) and (terϊ- butoxycarbonyl){[4-(dimethyliminio)pyridin-l(4H)-yl]sulfonyl}azanide (66 mg, 0.219 mmol) were stirred in 3 mL of DCE at 70°C for 2h. The solution was then passed through a plug of silica gel using EtOAc as eluent. The solvent was evaporated. The residue was dissolved in 3 mL of IM HCl/ AcOH and the solution was stirred at rt for Ih. The solvent was evaporated. The product was purified by reversed-phase HPLC using 10-60% CH₃CN/H₂O and then lyophilized affording the title compound as the corresponding TFA salt. The fractions were pooled and the solvent was concentrated. The residue was dissolved in 2M Na₂CO₃ and extracted with DCM (3X). The organic phase was dried over anhydrous MgSO₄ and the solvent was evaporated. Yield: 45 mg (59%). ¹H NMR (TFA salt) (400 MHz, METHANOL-D₄) δ 1.50 - 1.56 (m, 2 H), 1.57 - 1.62 (m, 2 H), 1.67 (s, 9 H), 2.33 - 2.42 (m, 1 H), 3.28 (s, 3 H), 3.34 (m, 2 H), 3.93 (m, 2 H), 4.53 (d, J=7.62 Hz, 2 H), 7.64 (dd, J=8.98, 1.95 Hz, 1 H), 7.77 (d, J=I.56 Hz, 1 H), 7.91 (d, J=8.98 Hz, 1 H); MS (ESI) (M+H)⁺381.0.

Example 5 N-[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yI]-N- methylmorpholine-4-sulfonamide

Following Step A in Example 4 using N-[2-tert-butyl-1-(tetrahydro-2H-pyran-4- ylmethyl)-1H-benzimidazol-5-yl]-N-methylsulfamide (45 mg, 0.118 mmol), NaH (14 nig, 0.354 mmol) and 2-bromoethyl ether (0.030 mL, 0.236 mmol) in 4 mL of DMF. The product was purified by reversed-phase HPLC using 10-60% CH₃CN/H₂O and lyophilized affording the title compound as the corresponding TFA salt. Yield: 42 mg (63%). ¹H NMR (400 MHz, METHANOL-D₄) δ 1.52 - 1.58 (m, 2 H), 1.59 - 1.66 (m, 2 H), 1.69 (s, 9 H), 2.34 - 2.43 (m, 1 H), 3.20 - 3.24 (m, 4 H), 3.32 - 3.40 (m, 5 H), 3.63 - 3.67 (m, 4 H), 3.93 (d, J=3.32 Hz, 1 H), 3.96 (d, J=3.71 Hz, 1 H), 4.54 (d, J=7.42 Hz, 2 H), 7.69 (dd, J=8.98, 1.95 Hz, 1 H), 7.82 (d, J=I.76 Hz, 1 H), 7.96 (d, J=8.98 Hz, 1 H); MS (ESI) (M+H)⁺451.0; Anal. Calcd(%) for C₂₂H₃₄N₄O₄S + 1.2 TFA + 1.0 H₂O: C, 48.41; H, 6.19; N, 9.25. Found: C, 48.29; H, 6.00; N, 9.53.

Example 6 N-[2-ferf-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-ljH-benzimidazol-5-yl]-N- methylpiperidine-1-sulfonamide

Following Step A in Example 4 using N-[2-tert-butyl-1-(tetrahydro-2H-pyran-4- ylmethyl)-1H-benzimidazol-5-yl]-N-methylsulfamide (40 mg, 0.105 mmol), NaH (13 mg, 0.315 mmol) and 1 ,5-dibromopentane (0.042 mL, 0.315 mmol) in 4 mL of DMF. The product was purified by reversed-phase HPLC using 10-60% CH₃CN/H₂O and lyophilized affording the title compound as the corresponding TFA salt. Yield: 42 mg (71%). ¹HNMR (400 MHz, METHANOL-D₄) δ 1.52 - 1.60 (m, 8 H), 1.59 - 1.67 (m, 2 H), 1.69 (s, 9 H), 2.34 - 2.43 (m, 1 H), 3.20 - 3.25 (m, 4 H)₅ 3.31 (s, 3 H), 3.35 (m, 2 H), 3.93 (d, J=3.12 Hz, 1 H), 3.96 (d, J=3.91 Hz, 1 H), 4.54 (d, J=7.62 Hz, 2 H), 7.67 (dd, J=8.98, 1.95 Hz, 1 H), 7.80 (d, J=I.76 Hz, 1 H), 7.95 (d, J=8.98 Hz, 1 H); MS (ESI) (M+H)⁺ 449.0; Anal. Calcd(%) for C₂₃H₃₆N₄O₃S + 1.3 TFA + 0.9 H₂O: C, 50.15; H, 6.43; N, 9.14. Found: C, 50.22; H, 6.52; N, 9.10. Example 7 N-{2-terf-Butyl-1-[(4,4-diifluorocyclohexyl)methyl]-l_JH^r-benziinidazol-5-yl}-N- methylpiperidine-1 -sulfonamide

2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-N-methyl-1H-benzimidazol-5-ainine (55 mg, 0.164 mmol) (for preparation, see Example 1, Steps B to G) and (tert- butoxy carbonyl) { [4-(dimethyliminio)pyridin- 1 (4/f)-yl] sulfonyl } azanide (54 mg, 0.180 mmol) were stirred in 3 mL of DCE at 70°C for 2h. The crude product was purified by silica gel flash chromatography using 1:1 / hexanes : EtOAc to EtOAc as a gradient. The resulting product was dissolved in 3 mL of IM ΗCl/AcOΗ and stirred at rt for Ih. The solvent was evaporated. The residue was dissolved in EtOAc and washed with saturated aqueous NaHCO₃ solution, brine and dried over anhydrous MgSO₄. The solvent was evaporated. The product was dissolved in 3 mL of DMF at O⁰C and NaH (20 mg, 0.492 mmol) was added, followed by 1,5-dibromopentane (0.033 mL, 0.246 mmol). The solution was stirred at rt for 2h. The reaction was quenched with saturated aqueous NaHCO₃ solution and the solvent was evaporated. The residue was dissolved in EtOAc and washed with saturated aqueous NaHCO₃ solution, brine and dried over anhydrous MgSO₄. The product was purified by reversed-phase HPLC using 10-60% CH₃CN/H₂O and lyophilized affording the title compound as the corresponding TFA salt. Yield: 15 mg (15%). ¹H NMR (400 MHz, METHANOL-D₄) δ 1.54 - 1.61 (m, 8 H), 1.68 (s, 9 H), 1.71 - 1.85 (m, 4 H)₅ 2.01 - 2.12 (m, 2 H), 2.21 - 2.33 (m, 1 H), 3.20 - 3.25 (m, 4 H), 3.31 (s, 3 H)₃ 4.56 (d, J=7.62 Hz, 2 H), 7.67 (dd, J=9.08, 2.05 Hz, 1 H), 7.81 (d, J-2.15 Hz, 1 H), 7.94 (d, J=9.18 Hz, 1 H); MS (ESI) (M+H)⁺ 483.0; Anal. Calcd(%) for C₂₄H₃₆N₄O₂SF₂ + 1.8 TFA + 0.4 H₂O: C, 47.69; H, 5.60; N, 8.06. Found: C, 47.66; H, 5.58; N, 8.07. Example 8 N-[2-(l,l-Difluoroethyl)-1-(tetrahydro-2J3-pyran-4-ylmethyl)-lir-benzimidazol-

5-yl]-N-methylisoxazolidine-2-sulfonamide

Step A- N-^-Cl-l-Difluoroethy^-1-Ctetrahydro-lH-pyran^-ylmethyl)-1H- benzimidazol-5-yl]-N-methylisoxazolidine-2-sulfonamide

Isoxazolidin-2-ium chloride (80 mg, 0.72 mmol) and DIPEA (0.12 mL, 0.72 mmol) were added to the reaction mixture (18 mL) prepared in step B in this example. The resulting reaction mixture was heated to 6O⁰C overnight and the solvent was concentrated. . The product was purified by reverse-phase preparative HPLC using MeCN 10 to 90% gradient in water to provide the TFA salt of the title compound as white solid. Yield: 50 mg (18%); ¹HNMR (400 MHz, CD₃OD) δ 1.38 - 1.51 (m, 4 H), 2.21 (t, J=19.34 Hz, 3 H)₅ 2.28 - 2.39 (m, 2 H), 3.29 - 3.35 (m, 2 H), 3.41 (s, 3 H), 3.53 (dd, J=8.01, 6.64 Hz, 2 H), 3.84 - 3.93 (m, 2 H), 4.12 (t, J=7.42 Hz, 2 H)₅ 4.32 (d, J=7.62 Hz, 2 H), 7.51 (dd, J=8.89, 2.05 Hz, 1 H)₅ 7.66 (d₅ J=8.98 Hz, 1 H)₅ 7.83 (d₅ J=1.95 Hz, 1 H); MS (ESI) (M+H)⁺ 445.0; Anal. Calcd for C₁₉H₂₆F₂N₄O₄S + 0.3 TFA + 0.1 H₂O: C, 48.99; H, 5.56; N₅ 11.16. Found: C, 49.02; H₅ 5.60; N, 11.67.

Step B. 1-{[[2-(l,l-Difluoroethyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-LH- benzimidazol-5-yl](methyl)amino]suIfonyl}-3-methyl-1H-imidazol-3-ium

l-(li7-Imidazol-1-ylsulfonyl)-3-methyl-li/-imidazol-3-ium difluoromethanesulfonate (1.05 g, 2.90 mmol) was added to a solution of 2-(l,l-difluoroethyl)-N-methyl-1- (tetrahydro-2H-pyran-4-ylmethyl)-lϋf-benzimidazol-5 -amine (0.60 g, 1.93 mmol) in MeCN (70 mL) at ambient temperature. The reaction mixture was stirred for 4 hrs. and methyl trifluoromethyl sulfone (0.21 mL, 1.93 mmol) was added. The reaction mixture was stirred for 2hrs and used directly for the next step.

Example 9 N-(1-{[[2-(l_?l-Difluoroethyl)-1-(tetrahydro-2fi^r-pyran-4-ylmethyl)-1H- benzimidazol-5-yl](methyl)amino]sulfonyl}piperidin-4-yl)acetamide

fert-Butyl piperidin-4-ylcarbamate (0.43 mg, 1.45 mmol) was added to the reaction mixture (52 mL) prepared in example 1, step B. The resulting reaction mixture was heated to 90⁰C overnight. tert-Butyl piperidin-4-ylcarbamate (0.43 mg, 1.45 mmol) was added again and the reaction mixture was heated to 90°C overnight. The solvent was concentrated and DCM (50 mL) was added to the residue. The resulting precipitate was filtered and air-dried to provide 404 mg of tert-butyl (1-{[[2-(l,l- difluoroethyl)- 1 -(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}piperidin-4-yl)carbamate intermediate. The solid was treated with TFA (10 mL) for 1.5 hr. and the solvent was concentrated. The resulting 4-amino-N-[2-(l,l-difluoroemyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-lJ^:f- benzimidazol-5-yl]-N-πiethylpiperidme-l -sulfonamide TFA salt intermediate was dissolved in DCM (100 mL) and the solution was neutralized with Et₃N (2 mL) at O⁰C. Acetyl chloride (10 drops) was added to the solution at 0°C, the reaction mixture was allowed to warm to ambient temperature and stirred overnight. The solvent was concentrated and the product was purified by reverse-phase preparative HPLC using MeCN 10 to 90% gradient in water to provide the TFA salt of the title compound as white solid. Yield: 160 mg (21%); ¹H NMR (400 MHz, CD₃OD) δ 1.35 - 1.54 (m, 6 H), 1.78 - 1.87 (m, 2 H), 1.90 (s, 3 H), 2.24 (t, J=19.33 Hz, 3 H), 2.30 (s, 1 H), 2.83 - 2.94 (m, 2 H), 3.27 - 3.30 (m, 3 H), 3.30 - 3.38 (m, 2 H), 3.60 - 3.77 (m, 4 H), 3.86 - 3.96 (m, 2 H), 4.35 (d, J=7.62 Hz, 2 H), 7.51 (dd, J=8.79, 2.15 Hz, 1 H), 7.71 (d,

J=8.98 Hz, 1 H), 7.79 (d, J=1.95 Hz, 1 H); MS (ESI) (M+H)⁺ 514.0; Anal. Calcd for C₂₃H₃₃F₂N₅O₄S + 0.7 TFA + 0.2 H₂O: C, 49.09; H, 5.76; N, 11.73. Found: C, 49.06; H, 5.69; N, 11.68.

Example 10 1-{[[2-terϊ-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}-N-cyclopropylpiperidine-4-carboxamide

Step A. 1-{[[2-tert-Butyl-1-(tetrahydro-2J3^r-pyran-4-ylmethyl)-1H-benzimidiazol- 5-yl](methyl)amino]sulfonyl}-N-cyclopropylpiperidine-4-carboxamide

To a solution of 1-{[[2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H- benzimidazol-5-yl](methyl)amino]sulfonyl}piperidine-4-carboxylic acid (70 mg, 0.142 mmol, see Steps B to E for its preparation), diisopropylethylamine (0.029 mL, 0.170 mmol), and cyclopropylamine (30 μL, excess) at room temperature in DMF (3 mL), was added HATU (64.6 mg, 0.170 mmol) in one portion. The solution was stirred at room temperature overnight. After evaporation of the solvent, the residue was purified by reversed-phase HPLC (10-60% CH₃CN in H₂O) to provide the title compound as its TFA salt (29.1 mg, 32%). ¹H NMR (400 MHz, CDCl₃) δ 0.47 - 0.54 (m, 2 H), 0.69 - 0.77 (m, 2 H), 1.52 - 1.70 (m, 6 H), 1.73 (s, 9 H), 1.75 - 1.82 (m, 2 H), 2.13 - 2.24 (m, 1 H), 2.26 - 2.39 (m, 1 H), 2.65 - 2.71 (m, 1 H), 2.71 - 2.81 (m, 2 H), 3.31 (s, 3 H), 3.32 - 3.41 (m, 2 H), 3.57 - 3.65 (m, 2 H), 4.00 - 4.07 (m, 2 H), 4.38 (d, J=7.42 Hz, 2 H), 6.43 - 6.48 (m, 1 H), 7.55 (d, J=8.98 Hz, 1 H), 7.66 (dd, J=8.98, 1.37 Hz, 1 H), 7.90 - 7.93 (m, 1 H); MS (ESI) (M+H)⁺ 532.0; Anal. (C, H, N) calcd for C₂₇H₄₁N₅O₄S+2.30CF₃COOH: C 47.80, H 5.50, N 8.82; found C 47.93, H 5.22, N 8.91.

Step B. N-[2-tert-ButyH-(tetrahydro-2H-pyran-4-ylmethyl)-lfT-benzimidazol-5- yl]-N-methyl-1H-imidazole-1-sulfonamide

To a solution of 2-fer^-butyl-N-methyl-1-(tetrahydro-2iϊ^'-pyran-4-ylmethyl)-1H- benzimidazol-5-amine (1.97 g, 6.54 mmol) at room temperature in MeCN (40 mL), was added l-(1H-imidazol-1-ylsulfonyl)-3-methyl-1H-imidazol-3-ium (3.6g, 9.81 mmol) in one portion. The solution was stirred at room temperature overnight. After evaporation of the solvent, the residue was purified by flash chromatography (0-100% EtOAc in hexanes, 50min; 100% EtOAc, lOmin; 0-2% MeOH in EtOAc, lOmin) to afford the product (1.24 g, 44%). MS (ESI) (M+H)⁺ 432.0.

Step C. 1-{[[2-tert-Butyl-1-(tetrahydro-2J3-pyran-4-ylmethyl)-1H-benzimidazol- 5-yl](methyl)amino]sulfonyl}-3-methyHH-imidazol-3-ium

To a solution of N- [2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethy I)-ITf - benzimidazol-5-yl]-N-methyl-liϊ^'-imidazole-1-sulfonamide (1.24 g, 2.88 mmol) at room temperature in MeCN (20 mL), was added methyl trifluoromethanesulfonate (0.49 mL, 4.32 mmol) dropwise. The solution was stirred at room temperature for 5 hours. After evaporation of the solvent, the residue was used directly for the next step without purification (1.0 g, 76%). MS (ESI) (M+H)⁺ 446.0.

Step D. 1-{[[2-ter^-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol- 5-yl](methyl)amino]sulfonyl}piperidine-4-carboxylate

To a solution of 1-{[[2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H- benzimidazol-5-yl](methyl)amino]sulfonyl}-3-methyl-1H-imidazol-3-ium (1 g, 2.2 mmol) and diisopropylethylamine (0.38 mL, 2.2 mmol) at room temperature in MeCN (15 mL), was added methyl isonipecotate (0.61 mL, 4.5 mmol) in one portion. The solution was stirred at room temperature overnight. After evaporation of the solvent, the residue was purified by flash chromatography (0-100% EtOAc in hexanes, 50min; 100% EtOAc, lOmin; 0-2% MeOH in EtOAc, lOmin) to provide the title compound (1.08 g, 97%). MS (ESI) (M+H)⁺ 507.0.

Step E. 1-{[[2-ter<-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benziinidazol- 5-yl] (methyl) amino] sulfonyl}piperidine-4-carboxylic acid

To a solution of methyl 1-{[[2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-li/^'- benzimidazol-5-yl](methyl)amino]sulfonyl}piperidine-4-carboxylate (1.08 g, 2.13 mmol) at O⁰C in MeOH:H₂O (3:1, 20 mL), was added LiOH (178.5 mg, 7.46 mmol) in one portion. The solution was stirred at O⁰C, slowly warmed to room temperature and stirred at room temperature overnight. The solution was adjusted to pH 2 with IN HCl (12 mL), the aqueous layer was extracted with DCM. The organic layers were dried over Na₂SO₄, and subjected to filtration. Evaporation of the solvent provided the title compound (2.2 g, 92%). MS (ESI) (M+H)⁺ 493.0.

Example 11 1-{[[2-te/^-Butyl-1-(tetrahydro-2N-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}-N-isopropylpiperidine-4-carboxamide

Following the procedure for Step A in Example 10, using 1-{[[2-tert-butyl-1- (tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}piperidine-4-carboxylic acid (200 mg, 0.41 mmol), diisopropylethylamine (0.17 mL, 0.96 mmol), isopropylamine (0.11 mL, 1.22 mmol), DMF (6 mL), and HATU (182.6 mg, 0.48 mmol) provided the title compound as its TFA salt (150 mg, 57 %) following purification by reversed-phase HPLC (10-60% CH₃CN in H₂O). ¹H NMR (400 MHz, CDCl₃) δ 1.13 (d, J=6.64 Hz, 6 H) 1.52 - 1.70 (m, 6 H) 1.72 (s, 9 H) 1.76 - 1.84 (m, 2 H) 2.13 - 2.23 (m, 1 H) 2.27 - 2.40 (m, 1 H) 2.71 - 2.85 (m, 2 H) 3.32 (s, 3 H) 3.34 - 3.41 (m, 2 H) 3.62 - 3.72 (m, 2 H) 3.98 - 4.09 (m, 3 H) 4.37 (d, J=7.42 Hz, 2 H) 5.97 (d, J=7.62 Hz, 1 H) 7.54 (d, J=8.98 Hz, 1 H) 7.68 (dd, J=8.98, 1.76 Hz, 1 H) 7.89 (d, J=I.76 Hz, 1 H); MS (ESI) (M+H)⁺ 534.0; Anal. (C, H, N) calcd for C₂₇H₄₃N₅O₄S+2.00CF₃COOH+0.1 OCH₃OH: C 48.83, H 5.98, N 9.15; found C 48.83, H 5.93, N 9.07.

Example 12 1-{[[2-tert-Butyl-1-(tetrahydro-2_Jfir-pyran-4-ylmethyl)-lH^r-benziraidazol-5- yl](methyl)amino]sulfonyl}-N-cyclobutylpiperidme-4-carboxamide

Following the procedure for Step A in Example 10, using l~{[[2-tert-butyl-l-

(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}piperidine-4-carboxylic acid (70 mg, 0.14 mmol), diisopropylethylamine (0.029 mL, 0.17 mmol), cyclobutylamine (0.030 mL, excess), DMF (3 mL), and HATU (64.6 mg, 0.17 mmol) provided the title compound as its TFA salt (37.8 mg, 40 %) following purification by reversed-phase HPLC (10-70% CH₃CN in H₂O). ¹H NMR (400 MHz, CDCl₃) δ 1.52 - 1.71 (m, 10 H), 1.72 (s, 9 H), 1.77 - 1.95 (m, 3 H), 2.12 - 2.23 (m, 1 H), 2.23 - 2.39 (m, 3 H), 2.74 - 2.85 (m, 2 H), 3.33 (s, 3 H), 3.34 - 3.41 (m, 2 H), 3.66 (d, J=15.04 Hz, 2 H), 4.04 (d, J=10.94 Hz, 2 H), 4.37 (d, J=7.42 Hz, 2 H), 6.35 (d, J=8.01 Hz, 1 H), 7.53 (d, J=8.98 Hz, 1 H), 7.69 (dd, J=9.08, 1.86 Hz, 1 H), 7.90 (d, J=I .76 Hz, 1 H); MS (ESI) (M+H)⁺ 546.0; Anal. (C, H, N) calcd for C_2SH₄₃N₅O₄S+2.1 OCF₃COOH: C 49.26, H 5.79, N 8.92; found C 49.21, H 5.65, N 9.07.

Example 13 1-{[[2-tert-Butyl-1-(tetrahydro-2J?-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}-N-cyclopentylpiperidine-4-carboxamide

Following the procedure for Step A in Example 10, using 1-{[[2-ter£-butyl-1- (tetrahydro-2H-pyran-4-ylmethyl)-l//-benzimidazol-5- yl](methyl)amino]sulfonyl}piperidine-4-carboxylic acid (70 mg, 0.14 mmol), diisopropylethylamine (0.029 mL, 0.17 mmol), cyclopentylamine (0.030 mL, excess), DMF (3 mL), and HATU (64.6 mg, 0.17 mmol) provided the title compound as its TFA salt (37.8 mg, 40 %) following purification by reversed-phase HPLC (10-70% CH₃CN in H₂O). ¹H NMR (400 MHz, CDCl₃) δ 1.32 - 1.42 (m, 2 H), 1.52 - 1.69 (m, 10 H), 1.72 (s, 9 H), 1.76 - 1.85 (m, 3 H), 1.89 - 2.01 (m, 2 H), 2.75 - 2.86 (m, 2 H), 3.34 (s, 3 H), 3.34 - 3.41 (m, 2 H), 3.65 - 3.73 (m, 2 H), 4.00 - 4.07 (m, 2 H), 4.11 - 4.21 (m, 1 H), 4.36 (d, J=6.84 Hz, 2 H), 7.52 (d, J=8.79 Hz, 1 H), 7.67 - 7.73 (m, J=7.81 Hz, 1 H), 7.91 - 7.95 (m, 1 H); MS (ESI) (M+H)⁺ 560.0; Anal. (C, H, N) calcd for C2₉H45N5O4S+I.7OCF₃COOH+O.2OH₂O +0.40CH₃OH: C 51.16, H 6.37, N 9.09; found C 51.15, H 6.34, N 9.00.

Example 14 1-{ [ [2-tørt-Butyl-1-(tetrahy dro-2i?-pyran-4-ylmethyl)-ljH^r-benzimidazol-5- yl](methyl)amino]sulfonyl}-N-pyrrolidin-1-ylpiperidine-4-carboxamide

Following the procedure for Step A in Example 10, using 1-{[[2-te?t-butyl-1- (tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}piperidine-4-carboxylic acid (70 mg, 0.14 mmol), diisopropylethylamine (0.029 mL, 0.17 mmol), 1-aminopyrrolidine hydrochloride (20.8 mg, 0.17 mmol), DMF (3 mL), and HATU (64.6 mg, 0.17 mmol) provided the title compound as its TFA salt (37.8 mg, 40 %) following purification by reversed- phase HPLC (10-60% CH₃CN in H₂O). ¹HNMR (400 MHz, CDCl₃) δ 1.52 - 1.70 (m, 7 H)₅ 1.72 (s, 9 H), 1.74 - 1.84 (m, 2 H), 2.12 - 2.23 (m, 4 H), 2.37 - 2.48 (m, 1 H), 2.87 - 3.00 (m, 3 H), 3.33 (s, 3 H), 3.34 - 3.41 (m, 2 H), 3.44 - 3.53 (m, 2 H), 3.65 - 3.74 (m, 4 H), 3.99 - 4.07 (m, 2 H), 4.38 (d, J=7.42 Hz, 2 H), 7.57 (d, J=8.89 Hz, 1 H), 7.69 (dd, J=8.89, 2.05 Hz, 1 H), 7.88 (d, J=2.05 Hz, 1 H); MS (ESI) (M+H)⁺ 561.0; Anal. (C₅ H, N) calcd for C₂sH₄₄N₆O₄S+2.75CF₃COOH+0.55H₂O +0.15CH₃OH: C 45.46, H 5.49, N 9.45; found C 45.47, H 5.49₅ N 9.46.

Example 15 1-{[[2-tert-Butyl-1-(tetrahydro-2Jy-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}-N-1H-pyrrol-1-ylpiperidine-4-carboxamide

Following the procedure for Step A in Example 10, using l-{[[2-tert-buty\-l- (tetrahydro-2H-pyran-4-ylmemyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}piperidine-4-carboxylic acid (70 mg, 0.14 mmol), diisopropylethylamine (0.029 mL, 0.17 mmol), 1-aminopyrrole (0.030 mL, excess), DMF (3 mL), and HATU (64.6 mg, 0.17 mmol) provided the title compound as its TFA salt (37.8 mg, 40 %) following purification by reversed-phase HPLC (10-70% CH₃CN in H₂O). ¹H NMR (400 MHz, CDCl₃) δ 1.50 - 1.63 (m, 4 H), 1.71 (s, 9 H), 1.72 - 1.95 (m, 2 H), 2.26 - 2.50 (m, 2 H), 2.75 - 2.86 (m, 2 H), 3.23 - 3.41 (m, 6 H), 3.58 - 3.72 (m, 3 H), 3.96 - 4.08 (m, 2 H), 4.37 (d, J=7.42 Hz, 2 H), 6.06 - 6.15 (m, 2 H), 6.56 - 6.61 (m, 2 H), 7.56 (d, J=9.18 Hz, 1 H), 7.68 - 7.73 (m, 1 H), 7.91 (d, J=I.17 Hz, 1 H); MS (ESI) (M+H)⁺ 557.0; Anal. (C₃ H, N) calcd for C₂₈H₄₀N₆O₄S+1.75CF₃COOH+0.35CH₃OH: C 49.85, H 5.67, N 10.95; found C 49.97, H 5.61, N 10.84.

Example 16 1-{[[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}-N-ethylpiperidine-4-carboxamide

Following the procedure for Step A in Example 10, using 1-{[[2-tert-butyl-1- (tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}piperidine-4-carboxylic acid (70 mg, 0.14 mmol), diisopropylethylamine (0.029 mL, 0.17 mmol), ethylamine (0.21 mL, 0.43 mmol), DMF (3 mL), and HATU (64.6 mg, 0.17 mmol) provided the title compound as its TFA salt (41.5 mg, 46 %) following purification by reversed-phase HPLC (10-65% CH₃CN in H₂O). ¹HNMR (400 MHz, CDCl₃) δ 1.12 (t, J=7.13 Hz, 3 H), 1.51 - 1.69 (m, 6 H), 1.72 (s, 9 H), 1.75 - 1.86 (m, 2 H)₅ 2.19 - 2.41 (m, 2 H), 2.70 - 2.82 (m, 2 H), 3.21 - 3.28 (m, 2 H), 3.30 (s, 3 H), 3.31 - 3.41 (m, 2 H), 3.56 - 3.67 (m, 2 H), 3.98 - 4.08 (m, 2 H), 4.39 (d, J=7.42 Hz, 2 H), 6.47 - 6.56 (m, 1 H), 7.56 - 7.62 (m, 1 H), 7.63 - 7.69 (m, 1 H), 7.87 (s, 1 H); MS (ESI) (M+H)⁺ 520.0; Anal. (C, H, N) calcd for C₂₆H₄₁N₅O₄S+2.35CF₃COOH: C 46.81, H 5.55, N 8.89; found C 46.49, H 5.09, N 9.32.

Example 17 N-(tert-Butyl)-1-{[[2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H- benzimidazol-5-yl](methyl)amino]sulfonyl}piperidine-4-carboxamide

Following the procedure for Step A in Example 10, using 1-{[[2-ter^-butyl-1- (tetrahydro-2H-pyran-4-ylmethyl)-li/-benzimidazol-5- yl](methyl)amino]sulfonyl}piperidine-4-carboxylic acid (70 mg, 0.14 mmol), diisopropylethylamine (0.029 mL, 0.17 mmol), f-butylamine (0.045 mL, 0.43 mmol), DMF (3 mL), and HATU (64.6 mg, 0.17 mmol) provided the title compound as its TFA salt (44.2 mg, 47 %) following purification by reversed-phase HPLC (10-70% CH₃CN in H₂O). ¹H NMR (400 MHz, CDCl₃) δ 1.32 (s, 9 H), 1.52 - 1.70 (m, 6 H), 1.71 (s, 9 H), 1.73 - 1.81 (m, 2 H), 2.05 - 2.18 (m, 1 H), 2.26 - 2.40 (m, 1 H), 2.69 - 2.81 (m, 2 H), 3.31 (s, 3 H), 3.32 - 3.42 (m, 2 H), 3.63 - 3.71 (m, 2 H)₃ 3.99 - 4.07 (m, 2 H), 4.38 (d, J=7.42 Hz, 2 H), 5.79 - 5.85 (m, 1 H), 7.57 (d, J=8.98 Hz, 1 H)₅ 7.68 (dd, J=8.98, 1.37 Hz, 1 H)₅ 7.82 - 7.86 (m, 1 H); MS (ESI) (M+H)⁺ 548.0; Anal. (C₅ H, N) calcd for C₂₈H₄₅N₅O₄S+2.10CF₃COOH+1.25H₂O: C 47.76, H 6.17, N 8.65; found C 47.45, H 5.88, N 8.96.

Example 18 1-{ [ [2-ter?-Butyl-1-(tetrahydro-2J?-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}-Λ^r,N-dimethylpiperidine-4-carboxamide

Following the procedure for Step A in Example 10, using 1-{[[2-tert-butyl-1- (tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}piperidine-4-carboxylic acid (70 mg, 0.14 mmol), diisopropylethylamine (0.029 μL, 0.17 mmol), NjN-dimethylamine (0.21 mL, 0.43 mmol), DMF (3 mL), and HATU (64.6 mg, 0.17 mmol) provided the title compound as its TFA salt (33.7 mg, 37 %) following purification by reversed-phase HPLC (10- 60% CH₃CN in H₂O). ¹H NMR (400 MHz, CDCl₃) δ 1.52 - 1.65 (m, 5 H), 1.65 - 1.79 (m, 12 H), 2.25 - 2.40 (m, 1 H), 2.63 - 2.75 (m, 1 H), 2.84 - 2.92 (m, 2 H), 2.93 (s, 3 H), 3.06 (s, 3 H), 3.32 (s, 3 H), 3.33 - 3.41 (m, 2 H), 3.68 - 3.77 (m, 2 H), 3.98 - 4.08 (m, 2 H), 4.37 (d, J=7.42 Hz, 2 H), 7.54 (d, J=8.98 Hz, 1 H), 7.68 (dd, J=8.98, 0.98 Hz, 1 H), 7.89 - 7.93 (m, 1 H); MS (ESI) (M+H)⁺ 520.0; Anal. (C, H, N) calcd for C₂₆H₄₁N₅O₄S+1.80CF₃COOH+0.75H₂O: C 48.14, H 6.05, N 9.48; found C 48.09, H 6.00, N 9.57.

Example 19 1-{[[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-beiizimidazol-5- yl](methyl)amino]sulfonyl}-N,iV-diethylpiperidine-4-carboxamide

Following the procedure for Step A in Example 10, using 1-{[[2-fert-butyl-1- (tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}piperidine-4-carboxylic acid (70 mg, 0.14 mmol), diisopropylethylamine (0.029 mL, 0.17 mmol), ΛζN-diethylamine (0.044 mL, 0.43 mmol), DMF (3 mL), and HATU (64.6 mg, 0.17 mmol) provided the title compound as its TFA salt (12.1 mg, 13 %) following purification by reversed-phase HPLC (10- 70% CH₃CN in H₂O). ¹H NMR (400 MHz, CDCl₃) δ 1.08 (t, J=7.13 Hz, 3 H), 1.19 (t, J=7.03 Hz, 3 H), 1.52 - 1.62 (m, 4 H), 1.65 - 1.69 (m, 1 H), 1.72 (s, 9 H), 1.72 - 1.87 (m, 3 H), 2.54 - 2.64 (m, 1 H), 2.86 - 2.96 (m, 2 H), 3.28 - 3.40 (m, 10 H), 3.71 - 3.80 (m, 2 H), 3.99 - 4.07 (m, 2 H), 4.35 (d, J=7.42 Hz, 2 H), 7.49 (d, J=8.98 Hz, 1 H), 7.70 (dd, J=8.98, 1.76 Hz, 1 H), 7.93 (d, J=I.76 Hz, 1 H); MS (ESI) (M+H)⁺ 548.0.

Example 20 1-{ [ P-tert-Butyl-1-Ctetrahydro-lH-pyran^-ylmethyl)-lN-benzimidazol-S- yl](methyl)amino]sulfonyl}-N-methylpiperidine-4-carboxamide

Following the procedure for Step A in Example 10, using 1-{[[2-tert-butyl~l- (tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}piperidine-4-carboxylic acid (70 mg, 0.14 mmol), diisopropylethylamine (0.029 mL, 0.17 mmol), methylamine (0.21 mL, 0.43 mmol), DMF (3 mL), and HATU (64.6 mg, 0.17 mmol) provided the title compound as its TFA salt (22.9 mg, 26 %) following purification by reversed-phase HPLC (10-60% CH₃CN in H₂O). ¹H NMR (400 MHz, CDCl₃) δ 1.57 (d, 4 H), 1.65 - 1.76 (m, 12 H), 1.81 - 1.90 (m, 3 H), 2.79 (d, J=4.49 Hz, 3 H), 2.80 - 2.87 (m, 2 H), 3.33 (s, 3 H), 3.34 - 3.41 (m, 2 H), 3.61 - 3.69 (m, 2 H), 3.99 - 4.08 (m, 2 H), 4.36 (d, J=7.42 Hz, 2 H), 7.52 (d, J=9.18 Hz, 1 H), 7.70 (dd, J=9.18, 1.66 Hz, 1 H), 7.96 - 7.99 (m, 1 H); MS (ESI) (M+H)⁺ 506.0; Anal. (C, H, N) calcd for

C25H₃₉N5O₄S+I.9OCF3COOH+O.2OH2O +0.25CH₃OH: C 47.54, H 5.81, N 9.54; found C 47.54, H 5.82, N 9.53.

Example 21 1-{[[2-tert-Butyl-1-(tetrahydro-2_JH-pyran-4-ylmethyl)-1H^r-benzimidazol-5- yl](methyl)amino]sulfonyl}-N-propylpiperidine-4-carboxamide

Following the procedure for Step A in Example 10, using 1-{[[2-tert-butyl-1- (tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}piperidine-4-carboxylic acid (70 mg, 0.14 mmol), diisopropylethylamine (0.074 mL, 0.43 mmol), λζN-diethylamine (0.035 mL, 0.43 mmol), DMF (3 mL), and ΗATU (81 mg, 0.21 mmol) provided the title compound as its TFA salt (31.1 mg, 34 %) following purification by reversed-phase ΗPLC (10-70% CH₃CN in H₂O). ¹H NMR (400 MHz, CDCl₃) δ 0.89 (t, J=7.42 Hz, 3 H), 1.44 - 1.71 (m, 8 H), 1.72 (s, 9 H), 1.75 - 1.87 (m, 2 H), 2.17 - 2.41 (m, 2 H)₅ 2.72 - 2.85 (m, 2 H), 3.14 - 3.23 (m, 2 H), 3.32 (s, 3 H), 3.33 - 3.42 (m, 2 H), 3.59 - 3.70 (m, 2 H), 3.98 - 4.09 (m, 2 H), 4.38 (d, J=7.42 Hz, 2 H), 6.30 - 6.42 (m, 1 H), 7.55 (d, J=8.98 Hz, 1 H), 7.68 (dd, J=8.98, 1.76 Hz, 1 H), 7.91 (d, J=I.76 Hz, 1 H); MS (ESI) (M+H)⁺ 534.0; Anal. (C, H, N) calcd for C₂₇H₄₃N₅O₄S+1.80CF₃COOH+0.90CH₃OH: C 49.28, H 6.29, N 9.06; found C 49.25, H 6.29, N 9.06. Example 22 N-Butyl-1-{[[2-ter-^I-butyl-1-(tetrahydro-2J9^r-pyran-4-yIraethyI)-l_Jff-benzimidazol-

5-yl](methyl)amino]sulfonyl}piperidine-4-carboxamide

Following the procedure for Step A in Example 10, using 1-{[[2-tert-butyl-1- (tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimiάazol-5- yl](methyl)amino]sulfonyl}piperidine-4-carboxylic acid (70 mg, 0.14 mmol), diisopropylethylamine (0.074 mL, 0.43 mmol), ΛζN-butylamine (42 μL, 0.43 mmol), DMF (3 mL), and HATU (81 mg, 0.21 mmol) provided the title compound as its TFA salt (31.1 mg, 34 %) following purification by reversed-phase HPLC (10-70%

CH₃CN in H₂O). ¹H NMR (400 MHz, CDCl₃) δ 0.90 (t, J=7.32 Hz, 3 H), 1.24 - 1.39 (m, 2 H), 1.41 - 1.52 (m, 2 H), 1.52 - 1.70 (m, 6 H), 1.72 (s, 9 H), 1.77 - 1.87 (m, 2 H), 2.15 - 2.41 (m, 2 H), 2.74 - 2.87 (m, 2 H), 3.16 - 3.26 (m, 2 H), 3.32 (s, 3 H), 3.33 - 3.41 (m, 2 H), 3.60 - 3.72 (m, 2 H), 3.98 - 4.08 (m, 2 H), 4.37 (d, J=7.42 Hz, 2 H), 6.18 - 6.30 (m, 1 H), 7.54 (d, J=8.98 Hz, 1 H), 7.67 (dd, J=8.98, 1.76 Hz, 1 H), 7.94 (d, J=I.76 Hz, 1 H); MS (ESI) (M+H)⁺ 548.0; Anal. (C, H, N) calcd for C₂₈H₄₅N₅O₄S+!.55CF₃COOH: C 50.56, H 6.48, N 9.67; found C 50.95, H 5.92, N 10.27.

Example 23 1-{[[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1-H^r-benzimidazol-5- yl](methyl)amino]sulfonyl}-N-(2,2,2-trifluoroethyl)piperidine-4-carboxamide

Following the procedure for Step A in Example 10, using 1-{[[2-tert-butyl-1- (tetrahydro-2i/-pyran-4-ylmetriyl)-lij^r-benzimidazol-5- yl](methyl)amino]sulfonyl}piperidine-4-carboxylic acid (100 mg, 0.20 mmol), diisopropylethylamine (0.1 mL, 0.61 mmol), 2,2,2-trifluoroethylamine (0.050 mL, 0.61 mmol), DMF (3 mL), and HATU (116 mg, 0.31 mmol) provided the title compound as its TFA salt (59.2 mg, 42 %) following purification by reversed-phase HPLC (10-70% CH₃CN Ui H₂O). ¹H NMR (400 MHz, CDCl₃) δ 1.51 - 1.70 (m, 6 H), 1.72 (S₅ 9 H), 1.76 - 1.85 (m, 2 H), 2.25 - 2.39 (m, 2 H), 2.72 - 2.84 (m, 2 H), 3.28 - 3.41 (m, 5 H), 3.58 - 3.65 (m, 2 H), 3.82 - 3.94 (m, 2 H), 4.00 - 4.07 (m, 2 H), 4.38 (d, J=7.42 Hz, 2 H), 7.05 - 7.14 (m, 1 H), 7.56 (d, J=8.98 Hz, 1 H), 7.68 (dd, J=8.98, 1.46 Hz, 1 H), 7.91 - 7.94 (m, 1 H); MS (ESI) (M+H)⁺ 573.8; Anal. (C, H, N) calcd for C₂₆H₃₈F₃N₅O₄S-Hl.85CF₃COOH: C 54.44, H 6.68, N 12.21; found C 45.49, H 4.94, N 8.87.

Example 24 N-Allyl-1-{[[2-tert-butyl-1-(tetrahydro-2jH-pyran-4-ylmethyl)-l_JH-benzimidazol-

5-yl](methyl)amino]sulfonyl}piperidine-4-carboxamide

Following the procedure for Step A in Example 10, using 1-{[[2-tert-butyl-1-

(tetrahydro-27f-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}piperidine-4-carboxylic acid (100 mg, 0.20 mmol), diisopropylethylamine (0.1 mL, 0.61 mmol), allylamine (0.1 mL, 0.61 mmol), DMF (3 mL), and HATU (116 mg, 0.31 mmol) provided the title compound as its TFA salt (27.6 mg, 25 %) following purification by reversed-phase HPLC (10-60% CH₃CN in H₂O). ¹H NMR (400 MHz, CDCl₃) δ 1.51 - 1.79 (m, 17 H), 1.80 - 1.90 (m, 2 H), 2.76 - 2.88 (m, 2 H), 3.33 (s, 3 H), 3.34 - 3.41 (m, 2 H), 3.63 - 3.72 (m, 2 H), 3.82 - 3.89 (m, 2 H), 3.98 - 4.08 (m, 2 H), 4.36 (d, J=7.42 Hz, 2 H), 5.07 - 5.20 (m, 2 H), 5.75 - 5.89 (m, 1 H), 6.25 - 6.33 (m, 1 H), 7.52 (d, J=8.98 Hz, 1 H), 7.69 (dd, JM8.98, 1.95 Hz, 1 H), 7.94 (d, J=I.95 Hz, 1 H); MS (ESI) (M+H)⁺ 532.0;

Example 25 1-{[[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}-N-isobutylpiperidine-4-carboxamide

Following the procedure for Step A in Example 10, using 1-{[[2-tert-butyl-1-

(tetrahydro-2Jf-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}piperidine-4-carboxylic acid (200 mg, 0.41 mmol), diisopropylethylamine (0.2 mL, 1.22 mmol), isobutylamine (0.12 mL, 1.22 mmol), DMF (6 mL), and HATU (236 mg, 0.62 mmol) provided the title compound as its TFA salt (99.6 mg, 37 %) following purification by reversed-phase HPLC (10-70% CH₃CN in H₂O). ¹H NMR (400 MHz, CD₃OD) δ 0.87 (d, J=6.84 Hz, 6 H) 1.51 - 1.67 (m, 7 H) 1.69 (s, 9 H) 1.70 - 1.77 (m, 3 H) 2.23 - 2.33 (m, 1 H) 2.81 - 2.91 (m, 2 H) 2.91 - 2.99 (m, 2 H) 3.33 (s, 3 H) 3.33 - 3.39 (m, 2 H) 3.66 - 3.74 (m, 2 H) 3.90 - 3.97 (m, 2 H) 4.54 (d, J=7.42 Hz, 2 H) 7.68 (dd, J=8.98, 1.95 Hz, 1 H) 7.81 (d, J=I.95 Hz, 1 H) 7.96 (d, J=8.98 Hz, 1 H); MS (ESI) (M+H)⁺ 458.0.

Example 26 1-{[[2-tert-Butyl-1-(tetrahydro-2ia^r-pyran-4-ylmethyl)-lJ3^r-benzimidazol-5- yl](methyl)amino]sulfonyl}-N-(2-hydroxy-1-methylethyl)piperidme-4- carboxamide

Following the procedure for Step A in Example 10, using 1-{[[2-tert-butyl-1- (tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}piperidine-4-carboxylic acid (175 mg, 0.36 mmol), diisopropylethylamine (0.15 mL, 0.85 mmol), DL-2-amino-1-propanol (0.08 mL, 1.07 mmol), DMF (5 mL), and HATU (162 mg, 0.43 mmol) provided the title compound as its TFA salt (66.9 mg, 28 %) following purification by reversed-phase HPLC (10- 40% CH₃CN in H₂O). ¹H NMR (400 MHz, CDCl₃) δ 1.13 (d, J=6.64 Hz, 3 H) 1.51 - 1.68 (m, 7 H) 1.72 (s, 9 H) 1.75 - 1.86 (m, 1 H) 2.19 - 2.41 (m, 2 H) 2.67 - 2.91 (m, 2 H) 3.32 (s, 2 H) 3.33 - 3.41 (m, 3 H) 3.43 - 3.70 (m, 4 H) 3.97 - 4.09 (m, 3 H) 4.39 (d, J=7.62 Hz, 2 H) 6.76 (d, J=7.42 Hz, 1 H) 7.55 - 7.60 (m, 1 H) 7.64 - 7.68 (m, 1 H) 7.84 (d, J=I.95 Hz, 1 H); MS (ESI) (M+H)⁺ 549.8.

Example 27 1-{[[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-l_JH^r-benzimidazol-5- yl](methyl)amino]sulfonyl}-N-(2-hydroxyethyl)piperidine-4-carboxamide

Following the procedure for Step A in Example 10, using 1-{[[2-tert-butyl-1-

(tetrahydro-2if-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}piperidine-4-carboxylic acid (70 mg, 0.14 mmol), diisopropylethylamine (0.042 mL₅ 0.24 mmol), ethanolamine (0.010 mL, 0.17 mmol), DMF (3 mL), and HATU (59.4 mg, 0.16 mmol) provided the title compound as its TFA salt (46.4 mg, 50 %) following purification by reversed-phase HPLC (10-60% CH₃CN in H₂O). ¹HNMR (400 MHz, CDCl₃) δ 1.52 - 1.66 (m, 6 H), 1.72 (s, 9 H), 1.82 (d, J=12.50 Hz, 2 H), 2.22 - 2.42 (m, 2 H), 2.71 - 2.83 (m, 2 H), 3.30 (s, 3 H), 3.32 - 3.44 (m, 4 H), 3.52 - 3.65 (m, 2 H), 3.66 - 3.78 (m, 2 H), 3.98 - 4.07 (m, 2 H), 4.39 (d, J=7.42 Hz, 2 H), 7.15 - 7.24 (m, J=32.62 Hz, 1 H), 7.56 - 7.62 (m, 1 H), 7.63 - 7.67 (m, 1 H), 7.81 - 7.88 (m, 1 H); MS (ESI) (MH-H)⁺ 536.0; Anal. (C, H₅ N) calcd for C₂₆H₄₁N₅O₅S+2.20CF₃COOH+1.00H₂O: C 45.38, H 5.66, N 8.70; found C 47.93, H 5.22, N 8.91.

Example 28

Ethyl 1-{[[2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benziraidiazol-5- yl] (methyl) amino] sulf onyl} pip eridine-4-carboxylate

Following the procedure for Step J in Example 10, using 1-{[[2-tert-butyl-1-

(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl](methyl)amino]sulfonyl}-3- methyl- lif-imidazol-3-ium (1.9 g, 4.25 mmol) and diisopropylethylamine (0.1 mL, 0.6 mmol) at room temperature in MeCN (40 mL) and ethyl isonipecotate (1.9 mL, 12.75 mmol), the solution was concentrated and the residue was redissolved in EtOAc (100 mL). The solution was washed with H₂O (3 x 30 mL), brine (30 mL), dried over Na₂SO₄ and filtered. After evaporation of the solvent, the residue was purified by flash chromatography (0-100% EtOAc in hexanes, 50mm; 100% EtOAc, lOmin; 0- 2% MeOH in EtOAc, lOmin) to provide the title compound (445 mg, 20%). ¹H NMR (400 MHz, CDCl₃) δ 1.24 (t, J=7.23 Hz, 3 H), 1.49 - 1.59 (m, 13 H), 1.64 - 1.77 (m, 2 H), 1.86 - 1.95 (m, 2 H), 2.22 - 2.39 (m, 2 H), 2.78 - 2.89 (m, 2 H), 3.28 (s, 3 H), 3.29 - 3.37 (m, 2 H), 3.63 - 3.71 (m, 2 H), 3.95 - 4.02 (m, 2 H), 4.13 (q, J=7.23 Hz, 2 H), 4.20 (d, J=7.42 Hz, 2 H), 7.30 (s, 1 H), 7.32 (d, J=I.95 Hz, 1 H), 7.72 (d, J=I.56 Hz, 1 H); MS (ESI) (M+H)⁺ 521.0; Anal. (C, H, N) calcd for C₂₆H₄₀N₄O₅S-HO-OOCH₃OH: C 59.17, H 7.92, N 10.38; found C 59.23, H 8.03, N 10.45.

Example 29 N-(1-{[[2-tert-Butyl-1-(tetrahydro-2J7-pyran-4-ylmethyl)-1H-benzimidazoI-5- yl](methyl)amino]sulfonyl}azetidin-3-yl)cyclopropanecarboxamide

Step A. N-(l-{ [[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-lJΪ- benzimidazol-5-yl] (methyl)amino] sulfonyl} azetidin-3- ytycyclopropanecarboxamide

To a solution of 3-amino-N-[2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H- benzimidazol-5-yl]-N-methylazetidine-1-sulfonamide (150 mg, 0.27 mmol, see Steps B and C for its preparation), diisopropylethylamine (0.14 mL, 0.82 mmol), and cyclopropanecarboxylic acid (0.33 mL, 0.41 mmol) at room temperature in DMF (1.5 mL), was added HATU (125.5 mg, 0.33 mmol) in one portion. The solution was stirred at room temperature for 3 hours. After evaporation of the solvent, the residue was purified by reversed-phase HPLC (10-65% CH₃CN in H₂O) to provide the title compound as its TFA salt (27.3 mg, 16%). ¹H NMR (400 MHz, CD₃OD) δ 0.72 - 0.85 (m, 4 H) 1.50 - 1.68 (m, 5 H) 1.69 (s, 9 H) 2.31 - 2.46 (m, 1 H) 3.31 - 3.40 (m, 5 H) 3.80 - 3.86 (m, 2 H) 3.91 - 3.98 (m, 2 H) 4.00 - 4.06 (m, 2 H) 4.50 - 4.59 (m, 3 H) 7.67 (dd, J=8.98, 2.15 Hz, 1 H) 7.79 (d, J=2.15 Hz, 1 H) 7.96 (d, J=8.98 Hz, 1 H); MS (ESI) (M+H)⁺ 503.8; Anal. (C, H, N) calcd for

C₂5H₃₉N₅O₄S+1.80CF₃COOH+0.05H₂O +0.45CH₃OH: C 48.18, H 5.66, N 9.67; found C 48.19, H 5.67, N 9.69.

Step B. 3-Araino-N-[2-fe^-butyl-1-(tetrahydro-2ir-pyran-4-ylmethyl)-lH^r- benziraidazol-5-yl]-N-methylazetidine-1-sulfonamide

To a solution of 1-{[[2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H- benzimidazol-5-yl](methyl)amino]sulfonyl}-3-methyl-1H-imidazol-3-ium (2.2 g, 4.9 mmol, see Example 10, Steps B-I for its preparation) and diisopropylethylamine (2.6 mL, 14.7 mmol) at rt in MeCN (30 mL), was added 3-N-Boc-ammo-azetidine (1.0 g, 5.9 mmol). The solution was stirred at rt overnight. After evaporation of the solvent, the residue was purified by flash chromatography (0-100% EtOAc in hexanes, 50 min; 100% EtOAc 10 min; 0-2% MeOH in EtOAc, 10 min) to provide the title compound (0.95 g, 36%). ¹H NMR (400 MHz, CD₃OD) δ 1.40 (s, 9 H) 1.49 - 1.65 (m, 5 H) 1.68 (s, 9 H) 2.30 - 2.45 (m, 1 H) 3.32 (s, 3 H) 3.33 - 3.39 (m, 2 H) 3.75 - 3.81 (m, 2 H) 3.89 - 4.00 (m, 4 H) 4.53 (d, J=7.62 Hz, 2 H) 7.65 (dd, J=8.98, 2.15 Hz, 1 H) 7.78 (d, J=2.15 Hz, 1 H) 7.95 (d, J=8.98 Hz, 1 H); MS (ESI) (M+H)⁺ 535.8; Anal. (C, H, N) calcd for C₂₆H₄₁N₅O5S+2.10CF₃COOH+0.60H₂O+0.45CH₃CN: C 46.44, H 5.72, N 9.49; found C 46.42, H 5.73, N 9.51.

Step C. 3-Amino-iV- [2-tert-butyl-1-(tetrahydro-2_JH^r-pyran-4-ylmethyl)-1H- benzimidazol-5-yl]-N-methylazetidine-l -sulfonamide

To a solution of terf-butyl (l-ltP-terf-butyl-1-Ctetrahydro^H-pyran^-ylmethyl)-!!/- benzimidazol-5-yl](methyl)amino]sulfonyl}azetidin-3-yl)carbamate (0.95 g, 1.77 mmol, see Step B for its preparation) at O⁰C in DCM (6 mL), was added TFA (6 mL, excess) dropwise. The solution was stirred at O⁰C for 20 min. The solution was concentrated. The residue was redissolved in DCM, washed with IN NaOH (x2), the aqueous layers were extracted with DCM (x4), the combined organic layers were dried over Na₂SO₄, and subjected to filtration. Evaporation of the solvent provided the title compound (778 mg, 100%). MS (ESI) (M+H)⁺ 436.1.

Example 30

N-(1-{[[2-tert-Butyl-1-(tetrahydro-2_JH^r-pyran-4-yImethyl)-lfl^r-benzimidazol-5- yl] (methyl)amino] sulf onyl} azetidm-3-yl)-2-methylpr op anamide

To a solution of 3-amino-N-[2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H- benzimidazol-5-yl]-N-methylazetidine-1-sulfonamide (150 mg, 0.27 mmol, see Example 29, Steps B and C for its preparation) and diisopropylethylamine (0.1 mL, 0.57 mmol) in DCM (3 mL) at O⁰C, was added isobutyryl chloride (0.06 mL, 0.57 mmol) dropwise. The solution was stirred at room temperature for 1.5 hours. After evaporation of the solvent, the residue was purified by reversed-phase ΗPLC (10-60% CH₃CN in H₂O) to provide the title compound as its TFA salt (21.7 mg, 15%). ¹H NMR (400 MHz, CD₃OD) δ 1.07 (d, J=7.03 Hz, 6 H) 1.49 - 1.67 (m, 5 H) 1.68 (s, 9 H) 2.32 - 2.46 (m, 2 H) 3.30 - 3.39 (m, 5 H) 3.78 - 3.84 (m, 2 H) 3.90 - 3.97 (m, 2 H) 3.99 - 4.05 (m, 2 H) 4.53 (d, J=7.42 Hz, 2 H) 7.65 (dd, J=8.98, 1.95 Hz, 1 H) 7.78 (d, J=I.95 Hz, 1 H) 7.95 (d, J=8.98 Hz, 1 H); MS (ESI) (M+H)⁺ 505.8; Anal. (C, H, N) calcd for C₂₅H₃₉N₅O₄S+!.60CF₃COOH+0.35CH₃CN: C 49.41, H 5.98, N 10.67; found C 49.55, H 5.84, N 10.61.

Example 31

A^r-(1-{[[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-lH^r-benzimidazol-5- yl](methyl)amino]sulfonyl}azetidin-3-yl)cyclobutanecarboxamide

Following the procedure for Step A in Example 30, using 3-amino-N-[2-tert-butyl-1- (tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-N-methylazetidine- 1 - sulfonamide (100 mg, 0.23 mmol), diisopropylethylamine (0.1 mL, 0.57 mmol), DCM (3 mL), and cyclobutane carbonyl chloride (0.07 mL, 0.57 mmol) provided the title compound as its TFA salt (11.8 mg, 8 %) following purification by reversed- phase ΗPLC (10-60% CH₃CN in H₂O). ¹H NMR (400 MHz, CD₃OD) δ 1.26 - 1.32 (m, 1 H) 1.49 - 1.66 (m, 5 H) 1.68 (s, 9 H) 1.78 - 1.88 (m, 1 H) 1.92 - 2.01 (m, 1 H) 2.04 - 2.24 (m, 4 H) 3.32 (s, 3 H) 3.33 - 3.40 (m, 2 H) 3.78 - 3.84 (m, 2 H) 3.90 - 3.98 (m, 2 H) 3.99 - 4.05 (m, 2 H) 4.47 - 4.56 (m 3 H) 7.64 (dd, J=9.08, 2.05 Hz, 1 H) 7.77 (d, J=2.05 Hz, 1 H) 7.94 (d, J=9.08 Hz, 1 H); MS (ESI) (M+H)⁺ 517.8.

Example 32 N-(1-{[[2-tert-Butyl-1-(tetrahydro-2i?-pyran-4-ylmethyl)-l_Jfir-benzimidazol-5- yl](methyl)amino]sulfonyl}azetidin-3-yl)butanamide

Following the procedure for Step A in Example 30, using 3-amino-N-[2-?ert-butyl-1- (tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5--yl]-N-methylazetidine-1- sulfonamide (100 mg, 0.23 mmol), diisopropylethylamine (0.1 mL, 0.57 mmol), DCM (3 mL), and butyryl chloride (0.06 mL, 0.57 mmol) provided the title compound as its TFA salt (11.8 mg, 8 %) following purification by reversed-phase HPLC (10-60% CH₃CN in H₂O). ¹H NMR (400 MHz, CD₃OD) δ 0.90 (t, J=7.42 Hz, 3 H) 1.50 - 1.66 (m, 7 H) 1.68 (s, 9 H) 2.14 (t, J=7.42 Hz, 2 H) 2.31 - 2.44 (m, 1 H) 3.32 (s, 3 H) 3.33 - 3.39 (m, 2 H) 3.78 - 3.84 (m, 2 H) 3.90 - 3.97 (m, 2 H) 4.00 - 4.05 (m, 2 H) 4.53 (d, J=7.62 Hz, 2 H) 7.65 (dd, J=8.98, 1.95 Hz, 1 H) 7.78 (d, J=1.95 Hz, 1 H) 7.95 (d, J=8.98 Hz, 1 H); MS (ESI) (M+H)⁺ 505.8; Anal. (C, H, N) calcd for C₂₅H₃₉N₅O₄S+1.75CF₃COOH+0.20H₂O+0.10CH₃CN: C 48.35, H 5.86, N 10.02; found C 48.33, H 5.86, N 10.01.

Example 33 N-(1-{[[2-fer^-Butyl-1-(tetrahydro-2_J&-pyran-4-ylmethyl)-1H-benzimidazol-5- yl] (methyl)amino] sulfonyl} azetidin-3-yl)propanamide

Following the procedure for Step A in Example 29, using 3-amino-N-[2-tert-butyl-1- (tetrahydro-2H-pyran-4-ylmethyl)-ljy^r-benzimidazol-5-yl]-N-methylazetidine-1- sulfonamide (150 mg, 0.27 mmol), diisopropylethylamine (0.14 mL, 0.82 mmol), DMF (1.5 mL), propionic acid (0.031 mL, 0.41 mmol) and HATU (125.5 mg, 0.33 mmol) provided the title compound as its TFA salt (15.5 mg, 9.5 %) following purification by reversed-phase HPLC (10-40% CH₃CN in H₂O). ¹H NMR (400 MHz, CD₃OD) δ 1.13 (t, J=7.62 Hz, 3 H) 1.51 - 1.72 (m, 5 H) 1.74 (s, 9 H) 2.28 (q, J=7.62 Hz, 2 H) 3.31 (s, 3 H) 3.32 - 3.40 (m, 2 H) 3.71 - 3.77 (m, 2 H) 4.00 - 4.07 (m, 2 H) 4.30 - 4.40 (m, 4 H) 4.64 - 4.75 (m, 1 H) 7.50 - 7.54 (m, 1 H) 7.57 - 7.61 (m, 1 H) 8.26 - 8.31 (m, 1 H) 8.34 (d, J=I .37 Hz, 1 H); MS (ESI) (M+H)⁺ 491.8.

Example 34

Methyl l-{ [ [2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl] (methyl)amino] sulf onyl} azetidine-3-carboxylate

Step A. Methyl 1-{[[2-tert-butyl-1-(tetrahydro-2N-pyran-4-ylmethyl)-1H- benzimidazol-5-yl](methyl)amino]sulfonyl} azetidine-3-carboxylate

To a solution of 1 - { [[2-tert-hutyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)- IH- benzimidazol-5-yl](methyl)amino]sulfonyl}-3-methyl-1H-imidazol-3-iuni (100 nig, 0.17 mmol, see Example 10, Steps B-I for its preparation) and diisopropylethylamine (0.12 mL, 0.68 mmol) at rt in MeCN (0.8 mL), was added methyl azetidine-3- carboxylate hydrochloride (51.5 mg, 0.34 mmol). The solution was stirred at rt overnight. After evaporation of the solvent, the residue was purified by flash chromatography (0-100% EtOAc in hexanes, 50 min; 100% EtOAc 10 min; 0-2% MeOH in EtOAc, 10 min) to provide the title compound (7.8 mg, 8%). ¹H NMR (400 MHz, CD₃OD) δ 1.50 - 1.55 (m, 5 H) 1.56 (s, 9 H) 2.23 - 2.36 (m, 1 H) 3.29 (s, 3 H) 3.30 - 3.42 (m, 2 H) 3.75 (s, 3 H) 3.95 - 4.08 (m, 4 H) 4.10 - 4.23 (m, 4 H) 7.28 - 7.31 (m, 2 H) 7.71 - 7.74 (m, 1 H); MS (ESI) (M+H)⁺ 478.8.

Step B. Methyl azetidine-3-carboxylate hydrochloride

To a stirring suspension of 3-azetidine carboxylic acid in MeOH at O⁰C₃ was added SOCl₂ dropwise. After 20 minutes, the ice bath was removed, the solution was warmed to rt and was stirred for 2 hours. The solvent was removed in vaccuo to afford the title compound as its HCl salt (1.5g, 100%). ¹H NMR (400 MHz, CD₃OD) δ 3.71 - 3.77 (m, 1 H) 3.77 (s, 3 H) 4.18 - 4.31 (m, 4 H).

Example 35 N-tZKljl-Dimethylethy^-1-I^etrahydro-aH-pyran^-yOmethylJ-1H- benzimidazol-S-yyhexahydro-N-methyl-1H-azepme-1-sulfonamide

Step A. N-[2-(l,l-Dimethylethyl)-1-[(tetrahydro-2J7-pyran-4-yl)methyl]-llT- benzimidazol-5-yl]hexahydro-N-methyl-lii^r-azepine-l -sulfonamide

To a solution of 1-{[[2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H- benzimidazol-5-yl](methyl)amino]sulfonyl}-3-methyl-1H-imidazol-3-ium (100 mg, 0.22 mmol, see Example 10, Steps B-I for its preparation) and diisopropylethylamine (0.045 mL, 0.26 mmol) at rt in DMF (1.2 mL), was added hexamethyleneimine (0.025 niL, 0.22 mmol). The solution was stirred at 8O⁰C for 1 hour. After evaporation of the solvent, the residue was purified by reversed-phase HPLC (20-50% MeCN in H₂O) to provide the title compound as its TFA salt (23 mg, 18%). ¹H NMR (400 MHz, CDCl₃) δ 1.54-1.61 (m, 8 H), 1.71 (m, 13 H), 2.27-2.35 (m, 1 H), 3.26 (s, 3 H), 3.30- 3.37 (m, 6 H), 4.01-4.03 (m, 2 H), 4.34 (d, J=7.42 Hz, 2 H), 7.48 (d, J=8.96 Hz, 1 H), 7.68 (dd, J=8.96, 1.79 Hz, 1 H), 7.88 (d, J=I.79 Hz, 1 H); MS (ESI) (M+H)⁺ 463.0; Anal. (C, H, N) calcd for C₂₄H₃₈N₄O₃SH-1.30CF₃COOH+1.10H₂O: C 50.66, H 6.63, N 8.88;. found C 50.64, H 6.59, N 8.92.

Example 36 N-[2-(l,l-Dimethylethyl)-1-[(tetrahydro-2iϊ-pyran-4-yl)methyl]-l_JEr- benzimidazol-5-yl]-N,4-dimethyl-1-piperidinesulfonamide

To a solution of 1-{[[2-tert-butyl-1-(tetrahydro-2K-pyran-4-ylmethyl)-1H- benzimidazol-5-yl](methyl)amino]sulfonyl}-3-methyl-li-^'-imidazol-3-ium (100 mg, 0.22 mmol, see Example 10, Steps B-I for its preparation) and diisopropylethylamine (0.045 mL, 0.26 mmol) at rt in DMF (1.0 mL), was added 4-methylpiperidine (0.026 mL, 0.22 mmol). The solution was stirred at 8O⁰C for 1.5 hours. After evaporation of the solvent, the residue was purified by reversed-phase HPLC (20-50% MeCN in H₂O) to provide the title compound as its TFA salt (27.3 mg, 22%). ¹H NMR (600 MHz, CDCl₃) δ 0.93 (d, J=6.67 Hz, 3 H), 1.17-1.25 (m, 2 H), 1.46-1.66(m, 7 H), 1.71 (s, 9 H), 2.27-2.35 (m, 1 H), 2.79-2.83 (m, 2 H), 3.29 (s, 3 H), 3.33-3.37 (m, 2 H), 3.65-3.67 (m, 2 H), 4.02-4.03 (m, 2 H), 4.34-4.35 (d, 2 H), 7.49 (d, J=8.96 Hz, 1 H), 7.67 (d, J=8.96 Hz, 1 H), 7.91 (s, 1 H); MS (ESI) (M+H)⁺ 463.0; Anal. (C, H, N) calcd for C₂₄H₃₈N₄O₃S+! .40CF₃COOH+0.30H₂O: C 51.28, H 6.42, N 8.93; found C 51.36, H 6.34, N 8.79. Example 37 N-IZ-Cl^-DimethylethyO-1-lCtetrahydro^H-pyran^-yl)methyll-1H- benzimidazol-5-yl]-3-(hydroxymethyl)-N-methyl-1-piperidinesulfonamide

To a solution of 1 - { [[2-tert-butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)- IH- benzimidazol-5-yl](methyl)amino]sulfonyl}-3-methyl-1H-imidazol-3-ium (100 mg, 0.22 mmol, see Example 10, Steps B-I for its preparation) and diisopropylethylamine (0.045 mL, 0.26 mmol) at rt in DMF (1.0 mL), was added 3-piperidine methanol (25.3 mg, 0.22 mmol). The solution was stirred at 8O⁰C for 1.5 hours. After evaporation of the solvent, the residue was purified by reversed-phase ΗPLC (10-90% MeCN in H₂O) to provide the title compound as its TFA salt (24.3 mg, 19%). ¹H NMR (600 MHz, CDCl₃) δ 1.04-1.10 (m, 1 H), 1.52-1.61 (m, 5 H), 1.71 (m, 12 H), 1.79-1.87 (m, 1 H), 2.28-2.35 (m, 1 H), 2.59-2.62 (m, 1 H), 2.87-2.90 (m, 1 H), 3.31 (s, 3 H), 3.32- 3.38 (m, 3 H), 3.60-3.65 (m, 3 H), 4.02-4.04 (m, 2 H), 4.36 (d, J=7.42 Hz, 2 H), 7.50 (d, J=8.70 Hz, 1 H), 7.67 (d, J=8.70 Hz, 1 H), 8.07 (s, 1 H); MS (ESI) (M+H)⁺ 479.0; Anal. (C, H, N) calcd for C₂₄H₃₈N₄O₄S+1.30CF₃COOH+0.90H₂O +0.20CH₃OH: C 49.56, H 6.50, N 8.63; found C 49.53, H 6.48, N 8.58.

Example 38 N-[2-(l,l-Dimethylethyl)-1-[(tetrahydro-2J9^r-pyran-4-yl)methyl]-1H- benzimidazol-5-yl]-4-hydroxy-N-methyl-1-piperidinesulfonamide

To a solution of 1-{[[2-tert-butyl-1-(tetrahydro-2ijr-pyran-4-ylmethyl)-1H- benzimidazol-5 -yl] (methy l)amino] sulfonyl} -3 -methyl- 1H-imidazol-3 -ium (100 mg, 0.22 mmol, see Example 10, Steps B-I for its preparation) and diisopropylethylamine (0.045 mL, 0.26 mmol) at rt in DMF (1.0 mL), was added 4-hydroxypiperidine (22.3 mg, 0.22 mmol). The solution was stirred at 8O⁰C for 1.5 hours. After evaporation of the solvent, the residue was purified by reversed-phase HPLC (10-95% MeCN in H₂O) to provide the title compound as its TFA salt (18.9 mg, 15%). ¹HNMR (600 MHz, CDCl₃) δ 1.54-1.65 (m, 6 H), 1.72 (s, 9 H)₅ 1.86-1.90 (m, 2 H)₃ 2.28-2.36 (m, 1 H), 3.07-3.11 (m, 2 H), 3.33 (s, 3 H), 3.33-3.38 (m, 2 H), 3.48-3.52 (m, 2 H), 3.79- 3.82 (m, 1 H), 4.02-4.04 (m, 2 H), 4.36 (d, J=7.42 Hz, 2 H), 7.51 (d, J=8.96 Hz, 1 H), 7.68 (dd, J=8.96, 1.66 Hz, 1 H), 8.07 (d, J=I.66 Hz, 1 H); MS (ESI) (M+H)⁺ 465.0; Anal. (C, H, N) calcd for C₂₃H₃₆N₄O₄S+1.10CF₃COOH+0.30H₂O +0.40CH₃OH: C 50.55, H 6.51, N 9.21; found C 50.53, H 6.50, N 9.19.

Example 39

^-^-(ljl-Dimethylethy^-1-f^etrahydro^H-pyran^-yOmethyll-1H- benzimidazol-5-yl]-4-methoxy-N-methyl-1-piperidinesulfonaniide

To a solution of 1-{[[2-tert-butyl-1-(tetrahydro-2/f-pyran-4-ylmethyl)-1H- benzimidazol-5-yl](methyl)amino]sulfonyl}-3-methyl-1H-imidazol-3-ium (100 mg, 0.22 mmol, see Example 10, Steps B-I for its preparation) and diisopropylethylamine (0.090 mL, 0.53 mmol) at rt in DMF (1.0 mL), was added 4-methoxypiperidine hydrochloride (25.3 mg, 0.22 mmol). The solution was stirred at 8O⁰C for 1 hour. After evaporation of the solvent, the residue was purified by reversed-phase HPLC (20-50% MeCN in H₂O) to provide the title compound as its TFA salt (6.74 mg, 5%). MS (ESI) (M+H)⁺ 479.0. Example 40

N-[2-(l,l-Dimethylethyl)-1-[(tetrahydro-2H-pyran-4-yl)methyl]-1H- benzimidazol-5-yl]-3-hydroxy-N-methyl-1-piperidinesulfonamide

To a solution of 1-{[[2-tert-butyl-1-(tetrahydro-2/i^'-pyran-4-ylmethyl)-1H- benzimidazol-5 -yl] (methyl)aniino] sulf onyl} -3 -methyl- l/i-imidazol-3 -ium ( 100 mg, 0.22 mmol, see Example 10, Steps B-I for its preparation) and diisopropylethylamine (0.090 mL, 0.53 mmol) at rt in DMF (1.0 mL), was added 3-hydroxypiperidine (22.3 mg, 0.22 mmol). The solution was stirred at 8O⁰C for 1 hour. After evaporation of the solvent, the residue was purified by reversed-phase HPLC (10-90% MeCN in H₂O) to provide the title compound as its TFA salt (16.0 mg, 13%). MS (ESI) (M+H)⁺ 465.0.

Example 41 N-[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-N- methylazetidine-1 -sulfonamide

To a solution of 1-{[[2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H- benzimidazol-5-yl](methyl)amino]sulfonyl} -3-methyl-1H-imidazol-3-ium triflate in acetonitrile (2.8 mL, 0.344 mmol) (for preparation, see Example 2, Step G) was added azetidine (35 μL; 0.516 mmol). The reaction mixture was stirred at room temperature overnight, then Hunig's base (72 μL; 0.413 mmol) was added and the reaction mixture stirred at room temperature for another day. The reaction mixture was concentrated under reduced pressure. The residue was taken in ethyl acetate and washed with IN hydrochloric acid, 2N sodium hydroxide, brine and water. The aqueous layers were combined and extracted with ethyl acetate. Organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure. Purification by reverse phase chromatography provided the title compound (14.5 mg, 10 %). ¹H NMR (600 MHz, CD₃OD) δ 1.40-1.53 (m, 4H), 1.57 (s, 9H), 2.14 (q, J= 7.68Hz, 2H), 2.23-2.33 (m, 1H), 3.22 (s, 3H), 3.25 (m, 2H), 3.80 (t, J= 7.68Hz, 4H), 3.84 (dd, J= 11.26, 3.58Hz, 2H), 4.41 (d, J= 7.42Hz, 2H), 7.51 (d, J= 8.70Hz, 1H), 7.67 (d, J= 1.79Hz, 1H), 7.80 (d, J= 8.45Hz, 1H); MS (ESI) (M+H)⁺ 421.0

Example 42

N-[2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-4,4- difluoro-N-methylpiperidine-1 -sulfonamide

Following the procedure for Step A in Example 41, using 4,4-difluoropiperidine (63 mg; 0.516 mmol) and Hunig's base (72 μL; 0.413 mmol) provided the title compound (68.4 mg; 41%). ¹H NMR (600 MHz, CD₃OD) δ 1.42-1.57 (m, 4H), 1.60 (s, 9H), 1.90 (m, 4H), 2.26-2.34 (br s, 1H), 3.24 (s, 3H), 3.25-3.34 (m, 6H), 3.84 (dd, J= 10.75, 2.56Hz, 2H), 4.46 (d, J= 6.91Hz, 2H), 7.60 (d, J= 8.19Hz, 1H), 7.76 (s, 1H), 7.90 (d, J= 8.70Hz, 1H); MS (ESI) (M+H)⁺ 485.0

Example 43

N-[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-3,3- difluoro-N-methylpy r rolidine-1-sulf onamide

Following the procedure for Step A in Example 41, using 3,3-difluoropyrrolidine (55 mg; 0.516 mmol) and Hunig's base (72 μL; 0.413 mmol) provided the title compound (40.0 mg; 24%). ¹HNMR (600 MHz, CD₃OD) δ 1.40-1.55 (m, 4H), 1.59 (s, 9H), 2.22-2.37 (m, 3H), 3.21-3.31 (m, 2H), 3.25 (s, 3H), 3.44 (t, J= 7.17Hz, 2H), 3.52 (t, J = 12.80Hz, 2H), 3.84 (m, 2H), 4.45 (d, J= 7.17Hz, 2H), 7.59 (d, J= 7.94Hz, 1H), 7.74 (s, 1H), 7.89 (d, J= 8.70Hz, 1H); MS (ESI) (M+H)+ 471.0

Example 44 Methyl 1-{[[2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol- 5-yl](methyl)amino]sulfonyl}piperidine-4-carboxylate

Following the procedure for Step A in Example 41, using methyl isonipecotate (70 μL; 0.516 mmol) and Hunig's base (72 μL; 0.413 mmol) provided the title compound (71.5 mg; 41%). ¹HNMR (600 MHz, CD₃OD) δ 1.37-1.55 (m, 6H), 1.59 (s, 9H)₃ 1.78 (m, 2H), 2.24-2.33 (br. s, 1H), 2.38 (m, 1H), 2.82 (m, 2H), 3.17-3.30 (m, 2H), 3.22 (s, 3H), 3.47-3.61 (m, 2H), 3.54 (s, 3H), 3.83 (d, J= 8.45Hz, 2H), 4.45 (d, J= 7.17Hz, 2H), 7.57 (d, J= 7.94Hz, 1H), 7.75 (s, 1H), 7.87 (d, J= 8.45Hz, 1H); MS (ESI) (M+H)+ 507.0

Example 45

N-[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-N- methylisoxazolidine-2-sulfonamide

Following the procedure for Step A in Example 41, using isoxazolidine (57 mg; 0.516 mmol) and Hunig's base (132 μL; 0.757 mmol) provided the title compound (51.3 mg; 34%). ¹H NMR (600 MHz, CD₃OD) δ 1.43-1.56 (m, 4H), 1.60 (s, 9H), 2.22-2.35 (m, 3H), 3.26 (m, 2H), 3.37 (s, 3H), 3.47 (t, J= 7.17Hz, 2H), 3.85 (m, 2H), 4.03 (t, J = 7.30Hz, 2H), 4.46 (d, J= 7.17Hz, 2H), 7.63 (dd, J= 8.70, 1.02Hz, 1H), 7.80-7.84 (d, J= 1.28Hz, 1H), 7.88 (d, J= 8.96Hz, 1H); MS (ESI) (M+H)+ 437.0

Example 46 (4R)-N-[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl]-4-hydroxy-N,4-dimethylisoxazolidine-2-sulfonamide

Following the procedure for Step A in Example 41, using 4-methylisoxazolidin-4-ol (57 mg; 0.41 mmol) and Hunig's base (57 μL; 0.33 mmol) provided the title compound. ¹H NMR (600 MHz, CD₃OD) δ 1.35 (s, 3H), 1.41-1.55 (m, 4H), 1.57 (s, 9H), 2.22-2.33 (m, 1H), 3.19 (s, 3H), 3.24 (m, 2H), 3.30-3.36 (m, 2H), 3.46 (d, J= 11.52Hz, 1H), 3.77-3.90 (m, 4H), 4.43 (d, J= 7.42Hz, 2H), 7.61 (d, J= 8.96Hz, 1H), 7.79 (s, 1H), 7.85 (d, J= 8.96Hz, 1H); MS (ESI) (M+H)+ 467.0

Example 47

N-(1-{[[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazoI-5- yl](methyl)amino]sulfonyl}piperidin-4-yl)acetamide

Step B. N-(l-{ [[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H- benziraidazol-5-yl](raethyl)amino]sulfonyl}piperidin-4-yl)acetamide

To a solution of 4-amino-N-[2-tert-butyl-1-(tetrahydro-2/i-pyran-4-ylmethyl)-1H- benzimidazol-5-yl]-N-methylpiperidine-1-sulfonamide in dichloromethane (0.516 mmol) (the preparation of it has followed the same procedure as for the synthesis of a compound in Example 1, Step J, by using 4-tetrahydropyranmethylamine as the coupling reagent for the SNAr reaction) was added triethylamine (143 μL; 1.032 mmol) followed by acethyl chloride (44 μL; 0.619 mmol). The reaction mixture was stirred at room temperature for two hours then was washed with water. The aqueous layer was extracted with dichloromethane. Combined dichloromethane extracts were dried over anhydrous magnesium sulphate, filtered and concentrated under reduced pressure. Purification by reverse phase chromatography provided the title compound (143.8 mg, 55%). ¹H NMR (600 MHz, CD₃OD) δ 1.29-1.40 (m, 2H), 1.40-1.54 (m, 4H), 1.58 (s, 9H), 1.74 (m, 2H), 1.81 (s, 3H), 2.27 (br s, 1H), 2.83 (m, 2H), 3.21 (s, 3H), 3.24 (m, 2H), 3.57 (m, 2H), 3.62 (t, J = 10.88Hz, 1H), 3.83 (dd, J = 11.52, 2.56Hz, 2H), 4.44 (d, J= 7.42Hz, 2H), 7.58 (d, J= 8.70Hz, 1H), 7.72 (s, 1H), 7.87 (d, J= 8.96Hz, 1H); MS (ESI) (M+H)+ 506.0

Example 48

N-(1-{[[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}piperidin-4-yl)-2,2-dimethylpropanamide

Following the procedure for Step B in Example 47, using trimethyl acetyl chloride (76 μL; 0.619 mmol) and triethylamine (143 μL; 1.032 mmol) provided the title compound (138.1 mg; 49%). ¹HNMR (600 MHz, CD₃OD) δ 1.04 (s, 9H), 1.37-1.53 (m, 6H), 1.55 (s, 9H), 1.68 (m, 2H), 2.21-2.32 (m, 1H), 2.77 (m, 2H), 3.20 (s, 3H), 3.24 (m, 2H), 3.57-3.67 (m, 3H), 3.83 (m, 2H), 4.38 (d, J= 7.42Hz, 2H), 7.48 (dd, J= 8.83, 1.41Hz, 1H), 7.68 (d, J= 1.54Hz, 1H), 7.75 (d, J= 8.96Hz, 1H); MS (ESI) (M+H)+ 548.0.

Example 49 tert-Butyl [l-({methyl[l-(tetrahydro-2fl-pyran-4-ylmethyl)-2-(trifluoromethyl)- lJϊ-benzimidazol-5-yl] amino}sulfonyl)piperidin-4-yl] carbamate

Step A. tert-Butyl [l-({methyl[l-(tetrahydro-2H-pyran-4-ylmethyl)-2- (trifluor omethyl)-1H-benzimidazol-5-yl] amino} sulfbnyl)piperidin-4- yl] carbamate

Following the procedure in Step I of Example I₃ 3 -methyl- l-({methyl[l -(tetrahydro- 2H-pyran-4-ylmethyl)-2-(trifluoromethyl)-1H-berizimidazol-5-yl]amino}sulfonyl)- 1H-imidazol-3-ium (crude product, 1.0 mmol) (see following steps B, C₃ D₃ E, F₃ G and H for preparation) was reacted with tert-butyl piperidin-4-ylcarbamate (0.40 g, 2.0 mmol). The crude product was purified by MPLC using Hex/EtOAc (1:1) on silica gel to give 0.33 g (55%) of a white solid as the title compound. ¹HNMR (400 MHz, CHLOROFORM-D): δ 1.41 (s, 9 H), 1.44 - 1.54 (m, 4 H), 1.77 - 1.93 (m, 3 H), 2.20 - 2.33 (m, 1 H), 2.83 - 2.97 (m, 3 H), 3.29 (s, 3 H), 3.32 - 3.44 (m, 3 H), 3.57 - 3.69 (m, 3 H), 3.88 - 3.97 (m, 2 H), 4.33 (d, J=7.42 Hz, 2 H), 7.58 (dd, J=8.79, 1.95 Hz, 1 H), 7.78 (d, J=8.79 Hz, 1 H), 7.85 (d, J=2.15 Hz, 1 H). MS (ESI) (M+H)⁺ = 576.0. Anal. Calcd for C₂₅H₃₆F₃N₅O₅S+ 0.10 TFA+0.10 H₂O+0.40 CH₃OH(624.10): C, 51.58; H, 6.38; N, 11.22; Found: C, 51.56; H, 6.31; N, 11.27.

Step B. N-(4-Fluoro-3-nitrophenyl)acetamide

4-Fluoro-3-nitro-aniline (45.0 g, 0.288 mol) was added in portions to acetic anhydride (150 mL) at room temperature. The reaction mixture was stirred at room temperature for 2 h. The white solid was collected and dried in vacuo to give the title compound (42.0 g, 70%). ¹H NMR (400 MHz, CHLOROFORM-D): δ 2.23. (s, 3 H), 7.26 (m, 1 H), 7.50 (s broad, 1 H), 7.87 (m, 1 H), 8.23 (dd, J=6.44, 2.73 Hz, 1 H).

Step C. N-(4-Fluoro-3-nitrophenyl)-N-methylacetamide

Sodium hydride (4.22 g, 60%, 106 mmol) was added portionwise to a solution of N- (4-fluoro-3-nitrophenyl)acetamide(13.9 g, 70 mmol) (for preparation, see the step B in Example 1) in THF (200 mL) at 0 ⁰C. Stirring for 20 min, iodomethane (18.5 g, 130 mmol) was added. The reaction mixture was stirred at room temperature for 2 h, quenched with saturaed NaHCO₃ (30 mL) and extracted with EtOAc (3x100 mL). The combined organic phases were washed with saturated NaCl (2x50 mL). After filtration and concentration, 13.1 g (88%) of the title compound was obtained as a yellow solid. ¹H NMR (400 MHz, CHLOROFORM-D): δ 1.92 (s, 3 H), 3.30 (s, 3 H), 7.38 (s, 1 H), 7.52 (s, 1 H), 7.95 (s, 1 H). Step D. N-Methyl-N-{3-nitro-4-[(tetrahydro-2J5r-pyran-4- ylmethyl)amino] phenyl} acetamide

4-Aminomethyltetrahydropyran (10.0 g, 86.5 mmol ) was added to a mixture of N-(4- fluoro-3-nitrophenyl)-N-methylacetarnide (15.6 g, 73.3 mmol) and TEA (15.3 mL, 11.1 g, 110 mmol) in EtOH (300 mL) at room temperature. The reaction mixture was heated for 6 h at reflux. Upon evaporation of ethanol, the residue was dissolved in EtOAc (400 mL), washed with H₂O (3x50 mL), saturated NaCl (3x50 mL), and dried over Na₂SO₄. After filtation and concentration, 21.7 g (96%) of the title compound was obtained as an orange-red solid. ¹H NMR (400 MHz, CHLOROFORM-D)_: δ 1.38 - 1.52 (m, 2 H), 1.72 - 1.81 (m, 2 H), 1.90 (s, 3 H), 1.93 - 2.02 (m, 1 H), 3.23 (s, 3 H), 3.23 - 3.27 (m, 2 H), 3.36 - 3.49 (m, 2 H), 4.01 - 4.07 (m, 2 H), 6.91 (d, J=9.18 Hz, 1 H), 7.29 (dd, J=9.08, 2.64 Hz, 1 H), 8.05 (d, J=2.34 Hz, 1 H), 8.22 (t, J=5.37 Hz, 1 H). MS (ESI) (M+H)⁺ = 309.12.

Step E. N-{3-Amino-4-[(tetrahydro-2jH^r-pyran-4-ylmethyl)ainino]phenyl}-N- methylacetamide

N-Methyl-N- {3-nitro-4-[(tetrahydro-2H-pyran-4-yltnethyl)amino]phenyl} acetamide (21.7 g, 70.5 mmol) was hydrogenated in ethyl acetate (500 mL) catalyzed by 10% Pd/C (1.0 g) at 30-40 psi H₂ in Parr shaker for 18 h at room temperature. After filtration through celite and concentration, 19.6 g (100%) of a purple solid was obtained. ¹H NMR (400 MHz, CHLOROFORM-D): δ 1.35 - 1.50 (m, 2 H), 1.67 (s, 1 H), 1.73 - 1.81 (m, 2 H), 1.88 (s, 3 H)₅ 1.88 - 1.99 (m, 1 H), 3.04 (d, J=6.64 Hz, 2 H), 3.20 (s, 3 H), 3.33 - 3.48 (m, 4 H), 3.97 - 4.08 (m, 2 H), 6.54 (d, J=I.76 Hz, 1 H), 6.60 - 6.63 (m, 2 H); MS (ESI) (M+H)⁺ = 278.7

Step F. N-Methyl-N-[l-(tetrahydro-2H-pyran-4-yImethyl)-2-(trifluoromethyl)- liZ-benziπiidazol-5-yl] acetamide

A solution of Λ^L{3-amino-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}-N- methylacetamide hydrochoride (2.77 g, 10 mmol) in trifluoroacetic acid (60 mL) was heated to reflux for 18 h. After evaporation of the solvent, the residue was disolved in EtOAc (200 mL), washed with 2JVNaOH (2x10 mL) and dried over Na₂SO₄. The crude product was purified by MPLC using EtOAc on silica gel to give 3.18 g (90%) of a white solid as the title compound. MS (ESI) (M+H)⁺ = 356.02.

Step G. N-Methyl-1-Ctetrahydro-ljEr-pyran^-ylmethyl)-1-Ctrifluoromethy^-lJΪ- benzimidazol-5-amine

N-Methyl-N-[l-(tetrahydro-2H-pyran-4-ylme%l)-2-(1xiiluorome%l)-1H- benzimidazol-5-yl]acetamide (3.18 g, 8.95 mmol) was dissolved in hydrochloric acid (37%, 60 mL) and then heated overnight at 95⁰C. After concentration, the residue was treated with 20 mL of 2JVNaOH, extracted with EtOAc (4x50 mL). The combined organic phaese were washed with brine (20 mL) and dried over Na₂SO₄. After evaporation, 2.80 g (100%) of a purple white solid was obtained as the title product, which was used directly for Step H. MS (ESI) (M+H)⁺ = 314.20. Step H. 3-Methyl-1-({methyl[l-(tetrahydro-2H-pyran-4-yImethyl)-2- (trifluoromethyl)-lJ3-benziinidazoI-5-yl]amino}sulfonyl)-1H-imidazol-3-ium.

Following the procedure in Step H of Example 1, N-methyl-1-(tetrahydro-2H-pyran- 4-ylmethyl)-2-(trifluoromethyl)-1H-benzimidazol-5-amme (0.32 g, 1.0 mmol) was converted to 3 -methyl- 1 -( {methyl[l -(tetrahydro-2H-pyran-4-ylmethyl)-2- (trifluoromethyl)- l#-benzimidazol-5-yl]amino} sulfonyl)- li7-imidazol-3-ium, which was used in Step A without any purification.

Example 50 tert-Butyl 4-({methym-(tetrahydro-2H-pyran-4-ylmethyl)-2-(trifluoromethyl)- liϊ-benziinidazol-5-yl]amino}sulfonyl)piperazine-1-carboxylate

Following the procedure in Step I of Example 1, 3 -methyl- l-({methyl[l -(tetrahydro- 2H-pyran-4-ylmethyl)-2-(trifluoromethyl)- li7-benzimidazol-5-yl]amino } sulfonyl)- 1H-imidazol-3-ium (crude product, 1.10 mmol) (for preparation see the step H in example 4) was reacted with tert-buty\ piperazine-1-carboxylate (0.38 g, 2.0 mmol). The.crude product was purified by MPLC using Hex/EtOAc (1:1) on silica gel to give 0.28 g (45%) of a white solid as the title compound. ¹HNMR (400 MHz, CHLOROFORM-D): δ 1.43 (s, 9 H), 1.45 - 1.54 (m, 4 H), 2.19 - 2.33 (m, 1 H), 3.15 - 3.22 (m, 4 H), 3.32 (s, 3 H)₅ 3.33 - 3.37 (m, 2 H), 3.38 - 3.45 (m, 4 H), 3.87 - 3.97 (m, 2 H)₃ 4.33 (d, J=7.62 Hz, 2 H), 7.60 (dd, J=8.89, 2.05 Hz, 1 H), 7.79 (d, J=8.59 Hz, 1 H), 7.87 (d, J=I.76 Hz, 1 H); MS (ESI) (M+H)⁺ = 562.0; Anal. Calcd for C24H34F3N5O5S+0.70 EtOAc(623.30): C, 51.64; H, 6.40; N, 11.24; Found: C, 51.60; H, 5.80; N, 11.13.

Example 51

4-{[(Cyclopropylamino)carbonyl]amino}-N-methyl-N-[l-(tetrahydro-2H^r-pyran-

4-ylmethyl)-2-(trifluoromethyl)-lJΪ-benzimidazol-5-yl]piperidine-1-sulfonamide

Step A. 4-{[(CycIopropylamino)carbonyl]amino}-Λ'-methyl-N-[l-(tetrahydro-2H- pyran-4-ylmethyl)-2-(trifluoromethyl)-1H-benzimidazol-5-yl]piperidine-1- sulfonamide

A solution of isocyanatocyclopropane in THF (1 mmol) (freshly prepared from cyclopropylamine and triphosgene) was added to a solution of 4-ammo~N-methyl--V- [ 1 -(tetrahydro-27f-pyran-4-ylmethyl)-2-(trifluoromethyl)- 1H-benzimidazol-5- yl]piperidine-l -sulfonamide (38 mg, 0.08 mmol) (see following step B for preparation) in THF (3 mL) at room temperature. The mixture was stirred for 1 h. After evaporation, the crude product was purified by MPLC using EtOAc/MeOH (20:1) on silica gel to give 45 mg (100%) of a white solid as the title compound. ¹HNMR (400 MHz, METHANOL-D₄): δ 0.34 - 0.47 (m, 2 H), 0.59 - 0.71 (m, 2 H), 1.33 - 1.53 (m, 6 H), 1.77 - 1.87 (m, 2 H), 2.16 - 2.30 (m, 1 H), 2.36 - 2.46 (m, 1 H), 2.83 - 2.94 (m, 2 H), 3.28 (s, 3 H), 3.30 - 3.37 (m, 2 H), 3.51 - 3.59 (m, 1 H), 3.58 - 3.68 (m, 2 H), 3.82 - 3.95 (m, 2 H), 4.31 (d, J=7.62 Hz, 2 H), 7.57 (dd, J=8.89, 2.05 Hz, 1 H), 7.76 (d, J=8.98 Hz, 1 H), 7.83 (d, J=I .76 Hz, 1 H); MS (ESI) (M+H)⁺ = 559.0; Anal. Calcd for C₂₄H₃₃N₆O₄SF₃+0.60 TFA+ 0.30 H₂O + 0.10 CH3OH (635.65): C, 47.81; H, 5.49; N, 13.22; Found: C, 47.83; H, 5.45; N, 13.20.

Step B. 4-Amino-N-methyl-N-[l-(tetrahydro-2_JH^r-pyran-4-ylmethyl)-2- (trifluoromethyl)-1H-benziinidazol-5-yl]piperidine-1-sulfonamide

TFA (3 mL) was added to a solution of tert-butyl [l-({methyl[l-(tetrahydro-2H- pyran-4-ylmethyl)-2-(trifluoromethyl)-1H-benzimidazol-5- yl]amino}sulfonyl)piρeridin-4-yl]carbamate (210 mg, 0.365 mmol) in DCM (3 mL) at 0 ⁰C. The mixture was stirred for 1 h. Upon evaporation, the residue was dissolved in DCM (50 mL), washed with 2iVNaOH (2x5 mL), brine (5 mL) and dried over Na₂SO₄. After concentration, 168 mg (97%) of a white solid was obtained the title compound. MS (ESI) (M+H)⁺ = 475.99.

Example 52 N-CyclopropyI-4-({methyl[l-(tetrahydro-2_Jfir-pyran-4-ylmethyl)-2- (trifluoromethyl)-llϊ-benzimidazol-5-yl]amino}sulfonyl)piperazine-1- carboxamide

Step A. N-Cyclopropyl-4-({methyl[l-(tetrahydro-2H-pyran-4-ylmethyl)-2-

(trifluoromethy^-lH-benzimidazol-S-yyaminolsulfony^piperazine-1- carboxamide

Following the procedure in Step A of Example 51, using N-methyl-N-[l-(tetrahydro- 2H-pyran-4-ylmethyl)-2-(trifluoromethyl)-1H-benzimidazol-5-yl]piperazine-1- sulfonamide (38 mg, 0.083 mmol) (see following step B for preparation) and a solution of isocyanatocyclopropane in THF (1 mmol). The crude product was purified by MPLC using EtOAcMeOH (20: 1) on silica gel to give 45 mg (99%) of a white solid as the title compound. ¹HNMR (400 MHz, METHANOL-D₄): δ 0.39 - 0.44 (m, 2 H), 0.60 - 0.68 (m, 2 H), 1.44 - 1.47 (m, 4 H), 2.19 - 2.35 (m, 1 H), 2.47 - 2.55 (m, 1 H), 3.13 - 3.22 (m, 4 H), 3.32 (s, 3 H), 3.32 - 3.38 (m, 6 H), 3.86 - 3.99 (m, 2 H), 4.33 (d, J=7.81 Hz, 2 H), 7.59 (dd, J=8.89, 2.05 Hz, 1 H), 7.79 (d, J=8.98 Hz, 1 H), 7.86 (d, J=I.76 Hz, 1 H); MS (ESI) (M+H)⁺ = 545.0; Anal. Calcd for

C₂₃H₃iF₃N₆O₄S+0.70 TFA(624.42): C, 46.94; H, 5.12; N₅ 13.46; Found: C, 46.90; H, 4.65; N, 13.45.

Step B . N-Methyl-N-[l-(tetrahydro-2J3^r-pyran-4-ylmethyl)-2-(trifluoromethyl)- lJ?-benzimidazol-5-yl]piperazine-l-sulfonamide

Following the procedure in Step B of Example 51, tert-butyl 4-({methyl[l-

(tetrahydro-2i-r-pyran-4-ylmethyl)-2-(trifluoromethyl)-1H-benzimidazol-5- yl]amino}sulfonyl)piperazine-1-carboxylate (234 mg, 0.417 mmol) was treated with TFA (3 mL) in DCM (3 mL). 176 mg (91%) of a white solid was obtained as the title compound. MS (ESI) (M+H)⁺ = 461.96.

Example 53

4-{[(Isopropylamino)carbonyl]amino}-N-methyl-N-[l-(tetrahydro-2H-pyran-4- ylmethy^-1-^rifluoromethy^-lJΪ-benziraidazol-S-yypiperidine-1-sulfonamide

Following the procedure in Step A of Example 51, using 4-amino-N-methyl-N-[l- (tetrahy dro-2H^*-pyran-4-ylmethyl)-2-(trifluoromethyl)- lif-benzimidazol-5- yl]piperidine-l -sulfonamide (38 mg, 0.08 mmol) and 2-isocyanatopropane (0.2 mL) in THF (3 mL). The crude product was purified by MPLC using EtOAc/MeOH (20:1) on silica gel to give 38 mg (85%) of a white solid as the title compound. ¹HNMR (400 MHz, METHANOL-D₄): δ 1.07 (d, J=6.45 Hz, 6 H)₃ 1.29 - 1.40 (m, 2 H)₅ 1.40 - 1.53 (m, 4 H), 1.78 - 1.87 (m, 2 H), 2.17 - 2.31 (m, 1 H), 2.85 - 2.95 (m, 2 H), 3.28 (s, 3 H), 3.30 - 3.37 (m, 2 H), 3.48 - 3.56 (m, 1 H), 3.56 - 3.66 (m, 2 H), 3.68 - 3.81 (m, 1 H), 3.85 - 3.98 (m, 2 H), 4.31 (d, J=7.62 Hz, 2 H), 7.57 (dd, J=8.89, 2.05 Hz, 1 H), 7.76 (d, J=8.98 Hz, 1 H), 7.83 (d, J=I.56 Hz, 1 H); MS (ESI) (M+H)⁺ = 561.0; Anal. Calcd for C₂₄H₃₅F₃N₆O₄S+0.70 TFA+ (640.46): C, 47.63; H, 5.62; N, 13.12; Found: C, 47.64; H, 5.51; N, 13.26.

Example 54 N-Isopropyl-4-({methyl[l-(tetrahydro-2H-pyran-4-ylmethyl)-2-(trifluoromethyl)- liϊ-benzimidazol-5-yl]amino}sulfonyl)piperazine-1-carboxamide

Following the procedure in Step A of Example 51, using N-methyl-N-[ l-(tetrahydro- 2i¥-pyran-4-ylmethyl)-2-(trifluoromethyl)-1H-benzimidazol-5-yl]piperazine- 1 - sulfonamide (40 mg, 0.087 mmol) and 2-isocyanatopropane (0.2 mL) in THF (3 mL). The crude product was purified by MPLC using EtOAc/MeOH (20: 1) on silica gel to give 48 mg (100%) of a white solid as the title compound. ¹HNMR (400 MHz, METHANOL-D₄): δ 1.09 (d, J=6.45 Hz, 6 H), 1.38 - 1.53 (m, 4 H), 2.15 - 2.34 (m, 1 H), 3.14 - 3.21 (m, 4 H), 3.31 (s, 3 H), 3.33 - 3.40 (m, 6 H), 3.78 - 3.87 (m, 1 H), 3.87 - 3.95 (m, 2 H), 4.31 (d, J=7.62 Hz, 2 H), 7.58 (dd, J=8.89, 2.05 Hz, 1 H)₃ 7.77 (d, J=8.79 Hz, 1 H), 7.85 (d, J=I.76 Hz, 1 H); MS (ESI) (M+H)⁺ = 547.0; Anal. Calcd for C₂₃H₃₃F₃N₆O₄S+0.50 TFA+ 0.20 H₂O + 0.40 CH₃OH (613.64): C, 47.37; H, 5.70; N, 13.70; Found: C₅47.41; H, 5.62; N, 13.65.

Example 55 N-ll-CIMethylll-^etrahydro-lH-pyran^-ylmethy^-1-Ctrifluoromethy^-lJΪ- benzimidazol-5-yl] amino} sulfonyl)piperidin-4-yl] acetamide

Acetyl chloride (9 mg, 0.11 mmol) was added to a solution of 4-amino-N-methyl-N- [l-(tetrahydro-2H-pyran-4-ylmethyl)-2-(trifluoromethyl)-1H-benzimidazol-5- yl]piperidine-l -sulfonamide (45 mg, 0.094 mmol) and triethylamine (12 mg, 0.12 mmol) in DCM (5 mL) at 0 ⁰C. The mixture was stirred for 3 h at room temperature. After evaporation, the crude product was purified by MPLC using EtOAc/MeOH (10:1) on silica gel to give 49 mg (100%) of a white solid as the title compound. ¹HNMR (400 MHz, METHANOL-D₄): δ 1.36 - 1.55 (m, 6 H)₅ 1.79 - 1.87 (m, 2 H)₅ 1.90 (s, 3 H), 2.19 - 2.33 (m, 1 H), 2.86 - 2.96 (m, 2 H), 3.30 (s, 3 H), 3.32 - 3.38 (m, 2 H), 3.63 - 3.70 (m, 2 H), 3.70 - 3.78 (m, 1 H), 3.89 - 3.96 (m, 2 H), 4.33 (d, J=7.62 Hz, 2 H), 7.59 (dd, J=8.89, 2.05 Hz, 1 H), 7.78 (d, J=8.98 Hz, 1 H), 7.85 (d, J=I .95 Hz, 1 H); MS (ESI) (M+H)⁺ = 518.0 Anal. Calcd for C₂₂H₃₀F₃N₅O₄S+0.60 TFA+ 0.10 CH₃OH (589.19): C, 47.50; H, 5.30; N, 11.89; Found: C, 47.61; H, 5.32; N, 11.82.

Example 56 2,2-Dimethyl-N-[l-({methyl[l-(tetrahydro-2_JH-pyran-4-ylmethyl)-2- (trifluororaethyl)-1H-benziraidazol-5-yl]amino}sulfonyl)piperidin-4- yl]propanamide

Following the procedure in Example 55, using 4-amino-N-methyl-N-[l-(tetrahydro- 2H-pyran-4-ylmethyl)-2-(trifluoromethyl)-1H-benzimidazol-5-yl]piperidine-1- sulfonamide (45 mg, 0.094 mmol), 2,2-dimethylpropanoyl chloride (14 mg, 0.11 mmol) was and triethylamine (12 mg, 0.12 mmol) in DCM (5 mL). The crude product was purified by MPLC using EtO Ac/Hex (2:1) on silica gel to give 44 mg (84%) of a white solid as the title compound. ¹HNMR (400 MHz, METHANOL-D₄): δ 1.12 (s, 9 H), 1.38 - 1.56 (m, 6 H), 1.75 - 1.78 (m, 2 H), 2.14 - 2.34 (m, 1 H) 2.80 - 2.90 (m, 2 H), 3.28 (s, 3 H), 3.30 - 3.39 (m, 2 H), 3.61 - 3.79 (m, 3 H), 3.86 - 3.98 (m, 2 H), 4.32 (d, J=7.62 Hz, 2 H), 7.57 (dd, J=8.98, 1.95 Hz, 1 H), 7.76 (d, J=8.79 Hz, 1 H), 7.84 (d, J=I.95 Hz, 1 H); MS (ESI) (M+H)⁺ = 560.0; Anal Calcd for C₂₅H₃₆F₃N₅O₄S+0.50 TFA (616.67): C, 50.64; H, 5.97; N, 11.36; Found: C, 50.76; H, 5.99; N, 11.37.

Example 57 2-Methyl-N-[l-({methyl[l-(tetrahydro-2H-pyran-4-ylmethyl)-2-

(trifluoromethyl)-1H-benzimidazol-5-yl]amino}sulfonyl)piperidin-4- yljpropanamide

Following the procedure in Example 55, using 4-amino-N-methyl-N-[l-(tetrahydro- 2H-pyran-4-ylmethyl)-2-(trifluoromethyl)-1H-benzimidazol-5-yl]piperidine- 1 - sulfonamide (45 mg, 0.094 mmol), 2-methylpropanoyl chloride (11 mg, 0.11 mmol) was and triethylamine (12 mg, 0.12 mmol) in DCM (5 niL) The crude product was purified by MPLC using EtO Ac/Hex (2: 1) on silica gel to give 46 mg (89%) of a white solid as the title compound. ¹HNMR (400 MHz, METHANOL-D₄): δ 1.05 (d, J=6.84 Hz, 6 H), 1.35 - 1.54 (m, 6 H), 1.76 - 1.86 (m, 2 H), 2.17 - 2.30 (m, 1 H), 2.32 - 2.44 (m, 1 H), 2.83 - 2.95 (m, 2 H), 3.28 (s, 3 H), 3.29 - 3.37 (m, 2 H), 3.58 - 3.76 (m, 3 H), 3.85 - 3.98 (m, 2 H)₅ 4.31 (d, J=7.42 Hz, 2 H), 7.57 (dd, JM8.89, 2.05 Hz, 1 H) 7.76 (d, J=8.98 Hz, 1 H), 7.83 (d, J=I.95 Hz, 1 H); MS (ESI) (M+H)⁺ = 546.0; Anal. Calcd for C₂₄H₃₄F₃N₅O₄S+0.10 TFA (557.03): C, 52.18; H, 6.17; N, 12.57; Found: C₃ 52.44; H, 6.03; N, 12.44.

Example 58 4-Acetyl-Λ'-methyl-N-[l-(tetrahydro-2H^r-pyran-4-ylmethyl)-2-(trifluoromethyl)- lJ?-benzimidazol-5-yl]piperazine-1-sulfonamide

Following the procedure in Example 55, using N-methyl-N-[ l-(tetrahy dro-2//-pyran- 4-ylmethyl)-2-(trifluoromethyl)-1H-benzimidazol-5-yl]ρiρerazine-1-sulfonamide (43 mg, 0.096 mmol), triethylamine (12 mg, 0.12 mmol) and acetyl chloride (9 mg, 0.12 mmol) in DCM (5 mL) .The crude product was purified by MPLC using EtOAc/MeOH (20:1) on silica gel to give 45 mg (92%) of a white solid as the title compound. ¹HNMR ^OO MHZ₃ METHANOL-D₄): δ 1.39 - 1.52 (m, 4 H), 2.06 (s, 3 H), 2.17 - 2.33 (m, 1 H), 3.17 - 3.27 (m, 4 H), 3.31 (s, 3 H), 3.32 - 3.36 (m, 2 H), 3.49 - 3.59 (m, 4 H), 3.86 - 3.96 (m, 2 H), 4.31 (d, J=7.62 Hz, 2 H), 7.58 (dd, JM8.79, 2.15 Hz, 1 H), 7.77 (d, J=8.98 Hz, 1 H), 7.85 (d, J=I.76 Hz, 1 H); MS (ESI) (M+H)⁺ = 504.0; Anal. Calcd for C₂₁H₂₈F₃N₅(WCOO TFA +0.10 CH₃OH (575.17): C₃ 46.57; H, 5.08; N, 12.18; Found: C, 46.67; H, 5.13; N, 12.16.

Example 59

4-(2,2-Dimethylpropanoyl)-N-methyl-N-[l-(tetrahydro-2H-pyran-4-ylmethyl)-2-

(trifluoromethy^-1H-benzimidazol-S-yllpiperazine-1-sulfonamide

Following the procedure in Example 55, using N-methyl-N-[l-(tetrahydro-2H-pyran- 4-ylmethyl)-2-(trifiuoromethyl)-1H-benzimidazol-5-yl]piperazine-1-sulfonamide (43 mg, 0.096 mmol), triethylamine (12 mg, 0.12 mmol) and 2,2-dimethylpropanoyl chloride (14 mg, 0.12 mmol) in DCM (5 mL). The crude product was purified by MPLC using EtOAc/Ηex(2:l) on silica gel to give 51 mg (97%) of a white solid as the title compound. ¹HNMR (400 MHz, METHANOL-D₄): δ 1.22 (s, 9 H), 1.40 - 1.54 (m, 4 H), 2.17 - 2.31 (m, 1 H), 3.17 - 3.23 (m, 4 H), 3.30 - 3.36 (m, 2 H), 3.31 (s, 3 H), 3.61 - 3.68 (m, 4 H), 3.86 - 3.95 (m, 2 H), 4.31 (d, J=7.62 Hz, 2 H), 7.58 (dd, J=8.89, 2.05 Hz, 1 H), 7.77 (d, J=8.79 Hz, 1 H), 7.85 (d, J=I.95 Hz, 1 H); MS (ESI) (M+H)⁺ = 546.0; Anal. Calcd for C₂₄H₃₄F₃N₅O₄S+0.30 TFA +0.20 CH₃OH (586.24): C, 50.81; H, 6.03; N, 11.95; Found: C, 50.81; H, 5.99; N, 11.90.

Example 60 N-(1-{[{2-tert-Butyl-1-[(4,4-difluorocycloliexyl)methyl]-lN-benzimidazol-5- yl}(methyl)amino]sulfonyl}piperidin-4-yl)acetamide

Step A. N-(1-{[{2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H- benzimidazol-5-yl}(methyl)amino]sulfonyl}piperidin-4-yl)acetamide

Acetic anhydride (2.0 mmol) was added into a solution of triethylamine (2.0 mmol) and 4-amino-N-{2-tert-butyl-1-[(4,4-difluorocyclohexyl)methyl]-l//^'-benzimidazol-5- yl}-N-methylpiperidine-l -sulfonamide (crude product from step D, 0.9 mmol) in CH₂Cl₂ (20 mL). After being stirred at room temperature for 1 hr, the reaction mixture was concentrated under reduced pressure. The residue was then purified by silica gel chromatography (AcOEt to MeOH/AcOEt (1:9)) to give N-(1-{[{2-tert-butyl-1-[(4,4- difluorocyclohexyl)methylJ-1H-benzimidazol-5- yl}(methyl)amino]sulfonyl}piperidin-4-yl)acetamide as a solid (235 mg, 48 % for steps A-D). ¹H NMR (400 MHz, CD₃OD, TFA salt) δ 1.28 (m, 2H), 1.40-1.76 (m, 8H), 1.64 (s, 9H), 1.88 (s, 3H), 2.04 (m, 2H), 2.24 (m, 1H), 2.90 (m, 2H), 3.28 (s, 3H), 3.68 (m, 3H), 4.50 (d, J = 8.0 Hz, 2H), 7.60 (d, J = 8.0 Hz, 1H), 7.77 (s, 1H), 7.86 (d, J= 8.0 Hz, 1H).

Step B. 1-{[{2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5- yl}(methyl)amino]sulfonyl}-3-methyl-li3-imidazol-3-ium triflate

3-(Imidazole-1-sulfonyl)-1-methyl-3H-imidazol-1-ium triflate (508 mg; 1.4 mmol) was added into a solution of 2-tert-butyl-1-[(4,4-difluorocyclohexyl)methyl]-N- methyl-l.H-benzimidazol-5 -amine (300 nig, 0.9 mmol) in acetonitrile (10 mL). After being stirred at room temperature for 2 hr, the reaction mixture was concentrated under reduced pressure. The residue was then dissolved in AcOEt (60 mL), washed with brine, and dried over Na₂SO₄. After removing of solvents provided a mixture (1 : 1) of N- {2-tert-butyl- 1 -[(4,4-difluorocyclohexyl)methyl]- 1H-benzimidazol-5ryl} - N-methyl- lϋf-imidazole- 1 -sulfonamide and 1 - { [ {2-tert-bntyl- 1 -[(4,4- difluorocyclohexyl)methyl]-l//-benzimidazol-5-yl}(methyl)amino]sulfonyl}-3- methyl-1H-imidazol-3-ium triflate, which was dissolved in dichloromethane (10 mL). The resulting solution was treated with methyl trifluoromethanesulfonate (0. 5 mmol) at O⁰C for 2 hr. The reaction mixture was then concentrated under reduced pressure to give 1 - { [ {2-tert-butyl- 1 -[(4,4-difluorocyclohexyl)methyl]- 1H-benzimidazol-S- yl}(methyl)amino]sulfonyl}-3-methyl-1H-imidazol-3-ium triflate as a solid, which was used in the step C without any purification.

Step C. tert-Butyl (1-{[{2-/ert-butyI-1-[(4,4-difluorocyclohexyl)methyl]-l_JH- benzimidazol-5-yl}(methyl)amino]sulfonyl}piperidin-4-yl)carbamate

A solution of Hunig's base (1.0 mmol), 1-{[{2-tert-butyl-1-[(4,4- difluorocyclohexy^methylJ-liϊ^'-benzimidazol-5-ylJ^ethy^aininoJsulfonyll-S- memyl-1H-imidazol-3-ium triflate (crude product from Step B, 0.9 mmol) and tert- butyl piperidin-4-ylcarbamate (200 mg, 1.0 mmol) in MeCN (20 mL) was heated for 1 hr at 80⁰C. The reaction mixture was then concentrated under reduced pressure to give crude tert-butyl (1-{[{2-tert-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H- benzimidazol-5-yl}(methyl)amino]sulfonyl}piperidin-4-yl)carbamate as a solid, which was used directly in Step D.

Step D. 4-Araino-N-{2-tert-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H- benzimidazol-5-yl}-N-methylpiperidine-1-sulfonaraide

A solution of tert-butyl (1-{[{2-tert-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1Hr- benzimidazol-5-yl}(methyl)amino]sulfonyl}piperidin-4-yl)carbamate (crude product from Step C, 0.9 mmol) in 10 mL CH₂Cl₂ was treated with 10 mL TFA at room temperature. After being stirred at room temperature for 1 hr, the reaction mixture was concentrated under reduced pressure. The residue was then dissolved in AcOEt (60 mL), washed with Na₂CO₃ solution and brine, and dried over Na₂SO₄. fter removing of solvents provided the crude 4-amino-N- {2-tert-butyl-l -[(4,4- difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl} -N-methylpiperidine- 1 - sulfonamide, which was used in Step A without purification. Example 61 N-(1-{[{2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5- yl}(methyl)amino]sulfonyl}piperidin-4-yl)-2,2-dimethylpropanamide

Following the procedure in Step A of Example 60, 4-amino-N-{2-tert-butyl-1-[(4,4- difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl}-N-methylpiperidine-1- sulfonamide (50 mg, 0.1 mmol) was reacted with 2,2-dimethylpropanoyl chloride (24 mg, 0.2 mmol), after being purified by reverse phase HPLC, to provide N-(1-{[{2- tert-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5- yl}(methyl)amino]sulfonyl}piperidin-4-yl)-2,2-dimethylpropanamide (TFA salt, 7 mg, 10 %). ¹H NMR (400 MHz, CD₃OD, TFA salt) δ 1.13 (s, 9H), 1.28 (m, 2H), 1.53 (m, 3H), 1.64 (s, 9H), 1.76 (m, 5H), 2.04 (m, 2H), 2.24 (m, 1H), 2.87 (m, 2H), 3.28 (s, 3H), 3.68 (m, 3H), 4.50 (d, J = 7.6 Hz, 2H), 7.60 (d, J = 9.0 Hz, 1H), 7.77 (s, 1H), 7.86 (d, J = 9.0 Hz, 1H); MS (ESI) (M+H)⁺ 582.0.

Example 62 N-{2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl}-N- methylmorphoIine-4-sulfonamide

Following the procedure in Step C of Example 60, 1-{[{2-tert-butyl-1-[(4,4- difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl}(methyl)amino]sulfonyl}-3- methyl-1H-imidazol-3-ium triflate (0.1 mmol) was reacted with morpholine (35 mg, 0.4 mmol), after being purified by reverse phase HPLC, to provide N-{2-tert-butyl-1- [(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl}-N-methylmorpholme-4- sulfonamide (TFA salt, 56 mg, 93 %). ¹HNMR (400 MHz, CD₃OD, TFA salt) δ 1.40- 1.76 (m, 6H), 1.64 (s, 9H), 2.04 (m, 2H), 2.24 (m, 1H)₅ 3.19 (m, 4H), 3.33 (s, 3H), 3.62 (m, 4H), 4.50 (d, J = 7.4 Hz, 2H), 7.61(d, J=9.0 Hz, 1H), 7.79 (s, 1H), 7.87(d, J=9.0 Hz, 1H).

Example 63 N-{2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-l_JH^r-benzimidazol-5-yl}-N- methylpyrrolidine-1 -sulfonamide

Following the procedure in Step C of Example 60, 1-{[{2-tert-butyl-1-[(4,4- difluorocyclohexyl)methyl]-li/-benzimidazol-5-yl}(methyl)amino]sulfonyl}-3- methyl-1H-imidazol-3-ium triflate (0.1 mmol) was reacted with pyrrolidine (28 mg, 0.4 mmol), after being purified by reverse phase HPLC, to provide N-{2-tert-butyl-1- [(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl}-N-methylpyrrolidine-1- sulfonamide (TFA salt, 26 mg, 48 %). ¹H NMR (400 MHz, CD₃OD, TFA salt) δ 1.23 (m, 2H), 1.40-1.76 (m, 6H), 1.64 (s, 9H), 1.86 (m, 2H), 2.01 (m, 2H), 2.24 (m, 1H), 3.04 (m, 2H), 3.27 (m, 2H), 3.28(s, 3H), 4.49 (d, J = 7.4 Hz, 2H), 7.58(d, J=9.0 Hz, 1H), 7.77 (s, 1H), 7.84(d, J=9.0 Hz, 1H); MS (ESI) (M+H)⁺ 469.0.

Example 64

N-{2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-lJE?-benzimidazol-5-yl}-3,3- difluoro-N-methylpyrrolidine-1-suIfonamide

Following the procedure in Step C of Example 60, 1-{[{2-tert-butyl-1-[(4,4- difluorocyclohexy^methylJ-1H-benzimidazol-5-ylj^ethy^aininolsulfonyl}-3- methyl-li/-imidazol-3-ium triflate (0.1 mmol) was reacted with 3,3- difluoropyrrolidine (42 mg, 0.4 mmol), after being purified by reverse phase HPLC, to provide N-{2-tert-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5- yl}-3,3-difluoro-N-methylpyrrolidme-1-sulfonamide (TFA salt, 18 mg, 26 %). ¹H NMR (400 MHz, CD₃OD, TFA salt) δ 1.40-1.76 (m, 6H)₃ 1.64 (s, 9H), 2.04 (m, 2H), 2.24 (m, 1H), 2.38 (m, 2H), 3.32 (s, 3H), 3.52 (m, 2H), 3.60 (m, 2H), 4.50 (d, J = 7.4 Hz, 2H), 7.59(d, J=9.0 Hz, 1H), 7.77 (s, 1H), 7.86(d, J=9.0 Hz, 1H); MS (ESI) (M+H)⁺ 505.0.

Example 65 N-{2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-l_JH-benzimidazol-5-yl}-N- methylisoxazolidine-2-sulfonamide

Following the procedure in Step C of Example 60, 1-{[{2-fert-butyl-1-[(4,4- difluorocyclohexyl)methyl]- l.H-benzimidazol-5-yl} (methyl)amino]sulfonyl} -3- methyl-1H-imidazol-3-ium triflate (0.1 mmol) was reacted with isoxazolidine hydrochloride (44 mg, 0.4 mmol) and Hunig's base (1.0 mL), , after being purified by reverse phase HPLC, to provide N-{2-tert-butyl-1-[(4,4- difluorocyclohexyl)methyl]-li-'^:-benzimidazol-5-yl}-N-methylisoxazolidine-2- sulfonamide (TFA salt, 58 mg, 99 %). ¹H NMR (400 MHz, CD₃OD, TFA salt) δ 1.40- 1.76 (m, 6H), 1.64 (s, 9H), 2.04 (m, 2H), 2.31 (m, 1H), 2.33 (m, 2H), 3.44 (s, 3H), 3.55 (m, 2H), 4.11 (m, 2H), 4.51 (d, J = 7.4 Hz, 2H), 7.60 (m, 1H), 7.87 (m, 2H); MS (ESI) (M+H)⁺ 471.0.

Example 66 N-{2-^^-Butyl-1-[(4,4-d[ifluorocyclohexyl)methyl]-1H-benzimidazol-5-yl}-4,4- difluoro-N-methylpiperidine-1-sulfonamide

Following the procedure in Step C of Example 60, 1-{[{2-terf-butyl-1-[(4,4- difluorocyclohexyl)methyl]-lH-benzimidazol-5-ylJ^ethy^ammojsulfonyl}-3- methyl-1H-imidazol-3-ium triflate (0.1 mmol) was reacted with 4,4- difluoropiperidine hydrochloride (62 mg, 0.4 mmol) and Hunig's base (1.0 mL), , after being purified by reverse phase HPLC, to provide N-{2-tert-butyl-1-[(4,4- difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl} -4,4-difluoro-N-methylpiperidine- 1-sulfonamide (TFA salt, 36 mg, 57 %). ¹H NMR (400 MHz, CD₃OD, TFA salt) δ 1.40-1.76 (m, 6H), 1.64 (s, 9H), 1.97 (m, 6H), 2.24 (m, 1H), 3.31 (s, 3H), 3.38 (m, 4H), 4.50 (m, 2H), 7.60(d, J=9.0 Hz, 1H), 7.78 (s, 1H), 7.87(d, J=9.0 Hz, 1H); MS (ESI) (M+H)⁺ 519.0.

Example 67 tert-Butyl 4-{[{2-ter_'-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazoI-

5-yl}(methyl)amino]suIfonyI}piperazine-1-carboxylate

Following the procedure in Step C of Example 60, 1-{[{2-tert-butyl-1-[(4,4- difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl}(methyl)amino]sulfonyl}-3- methyl-1H-imidazol-3-ium triflate (2.0 mmol) was reacted with tert-butyl piperazine- 1-carboxylate (930 mg, 5.0 mmol) and Hunig's base (1.0 mL), after being purified by silica gel chromatography, to provide tert-butyl 4-{[{2-tert-butyl-1-[(4,4- difluorocyclohexyl)methyl]-1H-benzimidazol-5- yl}(methyl)amino]sulfonyl}piperazine-1-carboxylate (730 mg, 63 %). ¹HNMR (400 MHz, CDCl₃) δ 1.39 (s, 9H), 1.46 (m, 3H), 1.51 (s, 9H), 1.67 (m, 3H), 2.09 (m, 3H), 3.12 (m, 4H), 3.25 (s, 3H), 3.35 (m, 4H), 4.16 (m, 2H), 7.22 (m, 2H), 7.28 (d, J = 8.6 Hz, 1H), 7.67 (s, 1H); MS (ESI) (M+H)⁺ 584.0.

Example 68

4-{[{2-tert-ButyI-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5- yl}(methyl)amino]sulfonyl}-N-isopropylpiperazine-1-carboxamide

Step A. 4-{[{2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5- yl}(methyl)amino]sulfonyl}-N-isopropylpiperazine-1-carboxamide

Isopropyl isocyanate (85 mg, 1.0 mmol) was added into a solution of triethylamine (1.0 mmol) and N-{2-fer^-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-beiizimidazol- 5-yl}-N-methylpiperazine-1-sulfonamide (100 mg, 0.21 mmol) in CH₂Cl₂ (10 mL). After being stirred at room temperature for 1 hr, the reaction mixture was concentrated under reduced pressure. The residue was then purified by silica gel chromatography (Hexane to AcOEt ) to give 4-{[{2-tert-Butyl-1-[(4,4- difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl} (methyl)amino]sulfonyl} -N- isopropylρiperazine-1-carboxamide (114 mg, TFA salt, 81 %). ¹H NMR (400 MHz, CDCl₃) δ 1.14 (d, J=6.5 Hz, 6H), 1.52 (m, 3H), 1.56 (s, 9H), 1.72 (m, 3H)₅ 2.14 (m, 3H), 3.20 (m, 4H), 3.30 (s, 3H), 3.35 (m, 4H), 3.94 (m, 1H), 4.22 (m, 2H), 4.35 (m, 1H), 7.28 (d, J = 8.6 Hz, 1H), 7.32 (d, J = 8.6 Hz, 1H), 7.72 (s, 1H); MS (ESI) (M+H)⁺ 569.0.

Step B. Λ^/-{2-terϊ'-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-l_Jfir-benzimidazol-5- yI}-N-methylpiperazine-1-sulfonamide

A solution of tert-bntyl 4-{[{2-tert-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H- benzimidazol-5-yl}(methyl)amino]sulfonyl}piperazine-1-carboxylate (720 mg, 1.23 mmol) in 10 mL CH₂Cl₂ was treated with 10 mL TFA at room temperature. After being stirred at room temperature for 1 hr, the reaction mixture was concentrated under reduced pressure. The residue was then dissolved in AcOEt (60 mL), washed with Na₂CO₃ solution and brine, and dried over Na₂SO₄. Removal of solvents provided crude N- {2-tert-butyl- 1 -[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol- 5-yl}-N-methylpiperazine-l -sulfonamide (434 mg, 73 %), which was used in Step A without purification.

Example 69

4-{[{2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5- yl}(methyl)amino]sulfonyl}-N-methylpiperazine-1-carboxamide

Following the procedure in Step A of Example 68, N- {2-tert-butyl- 1- [(4,4- difluorocyclohexyl)methyl]- lijT-benzimidazol-5-yl} -N-methylpiperazine- 1 - sulfonamide (56 mg, 0.116 mmol) was reacted with methyl isocyanate (57 mg, 1.0 mmol), after being purified by silica gel chromatography, to provide 4- {[{2-tert- butyl- 1 - [(4,4-difluorocy clohexyl)methyl] - 1H-benzimidazol-5 - yl}(methyl)amino]sulfonyl} -N-methylpiperazine- 1-carboxamide (TFA salt, 49 mg, 64 %). ¹H ΝMR (400 MHz, CDCl₃) δ 1.46 (m, 3H), 1.50 (s, 9H), 1.67 (m, 3H), 2.10 (m, 3H), 2.71 (m, 3H), 3.14 (m, 4H), 3.23 (s, 3H), 3.31 (m, 4H), 4.16 (d, J = 7.4 Hz, 2H), 4.68 (m, 1H), 7.22 (d, J = 8.6 Hz, 1H), 7.25 (d, J = 8.6 Hz, 1H), 7.65 (s, 1H); MS (ESI) (M+H)⁺ 541.0.

Example 70

4-{[{2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5- yl}(methyl)amino]sulfonyl}-N-cyclopropylpiperazine-1-carboxamide

Step A. 4-{[{2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5- yl}(methyl)amino]sulfonyl}-N-cyclopropylpiperazine-1-carboxamide

Following the procedure in Step A of Example 68, N-{2-tert-butyl-1-[(4,4- difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl}-N-methylpiperazine-1- sulfonamide (54 mg, 0.112 mmol) was reacted with cyclopropyl isocyanate (1.0 mmol), after being purified by silica gel chromatography, to provide 4-{[{2-tert- butyl-1-[(4,4-difiuorocyclohexyl)methyl]-1H-benzimidazol-5- yl}(methyl)amino]sulfonyl}-N-cyclopropylpiperazme-1-carboxamide (TFA salt, 48 mg, 63 %). ¹H NMR (400 MHz, CDCl₃) δ 0.45 (m, 1H), 0.54 (m, 1H), 0.72 (m, 2H), 1.54 (m, 2H), 1.56 (s, 9H), 1.72 (m, 3H), 2.14 (m, 3H), 2.50 (m, 1H), 2.60 (m, 1H), 3.18 (m, 4H), 3.29 (s, 3H), 3.34 (m, 4H), 4.22 (d, J = 7.4 Hz, 2H), 5.01 (m, 1H), 7.28 (d, J = 8.6 Hz, 1H), 7.32 (d, J = 8.6 Hz, 1H), 7.71 (s, 1H); MS (ESI) (M+H)⁺ 567.0.

Step B. Cyclopropyl isocyanate

A solution of cyclopropylamine (57 mg, 1.0 mmol) and DEPEA (3.0 mmol) in 5 mL THF was slowly added to a solution of triphosgene (105 mg, 0.35 mmol) in 10 mL THF at 0°C. After 30 min, the cyclopropyl isocyanate solution was used directly in Step A.

Example 71

4-{[{2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5- yl} (methyl)amino]sulfonyl}-N-cyclobutylpiperazine-1-carboxamide

Step A. 4-{[{2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5- yl}(methyl)amino]sulfonyl}-N-cyclobutylpiperazme-1-carboxaniide

Following the procedure in Step A of Example 68, N-{2-tert-butyl-1-[(4,4- difluorocyclohexy^methyy-1H-benzimidazol-5-yll-N-methylpiperazine-1- sulfonamide (58 mg, 0.12 mmol) was reacted with cyclobutyl isocyanate (1.0 rnmol), after being purified by silica gel chromatography, to provide 4-{[{2-tert-butyl-1- [(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl} (methyl)amino]sulfonyl} -N- cyclobutylpiperazine-1-carboxamide (TFA salt, 39 mg, 47 %). ¹HNMR (400 MHz, CDCl₃) δ 1.52 (m, 2H), 1.56 (s, 9H), 1.72 (m, 8H), 2.04 (m, 3H), 2.32 (m, 2H), 3.19 (m, 4H)₅ 3.30 (s, 3H), 3.34 (m, 4H), 4.21 (m, 2H), 4.25 (m, 1H), 4.65 (m, 1H), 7.27 (d, J = 8.6 Hz, 1H), 7.32 (d, J = 8.6 Hz, 1H), 7.72 (s, 1H); MS (ESI) (M+H)⁺ 581.0.

Step B: Cyclobutyl isocyanate

A solution of cyclobutylamine (71 mg, 1.0 mmol) and DIPEA (3.0 mmol) in 5 mL THF was slowly added to a solution of triphosgene (105 mg, 0.35 mmol) in 10 mL THF at O⁰C. After 30 min, the cyclopropyl isocyanate solution was used directly in Step A.

Example 72 N-{2-ferf-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-l_JH^r-benziinidazol-5-yl}-N- methyl-4-{[(methylamino)carbonyI]amino}piperidine-1-sulfonamide

Following the procedure in Step A of Example 68, 4-amino-N-{2-tert-butyl-1-[(4,4- difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl} -N-methylpiperidine- 1 - sulfonamide (50 mg, 0.1 mmol) was reacted with methyl isocyanate (57 mg, 1.0 mmol), after being purified by silica gel chromatography, to provide N-{2-tert-butyl- l-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl}-N-methyl-4- {[(methylamino)carbonyl]amino}piperidine-1-sulfonamide (TFA salt, 49 mg, 73 %). ¹H NMR (400 MHz, CDCl₃) δ 1.39 (m, 2H), 1.52 (m, 3H), 1.56 (s, 9H), 1.72 (m, 3H), 1.89 (m, 2H), 2.15 (m, 3H), 2.72 (s, 3H), 2.83 (m, 2H), 3.27 (s, 3H), 3.63 (m, 3H), 4.22 (d, J = 8.0 Hz, 2H), 5.15 (m, 1H), 7.30 (m, 2H), 7.71 (s, 1H); MS (ESI) ^■ (M+H)⁺ 555.0.

Example 73 N-[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benziinidazol-5-yl]-N- methylisoxazolidine-2-sulfonamide

Following the procedure in Step C of Example 60, ^{[p-tert-butyl-1-^etrahydro-ZH- pyran-4-ylmethyl)-1H-benzimidazol-5-yl](methyl)amino]sulfonyl}-3-methyl-1H- imidazol-3-ium triflate (500 mg, 0.84 mmol) was reacted with fert-butyl piperazine-1- carboxylate (558 mg, 3.0 mmol), after being purified by silica gel chromatography, to provide tert-butyl 4- { [ [2-tert-butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)- IH- benzimidazol-5-yl](methyl)amino]sulfonyl}piperazine-1-carboxylate (460 mg, 100 %). MS (ESI) (M+H)⁺ 550.0.

Example 74 4-Acetyl-N-[2-tert-butyl-1-(tetrahydro-2_Jfir-pyran-4-ylinethyl)-1H-benziinidazol- 5-yl]-N-methylpiperazine-l -sulfonamide

Step A. 4-Acetyl-Λ^r-[2-tert-butyl-1-(tetrahydro-2_JH^r-pyran-4-ylmethyl)-1H- benzimidazol-5-yl]-N-methylpiperazine-l -sulfonamide

Following the procedure in Step A of Example 60, N-[2-fert-butyl-1-(tetrahydro-2H- pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-N-methylpiperazme- 1 -sulfonamide trifluoroacetate (100 mg, 0.18 mmol) was reacted with acetyl chloride (79 mg, 1.0 mmol), after being purified by reverse phase ΗPLC, to provide 4-acetyl-N-[2-tert- butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-N- methylpiperazine-1-sulfonamide (TFA salt, 58 mg, 53 %). ¹HNMR (400 MHz, CD₃OD₅ TFA salt) δ 1.54 (m, 4H), 1.66 (s, 9H), 2.07 (s, 3H), 2.36 (m, 1H), 3.20 (m, 2H), 3.33 (s, 3H), 3.34 (m, 4H), 3.55 (m, 4H), 3.91 (m, 2H), 4.51 (d, J = 7.6 Hz, 2H), 7.65 (d, J=9.0 Hz, 1H)₅ 7.79 (s₅ 1H)₅ 7.92 (d, J=9.0 Hz, 1H); MS (ESI) (M+H)⁺ 492.0. Step B: N-[2-tert-Butyl-.l-(tetrahydro-2H-pyran-4-ylmethyl)-lJΪ-benzimidazol-5- yl]-N-methylpiperazine-1-sulfonamide

A solution of tert-butyl 4-{[[2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylnietliyl)-lH^r- benzimidazol-5-yl](methyl)amino]sulfonyl}piperazine-1-carboxylate (460 mg, 0.84 mmol) in 10 mL CH₂Cl₂ was treated with 10 mL TFA at room temperature. After being stirred at room temperature for 1 hr, the reaction mixture was concentrated under reduced pressure to provide N-[2-tert-butyl-1-(tetrahydro-2H-pyran-4- ylmethyl)-1H-benzimidazol-5-yl]-N-methylpiperazine-l -sulfonamide (TFA salt, 100 %), which was used in Step A without purification.

Example 75 N-[2-tert-Butyl-1-(tetrahydro-2_JH^r-pyran-4-ylmethyl)-lJΪ-benziinidazol-5-yl]-4- (2,2-dimethylpropanoyl)-Λ'-methylpiperazine-l -sulfonamide

Following the procedure in Step A of Example 60, N-[2-tert-butyl-1-(tetrahydro-2H- pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-N-methylpiperazine- 1 -sulfonamide trifluoroacetate (100 mg, 0.18 mmol) was reacted with 2,2-dimethylpropanoyl chloride (120 mg, 1.0 mmol), after being purified by reverse phase HPLC, to provide N-[2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-berizimidazol-5-yl]-4-(2,2- dimethylpropanoyl)-N-methylpiperazine-l -sulfonamide (TFA salt, 24 mg, 21 %). ¹H ΝMR (400 MHz, CD₃OD₃ TFA salt) δ 1.23 (s, 9H), 1.56 (m, 4H), 1.66 (s, 9H), 2.36 (m, 1H), 3.23 (m, 4H), 3.33 (s, 3H), 3.36 (m, 2H), 3.66 (m, 4H), 3.91 (m, 2H), 4.51 (d, J = 7.6 Hz, 2H), 7.65 (d, J=9.2 Hz, 1H), 7.79 (s, 1H), 7.92 (d, J=9.2 Hz, 1H); MS (ESI) (M+H)⁺ 534.0.

Example 76

4-Benzoyl-N-[2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-

5-yl]~N-methylpiperazine-1-sulfonamide

Following the procedure in Step A of Example 60, N-[2-tert-butyl-1-(tetrahydro-2H- pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-N-methylpiperazme-1-sulfonamide (45 mg, 0.10 mmol) was reacted with benzoyl chloride (28 mg, 0.2 mmol), after being purified by reverse phase HPLC, to provide 4-benzoyl-Λ^L[2-terϊ-butyl-1-(tetrahydro- 2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-N-methylpiperazine-1-sulfonamide (TFA salt, 64 mg, 96 %). ¹H ΝMR (400 MHz, CD₃OD, TFA salt) δ 1.58 (m, 4H), 1.67 (s, 9H), 2.36 (m, 1H), 3.28 (m, 6H), 3.33 (s, 3H), 3.47 (m, 2H), 3.74 (m, 2H), 3.92 (m, 2H), 4.52 (d, J = 7.6 Hz, 2H), 7.40 (m, 2H), 7.46 (m, 3H), 7.68 (d, J=9.0 Hz, 1H), 7.80 (s, 1H), 7.95 (d, J=9.0 Hz, 1H); MS (ESI) (M+H)⁺ 554.0.

Example 77 N-[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-N- methyl-4-(3-methylbutanoyl)piperazine-l -sulfonamide

Following the procedure in Step A of Example 60, N-[2-tert-butyl-1-(tetrahydro-2H- pyran-4-ylmethyl)- lif-benzimidazol-S-yy-N-methylpiperazine- 1 -sulfonamide (45 mg, 0.10 mmol) was reacted with 3-methylbutanoyl chloride (24 mg, 0.2 mmol), after being purified by reverse phase HPLC, to provide N-[2-tert-butyl-1-(tetrab.ydro-2H- pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-N-methyl-4-(3-me11iylbutanoyl)piperazme- 1 -sulfonamide (TFA salt, 63 mg, 97 %). ¹H NMR (400 MHz, CD₃OD, TFA salt) δ 0.87 (d, J=7.4 Hz, 6H), 1.45 (m, 4H), 1.49 (s, 9H), 2.00 (m, 1H), 2.09 (d, J=6.9 Hz, 2H), 2.22 (m, 1H), 3.06 (m, 2H), 3.16 (m, 2H), 3.22 (s, 3H), 3.23 (m, 2H), 3.39 (m, 2H), 3.52 (m, 2H), 3.91 (m, 2H), 4.12 (d, J = 7.6 Hz, 2H), 4.83 (m, 1H), 7.23 (m, 2H), 7.64 (s, 1H); MS (ESI) (M+H)⁺ 534.0.

Example 78 N-[2-to'-'-Butyl-1-(tetrahydro-2fl-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-4- (cyclopropylcarbonyl)~JV~methylpiperazine-l -sulfonamide

Following the procedure in Step A of Example 60, N-[2-tert-butyl-1-(tetrahydro-2H- pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-N-methylpiperazine-1-sulfonamide (50 mg, 0.11 mmol) was reacted with cyclopropanecarbonyl chloride (21 mg, 0.2 mmol), after being purified by reverse phase HPLC, to provide N-[2-tert-butyl-1-(tetrahydro- 2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-4-(cyclopropylcarbonyl)-N- methylpiperazine-1-sulfonamide (TFA salt, 45 mg, 71 %). ¹H NMR (400 MHz, CDCl₃) δ 0.76 (m, 2H), 0.95 (m, 2H), 1.53 (m, 4H), 1.57 (s, 9H), 1.69 (m, 1H), 2.32 (m, 1H), 3.21 (m, 2H), 3.28 (m, 2H), 3.30 (s, 3H), 3.33 (m, 2H), 3.60 (m, 2H), 3.70 (m, 2H), 3.98 (m, 2H), 4.20 (d, J = 7.6 Hz, 2H), 7.31 (m, 2H), 7.72 (s, 1H); MS (ESI) (M+H)⁺518.0.

Example 79 N-[2-rer^Butyl-1-(tetrahydro-2Jϊ-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-N- methyl-4-propionylpiperazme-1-sulfonamide

Following the procedure in Step A of Example 60, N-[2-tert-butyl-1-(tetrahydro-2H- pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-N-methylpiperazine-1-sulfonamide (60 mg, 0.13 mmol) was reacted with propanoic anhydride (26 mg, 0.2 mmol), after being purified by reverse phase HPLC, to provide N-[2-tert-butyl-1-(tetrahydro-2H- pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-N-methyl-4-propionylpiperazine-1- sulfonamide (TFA salt, 28 mg, 35 %). ¹HNMR (400 MHz, CDCl₃) δ 1.13 (t, J=7.4 Hz, 3H), 1.53 (m, 4H), 1.57 (s, 9H)₃ 2.32 (m, 3H), 3.14 (m, 2H), 3.25 (m, 2H), 3.30 (s, 3H), 3.33 (m, 2H), 3.45 (m, 2H), 3.60 (m, 2H), 3.98 (m, 2H), 4.20 (d, J = 7.6 Hz, 2H), 7.31 (m, 2H), 7.72 (s, 1H); MS (ESI) (M+H)⁺ 506.0.

Example 80 N-[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-4- isobutyryl-N-methylpiperazine-1 -sulfonamide

Following the procedure in Step A of Example 60, N-[2-tert-butyl-1-(tetrahydro-2H- pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-7Y-methylpiperazine-1-sulfonamide (50 mg, 0.11 mmol) was reacted with 2-methylρropanoyl chloride (22 mg, 0.2 mmol), after being purified by reverse phase ΗPLC, to provide N-[2-tert-butyl-1-(tetrahydro- 2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-4-isobutyryl-7Y-methylpiperazine-1- sulfonamide (TFA salt, 35 mg, 50 %). ¹H NMR (400 MHz, CDCl₃) δ 1.10 (d, J=6.6 Hz, 6H), 1.53 (m, 4H), 1.57 (s, 9H), 2.30 (m, 1H), 2.73 (m, 1H), 3.15 (m, 2H), 3.30 (m, 2H), 3.31 (s, 3H), 3.33 (m, 2H), 3.50 (m, 2H), 3.60 (m, 2H), 3.99 (m, 2H), 4.20 (d, J = 7.6 Hz, 2H), 7.31 (m, 2H), 7.72 (s, 1H); MS (ESI) (M+H)⁺ 520.0. Example 81 N-[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-4- (cyclobutylcarbonyl)-N-methylpiperazine-l -sulfonamide

Following the procedure in Step A of Example 60, N-[2-tert-butyl-1-(tetrahydro-2H- pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-N-methylpiperazine-l -sulfonamide (50 mg, 0.11 mmol) was reacted with cyclobutanecarbonyl chloride (24 mg, 0.2 mmol), after being purified by reverse phase HPLC₅ to provide N-[2-ter^-butyl-1-(tetrahydro- 2Jf-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-4-(cyclobutylcarbonyl)-N- methylpiperazine-1-sulfonamide (TFA salt, 34 mg, 48 %). ¹HNMR (400 MHz, CDCl₃) δ 1.53 (m, 4H), 1.57 (s, 9H), 1.80 -2.00 (m, 2H), 2.13 (m, 2H), 2.31 (m, 3H), 3.14 (m, 2H), 3.20 (m, 3H), 3.30 (s, 3H), 3.32 (m, 4H), 3.35 (m, 2H), 3.91 (m, 2H), 4.20 (d, J = 7.6 Hz, 2H), 7.31 (m, 2H), 7.72 (s, 1H); MS (ESI) (M+H)⁺ 532.0.

Example 82

Λ^r-[2-2'eri'-Butyl-1-(tetrahydro-2_JH^r-pyran-4-ylmethyl)-lJ7-benzimidazol-5-yl]-4- butyryl-N-methylpiperazine-1-sulfonamide

Following the procedure in Step A of Example 60, N-p-tert-butyl-1-^etrahydro^H- pyran-4-yrmethyl)-1H-benzimidazol-5-yl]-N-methylpiperazine-1-sulfonamide (50 mg, 0.11 mmol) was reacted with butanoyl chloride (21 mg, 0.2 mmol), after being purified by reverse phase HPLC, to provide N-[2-tert-butyl-1-(tetrahydro-2H-pyran-4- ylmethyl)- li-^r-benzimidazol-5-yl]-4-butyryl-Λ/^r-methylpiperazine-l -sulfonamide (TFA salt, 28 mg, 40 %). ¹HNMR (400 MHz, CDCl₃) δ 0.96 (t, J=7.4 Hz, 3H), 1.53 (m, 4H), 1.57 (s, 9H), 1.65 (m, 2H), 2.27 (t, J=7.4 Hz, 2H), 2.30 (m, 1H), 3.14 (m, 2H), 3.24 (m, 2H), 3.30 (s, 3H), 3.33 (m, 2H), 3.45 (m, 2H), 3.60 (m, 2H), 3.98 (m, 2H), 4.20 (d, J = 7.6 Hz, 2H), 7.32 (m, 2H), 7.72 (s, 1H); MS (ESI) (M+H)⁺ 520.0.

Example 83

4-{[[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-lJΪ-benzimidazol-5- yl](methyl)amino]sulfonyl}-i\yV-dimethylpiperazine-1-carboxamide

Following the procedure in Step A of Example 60, N-[2-tert-butyl-1-(tetrahydro-2H- pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-N-metriylpiperazine-1-sulfonamide (45 mg, 0.1 mmol) was reacted with dimethylcarbamoyl chloride (22 mg, 0.2 mmol), after being purified by reverse phase HPLC, to provide 4-{[[2-tert-butyl-1-(tetrahydro-2H- pyran-4-ylmethyl)-1H-benzimidazol-5 -yl] (methyl)amino]sulfonyl} -N,N- dimethylpiperazine-1-carboxamide (TFA salt, 56 mg, 88 %). ¹H NMR (400 MHz, CD₃OD, TFA salt) δ 1.54 (m, 4H), 1.67 (s, 9H), 2.37 (m, 1H), 2.82 (s, 6H), 3.23 (m, 6H), 3.33 (s, 3H), 3.36 (m, 4H), 3.91 (m, 2H), 4.53 (d, J = 7.6 Hz, 2H), 7.68 (d, J=9.2 Hz, 1H), 7.81 (s, 1H), 7.96 (d, JN9.2 Hz, 1H); MS (ESI) (M+H)⁺ 521.0.

Example 84

4-{[[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}-N-isopropylpiperazine-1-carboxamide

Following the procedure in Step A of Example 68, N-[2-tert-butyl-1-(tetrahydro-2i?- pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-N-methylpiperazine- 1 -sulfonamide (45 mg, 0.1 mmol) was reacted with isopropyl isocyanate (17 mg, 0.2 mmol), after being purified by reverse phase HPLC, to provide 4-{[[2-tert-butyl-1-(tetrahydro-2H-pyran- 4-ylmethyl)-1H-benzimidazol-5-yl](methyl)amino]sulfonyl}-N-isopropylpiperazine- 1-carboxamide (TFA salt, 64 mg, 98 %). ¹H NMR (400 MHz, CD₃OD, TFA salt) δ 1.10 (d, J=6.4 Hz, 6H), 1.58 (m, 4H), 1.67 (s, 9H), 2.35 (m, 1H), 3.20 (m, 4H), 3.33 (s, 3H), 3.37 (m, 6H), 3.85 (m, 1H), 3.91 (m, 2H), 4.53 (d, J = 7.6 Hz, 2H), 7.67 (d, J=9.2 Hz, 1H), 7.81 (s, 1H), 7.96 (d, J=9.2 Hz, 1H); MS (ESI) (M+H)⁺ 535.0.

Example 85

4-{[[2-ter^-Butyl-1-(tetrahydro-2J3^r-pyran-4-ylmethyl)-ljH^r-benzimidazol-5- yll^ethy^aminolsulfonyll-N-cyclopentylpiperazine-1-carboxamide

Following the procedure in Step A of Example 68, N-[2-tert-butyl-1-(tetrahydro-2H- pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-N-methylpiperazme-1-sulfonamide (90 mg, 0.2 mmol) was reacted with isocyanatocyclopentane (44 mg, 0.4 mmol), after being purified by reverse phase HPLC, to provide 4-{[[2-tert-butyl-1-(tetrahydro-2H- pyran-4-ylmethyl)-1H-benzimidazol-5-yl](methyl)amino]sulfonyl}-N- cyclopentylpiperazine-1-carboxamide (TFA salt, 135 mg, 100 %). ¹H NMR (400

MHz, CDCl₃) δ 1.28 (m, 2H), 1.54 (m, 4H), 1.57 (s, 9H), 1.59 (m, 4H), 1.97 (m, 2H), 2.30 (m, 1H), 3.19 (m, 4H), 3.30 (s, 3H), 3.33 (m, 6H), 4.02 (m, 2H), 4.07 (m, 1H), 4.20 (d, J = 7.6 Hz, 2H), 4.38 (m, 1H), 7.31 (m, 2H), 7.72 (s, 1H); MS (ESI) (M+H)⁺ 561.0.

Example 86

4-{[[2-te/Y-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-lN-benzimidazol-5- yl](methyl)amino]sulfonyl}-N-methylpiperazine-1-carboxamide

Following the procedure in Step A of Example 68, N-[2-tert-butyl-1-(tetrahydro-2H- pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-N-methylpiperazine- 1 -sulfonamide (60 mg, 0.13 mmol) was reacted with methyl isocyanate (17 mg, 0.3 mmol), after being purified by reverse phase ΗPLC, to provide 4-{[[2-tert-butyl-1-(tetrahydro-2H-pyran- 4-ylmethyl)-1H-benzimidazol-5-yl](methyl)amino]sulfonyl}-N-methylpiperazine-1- carboxamide (TFA salt, 75 mg, 93 %). ¹H NMR (400 MHz, CDCl₃) δ 1.45 (m, 4H), 1.48 (s, 9H)₃ 2.21 (m, 1H), 2.68 (m, 3H), 3.10 (m, 4H)₃ 3.21 (s, 3H), 3.28 (m, 6H), 3.91 (m, 2H), 4.12 (d, J = 7.6 Hz, 2H), 4.78 (m, 1H), 7.23 (m, 2H), 7.62 (s₃ 1H); MS (ESI) (M+H)⁺ 507.0.

Example 87

4-{[[2-ter^-Butyl-1-(tetrahydro-2_JH-pyran-4-ylmethyl)-l_JH^r-benzimidazol-5- yl](methyl)amino]sulfonyl}-N-cyclopropylpiperazine-1-carboxamide

Following the procedure in Step A of Example 68, N-[2-tert-butyl-1-(tetrahydro-2H- pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-N-methylpiperazine- 1 -sulfonamide (50 mg, 0.11 mmol) was reacted with cyclopropyl isocyanate (25 mg, 0.3 mmol), after being purified by reverse phase ΗPLC, to provide 4-{[[2-tert-butyl-1-(tetrahydro-2H- pyran-4-ylmethyl)-1H-benzimidazol-5-yl](methyl)amino]sulfonyl}-N- cyclopropylρiperazine-1-carboxamide (TFA salt, 56 mg, 78 %). ¹H NMR (400 MHz, CDCl₃) δ 0.53 (m, 2H), 0.68 (m, 2H), 1.53 (m₃ 4H)₃ 1.57 (s, 9H), 2.30 (m, 1H), 2.61 (m, 1H), 3.18 (m, 4H), 3.30 (s, 3H), 3.33 (m, 6H), 3.99 (m, 2H), 4.20 (d, J = 7.6 Hz, 2H), 5.01 (s, 1H), 7.31 (m₃ 2H), 7.70 (s₃ 1H); MS (ESI) (M+H)⁺ 533.0.

- Il l - Example 88

4-{[[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino lsulfonyl}-N-cyclobutylpiperazine-1-carboxamide

Following the procedure in Step A of Example 68, N-[2-tert-butyl-1-(tetrahydro-2H- pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-N-methylpiperazine-1-sulfonarnide (50 mg, 0.11 mmol) was reacted with cyclobutyl isocyanate (29 mg, 0.3 mmol), after being purified by reverse phase HPLC, to provide 4-{[[2-tert-butyl-1-(tetrahydro-2H- pyran-4-ylmethyl)-1H-benzimidazol-5-yl](methyl)amino]sulfonyl}-N- cyclobutylpiperazine-1-carboxamide (TFA salt, 39 mg, 54 %). ¹H ΝMR (400 MHz, CDCl₃) δ 1.53 (m, 4H), 1.57 (s, 9H), 1.69 (m, 2H), 1.79 (m, 2H), 2.30 (m, 3H), 3.19 (m, 4H), 3.30 (s, 3H), 3.34 (m, 6H), 3.98 (m, 2H), 4.20 (d, J = 7.6 Hz, 2H), 4.23 (m, 1H), 7.31 (m, 2H), 7.72 (s, 1H); MS (ESI) (M+H)⁺ 547.0.

Example 89

N-(tert-Butyl)-4-{[[2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H- benzimidazol-5-yl] (methyl) amino] sulfonyl} piperazine-1-carboxamide

Following the procedure in Step A of Example 68, N-[2-tert-butyl-1-(tetrahydro-2H- pyran-4-ylmethyl)- 1 H-benzimidazol-5 -yl] - N-methylpiperazine- 1 -sulfonamide (50 mg, 0.11 mmol) was reacted with tert-butyl isocyanate (29 mg, 0.3 mmol), after being purified by reverse phase HPLC, to provide N-(tert-butyl)-4-{[[2-tert-butyl-l- (tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}piperazine-1-carboxamide (TFA salt, 29 mg, 40 %). ¹H NMR (400 MHz, CDCl₃) δ 1.33 (s, 9H), 1.53 (m, 4H), 1.57 (s, 9H), 2.30 (m, 1H)₅ 3.20 (m, 4H), 3.30 (s, 3H), 3.33 (m, 6H), 3.98 (m, 2H), 4.20 (d, J = 7.6 Hz, 2H), 7.31 (m, 2H), 7.72 (s, 1H); MS (ESI) (M+H)⁺ 549.0.

Example 90 N-Butyl-4-{[[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-lir-benzimidazol-

5-yl](raethyl)amino]sulfonyl}piperazine-1-carboxamide

Following the procedure in Step A of Example 68, N-[2-fert-butyl-1-(tetrahydro-2H- pyran-4-ylmethyl)-1H-benzimidazol-5 -yl] -N-methylpiperazine- 1 -sulfonamide (50 mg, 0.11 mmol) was reacted with butyl isocyanate (29 mg, 0.3 mmol), after being purified by reverse phase ΗPLC, to provide N-butyl-4-{[[2-tert-butyl-1-(tetrahydro- 2H-pyran-4-ylmethyl)-li/-benzimidazol-5-yl](methyl)amino]sulfonyl}piperazine-1- carboxamide (TFA salt, 26 mg, 36 %). ¹H NMR (400 MHz, CDCl₃) δ 0.90 (t, J=7.2 Hz, 3H), 1.33 (m, 2H), 1.46 (m, 2H), 1.53 (m, 4H), 1.57 (s, 9H), 2.30 (m, 1H), 3.16 (m, 6H), 3.30 (s, 3H), 3.35 (m, 4H), 3.99 (m, 2H), 4.20 (d, J = 7.6 Hz, 2H), 7.31 (m, 2H), 7.72 (s, 1H); MS (ESI) (M+H)⁺ 549.0.

Example 91 N-Allyl-4-{[[2-ter^-butyl-1-(tetrahydro-2fl-pyran-4-ylmethyl)-1H-benzimidazol- 5-yl](methyl)amino]sulfonyl}piperazine-1-carboxamide

Following the procedure in Step A of Example 68, N-[2-tert-butyl-1-(tetrahydro-2i-^r- pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-N-methylpiperazine- 1 -sulfonamide (50 mg, 0.11 mmol) was reacted with 3-isocyanatoprop-1-ene (25 mg, 0.3 mmol), after being purified by reverse phase HPLC, to provide N-allyl-4-{[[2-tert-butyl-1- (tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}piperazine-1-carboxamide (TFA salt, 29 mg, 41 %). ¹H NMR (400 MHz, CDCl₃) δ 1.54 (m, 4H), 1.57 (s, 9H), 2.30 (m, 1H)₅ 3.21 (m, 4H), 3.30 (s, 3H)₅ 3.37 (m, 6H)₅ 3.84 (m, 2H), 3.98 (m, 2H), 4.20 (d, J = 7.6 Hz, 2H), 5.11 (m, 1H)₅ 5.17 (m, 1H), 5.85 (m, 1H)₅ 7.31 (m, 2H), 7.73 (s, 1H); MS (ESI) (M+H)⁺ 533.0.

Example 92

4-{[[2-ter^-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-l_JfiT-benzimidazol-5- yl](methyl)amino]sulfonyl}-N-ethylpiperazine-1-carboxamide

Following the procedure in Step A of Example 68, N-[2-tert-butyl-1-(tetrahydro-2H- pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-N-methylpiperazine-1-sulfonamide (50 mg₅ 0.11 mmol) was reacted with isocyanatoethane (21 mg, 0.3 mrnol), after being purified by reverse phase HPLC₅ to provide 4-{[[2-tert-butyl-1-(tetrahydro-2H-pyran- 4-ylmethyl)-1H-benzimidazol-5-yl](methyl)amino]sulfonyl}-N-ethylpiperazine-1- carboxamide (TFA salt, 13 mg, 19 %). ¹HNMR (400 MHz, CDCl₃) δ 1.13 (t, J=7.2 Hz, 3H)₅ 1.53 (m, 4H)₅ 1.57 (s, 9H)₅ 2.30 (m, 1H), 3.20 (m, 6H), 3.30 (s, 3H)₅ 3.33 (m, 4H)₅ 3.98 (m, 2H), 4.20 (d, J = 7.6 Hz, 2H), 7.31 (m, 2H), 7.72 (s, 1H); MS (ESI) (M+H)⁺ 521.0.

Example 93

4-{[[2-terf-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl] (methyl)amino] sulfonyl}-N-propylpiperazme-1-carboxamide

Following the procedure in Step A of Example 68, N-[2-tert-butyl-1-(tetrahydro-2i-⁷- pyran-4-ylme1hyl)-1H-benzimidazol-5-yl]-N^:-rriethylpiperazme-1-sulfonarnide (50 mg, 0.11 mmol) was reacted with 1-isocyanatopropane (25 mg, 0.3 mmol), after being purified by reverse phase HPLC, to provide 4-{[[2-tert-buryl-1-(tetrahydro-2/i^'- pyran-4-ylmethyl)-1H-benzimidazol-5-yl](methyl)amino]sulfonyl}-7V^'- propylpiperazine-1-carboxamide (TFA salt, 24 mg, 34 %). ¹H NMR (400 MHz, CDCl₃) δ 0.91 (t, J=7.6 Hz, 3H), 1.53 (m, 6H), 1.57 (s, 9H), 2.33 (m, 1H), 3.20 (m, 6H), 3.30 (s, 3H), 3.33 (m, 4H), 3.98 (m, 2H), 4.20 (d, J = 7.6 Hz, 2H), 7.31 (m, 2H), 7.72 (s, 1H); MS (ESI) (M+H)⁺ 535.0.

Example 94

4-{[[2-tert-ButyI-1-(tetrahydro-2H-pyran-4-ylmethyl)-li?-benzimidazol-5- yl](methyl)amino]sulfonyl}-N-(cyclopropylmethyl)piperazine-1-carboxamide

Following the procedure in Step A of Example 68, N-[2-te^butyl-1-(tetrahydro-2H- pyran-4-ylmethyl)- lu/-benzimidazol-5-yl]-N-methylpiperazine- 1 -sulfonamide (50 mg, 0.11 mmol) was reacted with (isocyanatomethytycyclopropane (28 mg, 0.3 mmol), after being purified by reverse phase HPLC, to provide 4-{[[2-tert-butyl-1- (tetrahydro-2/i^'-pyran-4-ylmethyl)-li-^r-benzimidazol-5-yl](methyl)amino]sulfonyl}-N- (cyclopropylmethy^piperazine-1-carboxamide (TFA salt, 35 mg, 48 %). ¹H NMR (400 MHz, CDCl₃) δ 0.17 (m, 2H), 0.50 (m, 2H), 0.94 (m, 1H), 1.54 (m, 4H), l_r57 (s, 9H), 2.30 (m, 1H), 3.06 (m, 2H), 3.20 (m, 4H), 3.30 (s, 3H), 3.37 (m, 6H), 3.99 (m, 2H), 4.20 (d, J = 7.6 Hz, 2H), 7.31 (m, 2H), 7.72 (s, 1H); MS (ESI) (M+H)⁺ 547.0. Example 95

N-[2-tert-Butyl-1-(tetrahydro-2fi^r-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-4-

(liϊ-imidazol-1-ylcarbonyl)-N-methylpiperazme-1-sulfonamide

A solution of N-[2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol- 5-yl]-N-methylpiperazme-l -sulfonamide (2.25 g, 5.0 mmol) and l,l'-biscarbonyl-1H- imidazole (0.97 g, 6.0 mmol) in THF (40 mL) was heated at 65⁰C for two days. The reaction mixture was concentrated under reduced pressure. The residue was then dissolved in AcOEt (60 mL), washed with brine, and dried over Na₂SO₄. Removal of solvents provided N-[2-t ert-butyl- 1 -(tetrahy&o-2H-pyτan-4-ylmethyl)- IH- benzimidazol-5 -yl] -4-( 1H-imidazol- 1 -ylcarbonyl)-N-methylpiperazine- 1 -sulfonamide (2.6 g, 96 %), ¹H NMR (400 MHz, CD₃OD, TFA salt) δ 1.54 (m, 4H), 1.68 (s, 9H), 2.37 (m, 1H), 3.32 (m, 2H), 3.34 (s, 3H), 3.42 (m, 4H), 3.65 (m, 4H), 3.92 (m, 2H), 4.54 (d, J = 7.6 Hz, 2H), 7.67 (m, 2H), 7.84 (s, 1H), 7.90 (s, 1H), 7.97 (d, J=8.8 Hz, 1H), 9.32 (s, 1H); MS (ESI) (M+H)⁺ 543.8.

Example 96

Isopropyl 4-{ [ p-terf-butyl-1-^etrahydro^H-pyran^-ylmethy^-1H- benzimidazol-5-yl](methyl)amino]sulfonyl}piperazine-1-carboxylate

Following the procedure in Step A of Example 60, N-[2-tert-butyl-1-(tetrahydro-2H- pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-N-methylpiperazine-1-sulfonamide (45 mg, 0.10 mmol) was reacted with isopropyl chloroformate (25 mg, 0.2 mmol), after being purified by reverse phase HPLC, to isopropyl 4-{[[2-tert-butyl-1-(tetrahydro- 2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl](methyl)amino]sulfonyl}piperazine-1- carboxylate (TFA salt, 62 mg, 94 %). ¹H NMR (400 MHz, CDCl₃) δ 1.16 (d, J=6.3 Hz, 6H), 1.47 (m, 4H), 1.49 (s, 9H), 2.22 (m, 1H)₅ 3.10 (m, 4H), 3.23 (s, 3H)₅ 3.23 (m, 2H), 3.37 (m₅ 4H), 3.91 (m, 2H), 4.13 (d, J = 7.6 Hz, 2H), 4.83 (m, 1H), 7.23 (m, 2H), 7.64 (S₅ 1H); MS (ESI) (M+H)⁺ 536.0.

Example 97 N-(1-{[[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benziinidazol-5- yl] (methyl)amino] sulfonyl}pyrrolidin-3-yl)acetamide

Step A. -V-(1-{ [ [2-ter^-Butyl-1-(tetrahydro-2J3^r-pyran-4-ylmethyl)-l_Jff- benzimidazol-5-yl](methyl)amino]sulfonyl}pyrrolidin-3-yl)acetamide

Following the procedure in Step A of Example 60, 3-amino-N-[2-tert-butyl-1-

(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-N-methylpyrrolidine-1- sulfonamide trifluoroacetate (100 mg, 0.18 mmol) was reacted with acetyl chloride (79 mg₃ 1.0 mmol), after being purified by reverse phase HPLC₅ to provide 2V-(I- { [[2-tert-butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}pyrrolidin-3-yl)acetamide (TFA salt, 25 mg, 23 %). ¹H NMR (400 MHz, CD₃OD₅ TFA salt) δ 1.54 (m, 4H), 1.67 (s, 9H)₃ 1.85 (m, 1H), 1.89 (s, 3H)₅ 2.13 (m, 1H), 2.36 (m, 1H)₅ 3.10 (m, 1H)₅ 3.31 (s, 3H), 3.33 (m, 3H)₅ 3.48 (m, 2H), 3.91 (m, 2H), 4.20 (m, 1H)₅ 4.52 (d, J = 7.6 Hz, 2H), 7.65 (d₅ J=9.0 Hz, 1H)₅ 7.79 (S₅ 1H)₅ 7.93 (d, J=9.0 Hz, 1H); MS (ESI) (M+H)⁺492.0. Step B. tert-Butyl (1-{[[2-tert-butyl-1-(tetrahydro-2_Jff-pyran-4-ylmethyl)-lJ3- benzimidazol-5-yl](methyl)amino]sulfonyl}pyrroIidin-3-yl)carbamate

Following the procedure in Step C of Example 60, 1-{[[2-tert-butyl-1-(tetrahydxo-2H- pyran-4-ylmethyl)-1H-benzimidazol-5-yl](methyl)amino]sulfonyl}-3-methyl-li/- imidazol-3-ium triflate (460 mg, 0.77 mrαol) was reacted with tert-butyl pyrrolidin-3- ylcarbamate (558 mg, 3.0 mmol), after being purified by silica gel chromatography, to provide tert-hutyl (1-{[[2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-lJf- benzimidazol-5-yl](methyl)amino]sulfonyl}pyrrolidin-3-yl)carbamate (385 mg, 91 %). MS (ESI) (M+H)⁺ 550.0.

Step C : 3-Amino-Λ^-[2-tert-butyl-1-(tetrahydro-2H-pyran-4-yImethyl)-1H- benzimidazol-5-yl]-N-methylpyrroHdine-1-sulfonamide

A solution of tert-butyl (1-{[[2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H- benzimidazol-5-yl](methyl)amino]sulfonyl}pyrrolidin-3-yl)carbamate (385 mg, 0.7 mmol) in 10 mL CH₂Cl₂ was treated with 10 mL TFA at room temperature. After being stirred at room temperature for 1 hr, the reaction mixture was concentrated under reduced pressure to provide 3-amino-N-[2-tert-butyl- 1 -(tetrahydro-2H-pyran-4- ylmethyO-1H-benzimidazol-5-ylJ-N-methylpyrrolidme-1-sulfonamide (TFA salt, 100 %), which was used in Step A without purification. Example 98 N-(l-{[[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}pyrrolidin-3-yl)-2,2-dimethylpropanamide

Following the procedure in Step A of Example 60, 3-amino-N-[2-tert-butyl-1- (tetrahydro-2H-pyran-4-ylmethyl)-l//-benzimidazol-5-yl]-N-methylpyrrolidme-1- sulfonamide trifluoroacetate (100 mg, 0.18 mmol) was reacted with 2,2- dimethylpropanoyl chloride (60 mg, 0.5 mmol), after being purified by reverse phase HPLC, to provide N-(1-{[[2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H- benzimidazol-5-yl](methyl)amino]sulfonyl}pyrrolidin-3-yl)-2,2- dimethylpropanamide (TFA salt, 39 mg, 33 %). ¹H NMR (400 MHz, CD₃OD₅ TFA salt) δ 1.12 (s, 9H), 1.57 (m, 4H), 1.67 (s, 9H), 1.96 (m, 1H), 2.11 (m, 1H), 2.36 (m, 1H), 3.10 (m, 1H), 3.31 (s, 3H), 3.33 (m, 3H), 3.48 (m, 2H), 3.91 (m, 2H), 3.94 (m, 1H), 4.52 (d, J = 7.6 Hz, 2H), 7.65 (d, J=9.0 Hz, 1H), 7.79 (s, 1H), 7.94 (d, J=9.0 Hz, 1H); MS (ESI) (M+H)⁺ 534.0.

Example 99 N-(1-{[[2-tert-Butyl-1-(tetrahydro-2_JH^r-pyran-4-ylmethyl)-ljEr-benzimidazol-5- yl] (methyl)amino] sulfonyl} azetidin-3-yl)acetamide

Following the procedure in Step A of Example 60, 3-amino-N-[2-tert-butyl-1- (tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-N-methylazetidme- 1 - sulfonamide (20 mg, 0.046 mmol) was reacted with acetic anhydride (51 mg, 0.5 mmol), after being purified by reverse phase HPLC, to provide N-(I- {[[2-tert-butyl- l-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}azetidin-3-yl)acetamide (TFA salt, 9 mg, 33 %). ¹H NMR (400 MHz, CD₃OD₅ TFA salt) δ 1.58 (m, 4H), 1.67 (s, 9H), 1.91 (s, 3H), 2.32 (m, 1H), 3.28 (s, 3H), 3.33 (m, 2H), 3.80 (m, 2H), 3.91 (m, 2H), 3.99 (m, 2H), 4.50 (m, 1H), 4.53 (d, J = 7.6 Hz, 2H), 7.65 (d, J=9.2 Hz, 1H), 7.78 (s, 1H), 7.95 (d, J=9.2 Hz, 1H); MS (ESI) (M+H)⁺ 478.0.

Example 100 N-{2-fert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-lJ9^r-benzimidazol-5-yl}-N- methyl-1H-imidazole-1-sulfonamide

3-(Imidazole-1-sulfonyl)-1-methyl-3H-imidazol-1-ium triflate (xx mg; 1.5 mmol) was added into a solution of 2-tert -butyl- l-[(4,4-difluorocyclohexyl)methyl]-N-inethyl- 1H-benzimidazol-5-amine (335 mg, 1.0 mmol) in acetonitrile (15 mL). After being stirred at room temperature overnight, the reaction mixture was concentrated under reduced pressure to give a residue, which was purified by HPLC to provide N-{2-tert- butyl- 1 - [(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl} -N-methyl- IH- imidazole-1 -sulfonamide (295 mg, 51 %). MS (ESI) (M+H)⁺ 466.0.

Example 101 N-{2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-lj9^r-benzimidazol-5-yl}--V- methyl-1H-l,2,4-triazole-1-sulfonamide

Following the procedure in Step C of Example 60, 1-{[{2-tert-butyl-1-[(4,4- difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl}(methyl)amino]sulfonyl}-3- methyl-1H-imidazol-3-ium triflate (50 rag, 0.08 mmol) was reacted with 1H-1,2,4- triazole (69 mg, 1.0 mmol), after being purified by reverse phase HPLC, to provide N-{2-tert-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl}-N- memyl-1H-l,2,4-triazole-1-sulfonamide (TFA salt, 15 mg, 32 %). ¹H NMR (400 MHz, CD₃OD, TFA salt) δ 1.40-1.76 (m, 6H), 1.62 (s, 9H), 2.03 (m, 2H), 2.20 (m, 1H), 3.55 (s, 3H), 4.48(d, J = 7.4 Hz, 2H), 7.36(d, J=9.0 Hz, 1H), 7.60 (s, 1H), 7.86(d, J=9.0 Hz, 1H), 8.28 (s, 1H), 8.72(s, 1H); MS (ESI) (M+H)⁺ 467.0.

Example 102 N-{2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl}-N- methyl-1H-l,2,3-triazole-1-sulfonamide

Following the procedure in Step C of Example 60, 1-{[{2-tert-butyl-1-[(4,4- difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl}(methyl)amino]sulfonyl}-3- methyl-1H-imidazol-3-ium triflate (50 mg, 0.08 mmol) was reacted with 1H-1,2,3- triazole (69 mg, 1.0 mmol), after being purified by reverse phase ΗPLC, to provide N-{2-tert-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl}-N- methyl-1H-l,2,3-triazole-1-sulfonamide (TFA salt, 14 mg, 30 %). ¹H NMR (400 MHz, CD₃OD, TFA salt) δ 1.40-1.76 (m, 6H), 1.59 (s, 9H), 2.03 (m, 2H), 2.20 (m, 1H), 3.56 (s, 3H), 4.42 (d, J = 7.4 Hz, 2H), 7.22(d, J=9.0 Hz, 1H), 7.47 (s, 1H), 7.75(d, J=9.0 Hz, 1H), 7.82 (d, J=1.1 Hz, 1H), 8.21 (d, J=Ll Hz, 1H); MS (ESI) (M+H)⁺ 467.0.

Example 103 N-[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benziinidazol-5-yl]-4- formyl-N-methyl-1H-pyrazole-1-sulfonamide

Following the procedure in Step C of Example 60, 1-{[2-tert-butyl-1-(tetrahydro-1H- pyran-4-ylmethyl)-1H-benzimidazol-5-yl](methyl)amino]sulfonyl}-3-methyl-1H- imidazol-3-ium triflate (1.89 g, 3.0 mmol) was reacted with 1H-pyrazole-4- carbaldehyde (576 mg, 6.0 mmol), after being purified by silica gel chromatography, to provide N-[2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl]-4-formyl-N-methyl-1H-pyrazole-l -sulfonamide (586 mg, 43 %). ¹H NMR (400 MHz, CDCl₃) δ 1.48 (m, 4H), 1.50 (s, 9H), 2.22 (m, 1H), 3.27 (m, 2H), 3.55 (s, 3H), 3.91 (m, 2H), 4.14 (d, J = 7.2 Hz, 2H), 6.98 (dd, J = 8.8, 2.0 Hz, 1H), 7.925 (d, J = 8.8 Hz, 1H), 7.37 (s, 1H), 8.14 (s, 1H), 8.18 (s, 1H), 9.81 (s, 1H); MS (ESI) (M+H)⁺ 460.0.

Example 104 1-{[[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}-N-cyclopropyl-1H-pyrazole-4-carboxaraide

Step A. 1-{ [ [2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol- 5-yl](methyl)amino]sulfonyl}-N-cyclopropyl-1H-pyrazole-4-carboxamide

HATU (150 mg, 0.4 mmol) was added to a solution of 1-{[[2-tert-butyl-1-(tetrahydro- 2/f-pyran-4-ylmethyl)- li7-benzimidazol-5-yl](methyl)amino]sulfonyl} -1H-pyrazole- 4-carboxylic acid (100 mg, 0.21 mmol), cyclopropylamine (57 mg, 1.0 mmol) and DIPEA (0.2 mL) in DMF (3.0 mL) at r.t. After 30 min, the reaction mixture was condensed to give a residue, which was purified by reverse phase HPLC to provide 1- { [[2-tert-butyl-l -(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}-N-cyclopropyl-1H-pyrazole-4-carboxamide (TFA salt, 29 mg, 22 %). ¹H NMR (400 MHz, CDCl₃) δ 0.59 (m, 2H), 0.80 (m, 2H), 1.54 (m, 4H), 1.56 (s, 9H), 2.33 (m, 1H), 2.82 (m, 1H), 3.33 (m, 2H), 3.55 (s, 3H), 3.99 (m, 2H), 4.20 (d, J = 7.6 Hz, 2H), 6.40 (s, 1H), 7.06 (dd, J = 9.0, 2.0 Hz, 1H), 7.28 (d, J = 9.0 Hz, 1H), 7.38 (s, 1H), 8.02 (s, 1H), 8.05 (d, J=3.5 Hz, 1H); MS (ESI) (M+H)⁺515.0.

Step B. 1-{[[2-tert-Butyl-1-(tetrahydro-2_JH^r-pyran-4-ylmethyl)-l_JH-benzimidazol- 5-yl] (methyl) amino] sulfonyl} -1H-pyrazole-4-carboxylic acid

N-[2-ført-butyl-1-(tetrahydro-2H-pyran-4-ylmemyl)-1H-benzimidazol-5-yl]-4-formyl- ΛT-methyl-1H-pyrazole-1 -sulfonamide (460 mg, 1.0 mmol) and ozone (1.0 g, 1.6 mmol) was heated in DMF (15 mL) at 50 ⁰C for 2 hr. The resulting 1-{[[2-fert-butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)-1H-berizimidazol-5-yl](me&yl)amino]sulfonyl} - 1H-pyrazole-4-carboxylic acid solution in DMF was used directly in Step A. MS (ESI) (M+H)⁺ 476.0. Example 105 1-{[[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylraethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}-N-ethyl-1H^r-pyrazole-4-carboxamide

Following the procedure in Step A of Example 104, 1-{[[2-tert-butyl-1-(tetrahydro- 2H-pyran-4-ylmethyl)-li/-benzimidazol-5-yl](methyl)amino]sulfonyl}-1H-pyrazole- 4-carboxylic acid (96 mg, 0.20 mmol) was reacted with ethylamine (90 mg, 2.0 mmol), after being purified by reverse phase HPLC, to provide 1-{[[2-føt-butyl-1- (tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5 -yl] (methyl)amino] sulfonyl} -N- ethyl-1H-pyrazole-4-carboxamide (TFA salt, 33 mg, 27 %). ¹H NMR (400 MHz, CD₃OD₅ TFA salt) δ 1.14 (d, J = 7.4 Hz, 3H), 1.52 (m, 4H), 1.65 (s, 9H), 2.33 (m, 1H), 3.32 (m, 4H)₃ 3.51 (s, 3H), 3.91 (m, 2H), 4.51 (d, J = 7.6 Hz, 2H), 7.42 (dd, J = 9.0, 2.0 Hz, 1H), 7.66 (d, J = 2.0 Hz, 1H), 7.95 (d, J = 9.0 Hz, 1H), 8.18 (s, 1H), 8.30 (s, 1H); MS (ESI) (M+H)⁺502.8.

Example 106 N-Allyl-1-{[[2-tert-butyl-1-(tetrahydro-2J9^r-pyran-4-yImethyl)-1H-benzimidazol- 5-yl] (methyl) amino] sulfonyl} -lIZ-pyrazole-4-carb oxamide

Following the procedure in Step A of Example 104, 1 - { [[2-tert-butyl- 1 -(tetrahydro- 2H-pyran-4-ylmeώyl)-1H-benzimidazol-5-yl](methyl)amino]sulfonyl}-1H-pyrazole- 4-carboxylic acid (96 mg, 0.20 mmol) was reacted with allylamine (114 mg, 2.0 mmol), after being purified by reverse phase HPLC, to provide N-allyl-1-{[[2-tert- butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)ainino]sulfonyl}-1H-pyrazole-4-carboxamide (TFA salt, 38 mg, 30 %). ¹H NMR (400 MHz, CD₃OD, TFA salt) δ 1.52 (m, 4H), 1.65 (s, 9H), 2.33 (m, 1H), 3.32 (m, 4H), 3.52 (s, 3H), 3.91 (m, 4H), 4.51 (d, J = 7.6 Hz, 2H), 5.09 (m, 1H), 5.17 (m, 1H), 5.85 (m, 1H), 7.42 (dd, J = 9.0, 2.0 Hz, 1H), 7.67 (d, J = 2.0 Hz, 1H), 7.95 (d, J = 9.0 Hz, 1H), 8.20 (s, 1H), 8.32 (s, 1H); MS (ESI) (M+H)⁺515.0.

Example 107 1-{ [[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}-N-propyl-1H-pyrazole-4-carboxamide

Following the procedure in Step A of Example 104, 1-{[[2-tert-butyl-1-(tetrahydro- 2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl](methyl)amino]sulfonyl} -1H-pyrazole- 4-carboxylic acid (96 mg, 0.20 mmol) was reacted with propylamine (118 mg, 2.0 mmol), after being purified by reverse phase HPLC, to provide 1-{[[2-tert-butyl-1- (tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl](methyl)amino]sulfonyl}-N- propyl-1H-ρyrazole-4-carboxamide (TFA salt, 44 mg, 35 %). ¹H NMR (400 MHz, CD₃OD, TFA salt) δ 0.91 (d, J = 7.4 Hz, 3H), 1.52 (m, 6H), 1.65 (s, 9H), 2.33 (m, 1H), 3.23 (t, J=7.2 Hz, 2H), 3.32 (m, 2H), 3.52 (s, 3H), 3.91 (m, 2H), 4.51 (d, J = 7.6 Hz, 2H), 7.41 (dd, J = 9.0, 2.0 Hz, 1H), 7.66 (d, J = 2.0 Hz, 1H), 7.95 (d, J = 9.0 Hz, 1H), 8.19 (s, 1H), 8.31 (s, 1H); MS (ESI) (M+H)⁺516.8.

Example 108 1-{[[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]suIfonyl}-N^V-dimethyl-1H-pyrazole-4-carboxamide

Following the procedure in Step A of Example 104, 1-{[[2-tert-butyl-1-(tetrahydro- 2H-pyran-4-ylmethyl)-liif-benzimidazol-5-yl](methyl)amino]sulfonyl}-l//^'-pyrazole- 4-carboxylic acid (96 mg, 0.20 mmol) was reacted with dimethylamine (90 mg, 2.0 mmol), after being purified by reverse phase HPLC, to provide 1-{[[2-tert-butyl-1- (tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl](methyl)amino]sulfonyl}- N,N-dimethyl-1H-ρyrazole-4-carboxamide (TFA salt, 79 mg, 64 %). ¹H NMR (400 MHz, CD₃OD, TFA salt) δ 1.53 (m, 4H), 1.66 (s, 9H), 2.33 (m, 1H), 3.02 (s, 3H), 3.12 (s, 3H), 3.32 (m, 2H), 3.51 (s, 3H), 3.89 (m, 2H), 4.52 (d, J = 7.6 Hz, 2H), 7.41 (dd, J = 9.0, 2.0 Hz, 1H), 7.61 (d, J = 2.0 Hz, 1H), 7.95 (d, J = 9.0 Hz, 1H), 8.09 (s, 1H), 8.16 (s, 1H); MS (ESI) (M+H)⁺502.8.

Example 109 1-{[[2-tert-Butyl-1-(tetrahydro-2i?-pyran-4-ylmethyl)-lJ3-benzimidazol-5- yl] (methyl)amino] sulfonyl}-N-methyl-l£?-pyrazole-4-carboxaraide

Following the procedure in Step A of Example 104, 1-{[[2-tert-butyl-1-(tetrahydro-

2#-pyran-4-ylmethyl)-1H-berizm

4-carboxylic acid (96 mg, 0.20 mmol) was reacted with methylamine (31 mg, 1.0 mmol), after being purified by reverse phase HPLC, to provide 1-{[[2-tert-butyl-1-

(tetrahydro-2H-pyran-4-ylmethyl)-1H-berizimidazol-5-yl](methyl)amino]sulfonyl}-N- methyl-1H-ρyrazole-4-carboxamide (TFA salt, 24 mg, 20 %). ¹H NMR (400 MHz,

CD₃OD, TFA salt) δ 1.52 (m, 4H), 1.65 (s, 9H), .2.33 (m, 1H), 2.81 (s, 3H), 3.32 (m, 2H), 3.52 (s, 3H), 3.91 (m, 2H), 4.51 (d, J = 7.6 Hz, 2H), 7.41 (dd, J = 9.0, 2.0 Hz, 1H), 7.66 (d, J = 2.0 Hz, 1H), 7.95 (d, J = 9.0 Hz, 1H), 8.17 (s, 1H), 8.27 (s, 1H); MS (ESI) (M+H)⁺488.7.

Example 110 N-(tert-Butyl)-1-{[[2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H- benzimidazol-5-yl}(methyl)amino ]sulfonyl}-1H-pyrazole-4-carboxamide

Following the procedure in Step A of Example 104, 1-{[[2-tert-butyl-1-(tetrahydro- 2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl](methyl)amino]sulfonyl}-1H-pyrazole- 4-carboxylic acid (96 mg, 0.20 mmol) was reacted with t-butylamine (73 mg, 1.0 mmol), after being purified by reverse phase HPLC, to provide N-(tert-butyl)-1-{[[2- tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}-1H-pyrazole-4-carboxamide (TFA salt, 26 mg, 20 %). ¹H NMR (400 MHz, CD₃OD, TFA salt) δ 1.37 (s, 9H), 1.52 (m, 4H), 1.66 (s, 9H), 2.33 (m, 1H), 3.32 (m, 2H), 3.51 (s, 3H), 3.91 (m, 2H), 4.51 (d, J = 7.6 Hz, 2H), 7.44 (dd, J = 9.0, 2.0 Hz, 1H), 7.66 (d, J = 2.0 Hz, 1H), 7.96 (d, J = 9.0 Hz, 1H), 8.17 (s, 1H), 8.36 (s, 1H); MS (ESI) (M+H)⁺530.8.

Example 111 N-(1-{[[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl] (methyl)amino] sulfonyl}-1H-pyrazol-3-yl)acetamide

Step A. N-(1-{[[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H- benzimidazol-5-yl](methyl)amino]sulfonyl}-1H-pyrazoI-3-yl)acetamide

Following the procedure in Step A of Example 60, 3-amino-N-[2-tert-butyl-1- (tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-N-methyl-1H-pyrazole-1- sulfonamide (from Step B) was reacted with acetic anhydride (530 mg, 5.0 mmol), after being purified by silica gel chromatography, to provide N-(1-{[[2-tert-butyl-1- (tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl](methyl)amino]sulfonyl}- 1H-pyrazol-3-yl)acetamide (3 mg, 2 %). ¹H NMR (400 MHz, CD₃OD, TFA salt) δ 1.52 (m, 4H), 1.66 (s, 9H), 2.14 (s, 3H), 2.34 (m, 1H), 3.32 (m, 2H), 3.51 (s, 3H), 3.91 (m, 2H), 4.51 (d, J = 7.6 Hz, 2H), 6.75 (d, J = 2.8 Hz, 1H), 7.41 (dd, J = 9.0, 2.2 Hz, 1H), 7.54 (s, 1H), 7.68 (d, J = 2.8 Hz, 1H), 7.93 (d, J = 9.0 Hz, 1H); MS (ESI) (M+H)⁺489.0.

Step B. 3-Amino-N-[2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H- benzimidazol-5-yl]-N-methyI-1H-pyrazole-1-sulfonamide

Following the procedure in Step C of Example 60, 1-{[[2-tert-butyl-1-(tetrahydro-2H- pyran-4-yrmethyl)-1H-benzimidazol-5-yl](methyl)amino]sulfonyl}-3-methyl-1H- imidazol-3-ium triflate (189 mg, 0.3 mmol) was reacted with 1H-pyrazol-3-amine (83 mg, 1.0 mmol), after being purified by silica gel chromatography, to provide crude 3- amino-N-[2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-N- methyl-1H-pyrazole-l -sulfonamide, which was used in Step A without further purification. Example 112 N-[2-fer/-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-4- formyl-N-methyl-llZ-imidazole-1-sulfonamide

Following the procedure in Step C of Example 60, 1-{[[2-fert-butyl-1-(tetrahydro-2if- pyran-4-ylmethyl)-1H-benzimidazol-5-yl](methyl)amino]sulfonyl}-3-methyl-1H- imidazol-3-ium triflate (630 g, 1.0 mmol) was reacted with lϋ/^'-imidazole-4- carbaldehyde (288 mg, 3.0 mmol), after being purified by silica gel chromatography, to provide N-[2-tert-butyl-1-(tetrahydro-2/i^'-pyran-4-ylmethyl)-1H-benzimidazol-5- yl]-4-formyl-N-methyl-1H-imidazole-1-sulfonarnide (335 mg, 73 %). ¹H NMR (400 MHz, CDCl₃) δ 1.52 (m, 4H), 1.54 (s, 9H), 2.25 (m, 1H), 3.32 (m, 2H), 3.60 (s, 3H), 3.98 (m, 2H), 4.19 (d, J = 7.6 Hz, 2H), 6.81 (s, 1H), 7.01 (dd, J = 8.6, 1.9 Hz, 1H), 7.32 (d, J = 8.6 Hz, 1H)₅ 7.41 (s, 1H), 7.74 (s, 1H), 10.12 (s, 1H); MS (ESI) (M+H)⁺ 460.0.

Example 113 1-{[[2-terf-Butyl-1-(tetrahydro-2i?-pyran-4-ylmethyl)-l/ir-benzimidazol-5- yl](methyl)amino]sulfonyl}-N-cyclopropyl-ljH-imidazole-4-carboxamide

Step A. l-{[[2-ter^-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol- 5-yl](methyl)amino]sulfonyl}-N-cyclopropyl-1H-imidazole-4-carboxamide

HATU (15 mg, 0.04 mmol) was added to a solution of 1-{[[2-tert-butyl-1-(tetrahydro- 2/i-pyran-4-ylmethyl)-1H-benzimidazol-5-yl](methyl)amino]sulfonyl}-li/- imidazole-4-carboxylic acid (10 mg, 0.02 mmol), cyclopropylamine (6 mg, 0.1 mmol) and DIPEA (0.1 niL) in DMF (1.0 mL) at r.t. After 30 min, the reaction mixture was condensed to give a residue, which was purified by reverse phase HPLC to provide 1- {[[2-tert-butyl-1-(tetrahydro-2J^c-^r-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}-N-cyclopropyl-li/-imidazole-4-carboxamide (TFA salt, 2 mg, 15 %). ¹H NMR (400 MHz, CDCl₃) δ 0.61 (m, 2H), 0.80 (m, 2H), 1.54 (m, 4H), 1.68 (s, 9H), 2.35 (m, 1H), 2.80 (m, 1H), 3.33 (m, 2H), 3.46 (s, 3H), 3.93 (m, 2H), 4.54 (d, J - 7.6 Hz, 2H), 7.37 (dd, J = 9.0, 1.9 Hz, 1H), 7.56 (d, J = 1.9 Hz, 1H), 7.72 (s, 1H), 7.91 (s, 1H), 7.99 (d, J = 9.0 Hz, 1H); MS (ESI) (M+H)⁺514.8.

Step B. 1-{[[2-tert-Butyl-1-(tetrahydro-2JY-pyran-4-yImethyl)-1H-benzimidazol- 5-yl](methyl)amino]sulfonyl}-ljH^r-imidazole-4-carboxylic acid

N-[2-tert-Butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)- l#-benzimidazol-5-yl]-4- formyl-N-methyl-1H-imidazole-1-sulfonainide (320 mg, 0.7 mmol) and ozone (650 mg, 1.1 mmol) was heated in DMF (6 mL) at r.t for 24 hr. The resulting \-{[[2-tert- butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](memyl)amino]sulfonyl}-1H-imidazole-4-carboxylic acid solution in DMF was used directly in Step A. MS (ESI) (M+H)⁺ 476.0. Example 114 1-{[[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino ]sulfonyl}-N-cyclopropyl-1H-pyrazole-3-carboxamide

Step A. 1-{[[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol- 5-yl](methyl)amino]sulfonyl}-N-cyclopropyl-1H-pyrazole-3-carboxamide

HATU (250 mg, 0.66 mmol) was added to a solution of 1-[[[2-tert-butyl-1- (tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino](methylene)oxido-λ⁴-sulfanyl]-1H-pyrazole-3-carboxylic acid (65 mg, 0.14 mmol), cyclopropylamine (57 mg, 1.0 mmol) and DIPEA (0.4 mL) in DMF (1.0 mL) at r.t. After 30 min, the reaction mixture was condensed to give a residue, which was purified by reverse phase HPLC to provide 1-{[[2-tert-butyl-1-(tetrahydro- 2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl](methyl)amino]sulfonyl} -N- cycloρropyl-1H-pyrazole-3-carboxamide (TFA salt, 19 mg, 22 %). ¹HNMR (400 MHz, CDCl₃) δ 0.64 (m, 2H), 0.81 (m, 2H), 1.52 (m, 4H), 1.65 (s, 9H), 2.33 (m, 1H), 2.84 (m, 1H), 3.33 (m, 2H), 3.56 (s, 3H), 3.91 (m, 2H), 4.51 (d, J = 7.6 Hz, 2H), 6.80 (d, J = 2.8 Hz, 1H), 7.39 (dd, J = 9.0, 2.0 Hz, 1H), 7.52 (s, 1H), 7.88 (d, J = 2.8 Hz, 1H), 7.95 (d, J = 9.0 Hz, 1H); MS (ESI) (M+H)⁺514.8.

Step B. N-[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl]-3-formyl-N-methyl-1H-pyrazole-1-sulfonamide

Following the procedure in Step C of Example 60, 1-{[[2-tert-butyl-1-(tetrahydro-2H- pyran-4-ylmethyl)-1H-benzimidazol-5-yl](methyl)amino]sulfonyl}-3-methyl-l//- imidazol-3-ium triflate (630 g, 1.0 mmol) was reacted with 1H-pyrazole-3- carbaldehyde (288 mg, 3.0 mmol), after being purified by silica gel chromatography, to provide Λ^r-[2-tert-butyl-1-(tetrahydro-2/i-pyran-4-ylmethyl)-l/i^'-benzimidazol-5- yl]-3-formyl-N-methyl-1H-pyrazole-1-sulfonamide (320 mg, 70 %). MS (ESI) (M+H)⁺ 460.0.

Step C. l-[[[2-tert-Butyl-1-(tetrahydro-2_Jfir-pyran-4-ylmethyl)-1H^r-benzimidazol- 5-yl](methyl)amino](methylene)oxido-λ⁴-sulfanyl]-1H-pyrazole-3-carboxylic acid

N-[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-3- formyl-N-methyl-1H-pyrazole-1-sulfonamide (320 mg, 0.7 mmol) and ozone (615 mg, 1.0 mmol) was heated in DMF (6 mL) at 50⁰C for 4 hr. The resulting 1 -[[[2-tert- butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino](methylene)oxido-λ⁴-sulfanyl]-1H-pyrazole-3-carboxylic acid solution in DMF was used directly in Step A. MS (ESI) (M+H)⁺ 476.0.

Example 115 l-{[[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-lIf-benzimidazol-5- yl](raethyl)amino]sulfonyl}-Λ'-isopropyl-ljH^r-pyrazole-3-carboxamide

Following the procedure in Step A of Example 114, l-[[[2-tert-butyl-1-(tetrahydro- 2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl](methyl)arniB.o](methylene)oxido-λ⁴- sulfanylJ-1H-pyrazole-S-carboxylic acid (65 mg, 0.14 mmol) was reacted with isopropylamine (59 mg, 1.0 mmol), after being purified by reverse phase HPLC to provide 1-{[[2-tert-butyl-1-(tetrahydro-2Ii-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}-N-isopropyl-li/-pyrazole-3-carboxamide (TFA salt, 31 mg, 36 %). ¹H NMR (400 MHz, CDCl₃) δ 1.24 (d, J = 6.6 Hz, 6H), 1.52 (m, 4H), 1.65 (s, 9H), 2.33 (m, 1H), 3.33 (m, 2H), 3.56 (s, 3H), 3.91 (m, 2H), 4.20 (m, 1H), 4.51 (d, J = 7.6 Hz, 2H), 6.80 (d, J = 2.8 Hz, 1H), 7.40 (dd, J = 9.0, 2.0 Hz, 1H), 7.53 (s, 1H), 7.88 (d, J = 2.8 Hz, 1H), 7.95 (d, J = 9.0 Hz, 1H); MS (ESI) (M+H)⁺516.8.

Example 116 1-{[[2-terr-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl] (methyl)amino] sulfonyl}-N-propyl-1H-pyrazole-3-carboxamide

Following the procedure in Step A of Example 114, l-[[[2-tert-butyl-1-(tetrahydro- 2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl](methyl)amino](methylene)oxido-λ⁴- sulfanyl]-1H^~-pyrazole-3-carboxylic acid (65 mg, 0.14 mmol) was reacted with propylamine (59 mg, 1.0 mmol), after being purified by reverse phase HPLC to provide 1 - { [[2-tert-butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)- 1H-benzimidazol-5- yl](methyl)amino]sulfonyl}-N-propyl-1H-pyrazole-3-carboxamide (TFA salt, 26 mg, 30 %). ¹HNMR (400 MHz, CDCl₃) δ 0.95 (t, J = 7.4 Hz, 3H), 1.52 (m, 4H), 1.62 (m, 2H), 1.65 (s, 9H), 2.33 (m, 1H), 3.28 (m, 2H), 3.33 (m, 2H), 3.58 (s, 3H), 3.91 (m, 2H), 4.51 (d, J = 7.6 Hz, 2H), 6.80 (d, J = 2.8 Hz, 1H), 7.39 (dd, J = 9.0, 2.0 Hz, 1H), 7.53 (s, 1H), 7.88 (d, J = 2.8 Hz, 1H), 7.95 (d, J = 9.0 Hz, 1H); MS (ESI) (M+H)⁺516.8.

Example 117

N-Allyl-1-{[[2-ter^-butyl-1-(tetrahydro-2_JH^r-pyran-4-ylmethyl)-1H-benzimidazol-

5-yl](methyl)amino]sulfonyl}-1H-pyrazole-3-carboxamide

Following the procedure in Step A of Example 114, l-[[[2-tert-butyl-1-(tetrahydro- 2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl](methyl)amino](methylene)oxido-λ⁴- sulfanyl]-1H-pyrazole-3-carboxylic acid (65 mg, 0.14 mmol) was reacted with allylamine (57 mg, 1.0 mmol), after being purified by reverse phase HPLC to provide N-allyl- 1 -{[[2-tert-butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)- 1H-benzimidazol-5- yl](methyl)amino]sulfonyl}-1H-pyrazole-3-carboxamide (TFA salt, 18 mg, 21 %). ¹H NMR (400 MHz, CDCl₃) δ 1.50 (m, 4H), 1.62 (m, 2H), 1.64 (s, 9H), 2.32 (m, 1H), 3.31 (m, 2H), 3.57 (s, 3H), 3.91 (m, 2H), 3.97 (d, J=5.3 Hz, 2H), (m, 1H), 4.49 (d, J = 7.6 Hz, 2H), 5.11 (m, 1H), 5.21 (m, 1H), 5,88 (m, 1H), 6.80 (d, J = 2.8 Hz, 1H), 7.39 (dd, J = 9.0, 2.0 Hz, 1H), 7.52 (s, 1H), 7.88 (d, J = 2.8 Hz, 1H), 7.94 (d, J = 9.0 Hz, 1H); MS (ESI) (M+H)⁺514.8.

Example 118 1-{[[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-li3-benzimidazol-5- yl](methyl)amino]sulfonyl}-N-ethyl-lJ3-pyrazole-3-carboxamide

Following the procedure in Step A of Example 114, l-[[[2-tert-butyl-1-(tetrahydro- 2H-pyran-4-ylmethyl)-lH-benzimidazol-5-yl](methyl)amino](methylene)oxido-λ⁴- sulfanyl]-li/-pyrazole-3-carboxylic acid (65 mg, 0.14 mmol) was reacted with ethylamine (45 mg, 1.0 mmol), after being purified by reverse phase HPLC to provide 1 - { [[2-tert-butyl- 1 -(tetr ahy dro-2H-pyran-4-y lmethyl)- 1H-benzimidazol-5 - yl](methyl)amino]sulfonyl}-N-ethyl-1H-pyrazole-3-carboxamide (TFA salt, 30 mg, 36 %). ¹H NMR (400 MHz, CDCl₃) δ 1.21 (d, J = 7.4 Hz, 3H), 1.52 (m, 4H), 1.65 (s, 9H), 2.33 (m, 1H), 3.32 (m, 2H), 3.40 (q, J =7.4 Hz, 2H), 3.58 (s, 3H), 3.91 (m, 2H), 4.51 (d, J = 7.6 Hz, 2H), 6.80 (d, J = 2.8 Hz, 1H), 7.40 (dd, J = 9.0, 2.0 Hz, 1H)₅ 7.53 (s, 1H), 7.88 (d, J = 2.8 Hz, 1H), 7.95 (d, J = 9.0 Hz, 1H); MS (ESI) (M+H)⁺502.8.

Example 119 N-[2-tert-ButyI-1-(tetrahydro-2ia^r-pyran-4-ylmethyl)-1H-benzimidazol-S-yl]-7Λ'- methyl-4-(morpholm-4-ylcarbonyl)piperazme-l -sulfonamide

Step A. 7Λ^ir-[2-tert-Butyl-1-(tetrahydro-2iϊ-pyran-4-ylmethyl)-l_JH^r-benzimidazol-5- yl]-/y-methyl-4-(morpholin-4-ylcarbonyl)piperazine-1-sulfonamide

A solution of l-[(4-{[[2-terf-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H- benzimidazol-5-yl](methyl)amino]sulfonyl}piperazin-1-yl)carbonyl]-3-methyl-l/i^:- imidazol-3-ium triflate (20 mg, 0.03 mmol), morpholine (87 mg, 1 mmol), and Hunig's base (0.2 mL) in MeCN (2 mL) was stirred overnight at r.t. The reaction mixture was then condensed to give a residue, which was purified by reverse phase HPLC to provide N-[2-tert-butyl-1-(tetrahydro-2/J-pyran-4-ylmethyl)-1H- benzimidazol-5-yl]-N-methyl-4-(morpholm-4-ylcarbonyl)piperazine-1-sulfonamide (TFA salt, 5 mg, 26 %). ¹H NMR (400 MHz, CDCl₃) δ 1.55 (m, 4H), 1.68 (s, 9H)₅ 1.83 (m, 4H), 2.37 (m, 1H), 3.25 (m, 8H), 3.29 (m, 6H), 3.33 (s, 3H), 3.62 (m, 4H), 3.93 (m, 2H), 4.54 (d, J = 7.6 Hz, 2H), 7.69 (d, J=9.2 Hz, 1H), 7.81 (s, 1H), 7.97 (d, J=9.2 Hz, 1H); MS (ESI) (M+H)⁺562.8.

Step B. l-[(4-{[[2-tert-Butyl-1-(tetrahydro-2J3-pyran-4-ylmethyl)-l_JfiT- benzimidazol-S-yl}(methyl)amino lsulfonyl}piperazin-1-yl)carbonyy-S-methyl- 1H-imidazol-3-ium triflate

N-[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-lH^r-benzimidazol-5-yl]-4-(li7- imidazol-1-ylcarbonyl)-N-methylpiperazine-l -sulfonamide (1.09 g, 2.0 mmol) in acetonitrile (20 mL) was treated with methyl trifluoromethanesulfonate (1.0 g, 6.0 mmol) at r.t for 0.5 hr. The resulting l-[(4-{[[2-tert-butyl-1-(tetrahydro-2H-pyran-4- ylmethyl)-1H-benzimidazol-5-yl](methyl)amino]sulfonyl}piperazin- 1 -yl)carbonyl]-3- methyl- li7-imidazol-3-ium triflate solution in MeCN was used in the step A directly. Example 120

4-{[[2-fe^-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-l_JET-benzimidazoI-5- yl](methyl)amino]sulfonyl}-Λ^r-(2-hydroxyethyl)piperazine-1-carboxamide

Following the procedure in Step A of Example 119, l-[(4-{[[2-tert-butyl-1-

(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl] (methyl)amino] sulfonyl} piperazin- 1 -yl)carbonyl]-3-methyl- 1H-imidazol-3-ium triflate (40 mg, 0.06 mmol) was reacted with 2-aminoethanol (61 mg, 1.0 mmol), after being purified by reverse phase HPLC to provide 4-{[[2-ter^-butyl-1-(tetrahydro-2H- pyran-4-yhτiethyl)-1H-benzimidazol-5-yl](methyl)amino]sulfonyl}-N-(2- hydroxyethyl)piρerazine-1-carboxamide (TFA salt, 19 mg, 52 %). ¹H NMR (400 MHz, CDCl₃) δ 1.55 (m, 4H), 1.68 (s, 9H), 2.37 (m, 1H), 3.24 (m, 8H), 3.33 (s, 3H), 3.40 (m, 4H), 3.55 (m, 2H), 3.93 (m, 2H), 4.54 (d, J = 7.6 Hz, 2H), 7.69 (d, J=9.2 Hz, 1H), 7.82 (s, 1H), 7.97 (d, J=9.2 Hz, 1H); MS (ESI) (M+H)⁺536.8.

Example 121 N-[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-Λ^r- methyl-4-(liϊ-pyrazol-1-ylcarbonyl)piperazine-1-sulfonamide

Following the procedure in Step A of Example 119, l-[(4-{[[2-ter?-butyl-1- (tetrahydro-2H^:-pyran-4-ylmethyl)-liJ-benzimidazol-5- yl](methyl)amino]sulfonyl}piperazin-1-yl)carbonyl]-3-methyl-1H-imidazol-3-ium triflate (40 mg, 0.06 mmol) was reacted with 1H-pyrazole (68 mg, 1.0 mmol), after being purified by reverse phase HPLC to provide N-[2-tert-butyl-1-(tetrahydro-2H- pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-N-methyl-4-(1H-pyrazol-1- ylcarbonyl)ρiρerazine-l -sulfonamide (TFA salt, 29 mg, 78 %). ¹H ΝMR (400 MHz, CDCl₃) δ 1.56 (m, 4H), 1.68 (s, 9H), 2.37 (m, 1H), 3.35 (m, 9H)₅ 3.81 (m, 4H), 3.93 (m, 2H), 4.54 (d, J = 7.6 Hz, 2H), 6.44 (m, 1H), 7.68 (s, 1H), 7.69 (d, J=9.2 Hz, 1H), 7.84 (s, 1H), 7.97 (d, J=9.2 Hz, 1H), 8.11 (s, 1H); MS (ESI) (M+H)⁺543.8.

Example 122

N-[2-tert-Butyl-1-(tetrahydro-2H^r-pyran-4-ylraethyl)-l_J9^r-benziraidazol-5-yl]-N- methyl-4-(pyrrolidin-1-ylcarbonyl)piper azine-1-sulf bnamide

Following the procedure in Step A of Example 119, l-[(4-{[[2-tert-butyl-1- (tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}piperazin-1-yl)carbonyl]-3-methyl-1H-imidazol-3-ium triflate (40 mg, 0.06 mmol) was reacted with pyrrolidine (71 mg, 1.0 mmol), after being purified by reverse phase HPLC to provide AT-[2-tert-butyl-1-(tetrahydro-2H- pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-N-methyl-4-(pyrrolidin-1- ylcarbonyl)piperazine-l -sulfonamide (TFA salt, 26 mg, 70 %). ¹H NMR (400 MHz, CDCl₃) δ 1.58 (m, 4H)₅ 1.68 (s, 9H)₅ 1.83 (m, 4H)₅ 2.37 (m, 1H), 3.25 (m, 8H)₅ 3.34 (m, 9H)₅ 3.93 (m, 2H), 4.54 (d, J = 7.6 Hz, 2H), 7.69 (d, J=9.2 Hz, 1H), 7.82 (s, 1H)₅ 7.97 (d, JM9.2 Hz, 1H); MS (ESI) (M+H)⁺547.0.

Claims

What is claimed is:

1. A compound of formula I, a pharmaceutically acceptable salt thereof, diastereomers, enantiomers, or mixtures thereof:

I wherein

G is selected from -O-, -CHF-, and -CF₂-;

R¹ is a C_2-6heterocyclyl, wherein said C_2-6heterocyclyl includes at least one nitrogen on said C_2-6heterocyclyl ring, one of said at least one nitrogen is directly linked to the sulfonyl group of formula I, and said C_2-6heterocyclyl is optionally substituted with one or more groups selected from halogen, hydroxy, R⁵-C(=O)-, R⁵- C(=O)-NH-, R⁵R⁶-NH-C(=O)-, R⁵R⁶-NH-C(=O)-NH-, R⁵-O-C(=O)-, R⁵-O-C(=O)- NH-, C_1-6alkoxy, and

wherein said R⁵, R⁶ are independently selected from -H, Q,₆alkyl, C_6-10aryl, C_2-6alkenyl, C_3-6cycloalkyl, C_2-6heterocyclyl, halogenated C_1-6alkyl, and hydroxy-C_1-6alkyl; and

R², R³ and R⁴ are independently selected from fluoro and methyl.

2. A compound as claimed in claim 1, wherein G is selected from -O- and -CF₂-; R¹ is a C_2-6heterocycloalkyl, wherein said C_2-6heterocycloalkyl includes at least one nitrogen on said C_2-6heterocycloalkyl ring, one of said at least one nitrogen is directly linked to the sulfonyl group of formula I, and said C_2-6heterocycloalkyl is optionally substituted with one or more groups selected from halogen, hydroxy, R⁵- C(=O)-, R⁵-C(=O)-NH-, R⁵R⁶-NH-C(=O>, R⁵R⁶-NH-C(=O)-NH-, R⁵-O-C(=O)-, R⁵- O-C(=O)-NH-, Ci.βalkoxy, and C_1-6alkylamino, wherein said R⁵, R⁶ are independently selected from -H, Q-βalkyl, C_2-6alkenyl, C_3-6cycloalkyl, C_2-5heterocycloalkyl, halogenated Ci_₆alkyl, and hydroxy-C_1-6alkyl; and

R², R³ and R⁴ are independently selected from fluoro and methyl.

3. A compound as claimed in claim 1, wherein G is selected from -O- and -CF₂-;

R¹ is selected from piperidinyl, imidazolyl, pyrrolyl, pyrazolyl, morpholinyl, pyrrolidinyl, azetidinyl, and isoxazolidinyl, wherein said piperidinyl, imidazolyl, pyrrolyl, pyrazolyl, morpholinyl, pyrrolidinyl, azetidinyl, and isoxazolidinylare optionally substituted with one or more groups selected from fluoro and C_2- sacylamino;

4. A compound as claimed in claim 1 , wherein G is selected from -O- and -CF₂-;

R¹ is selected from

and ; wherein said

a

nd are optionally substituted by one or more groups selected from

fluoro,

and ; and

5. A compound as claimed in claim 1, wherein G is selected from -O- and -CF₂-;

R¹ is selected from Cs-sheterocycloalkyl and C_2-5heteroaryl, wherein said Q.sheterocycloalkyl or C_2-5heteroaryl includes at least one nitrogen on said Q-sheterocycloalkyl or C_2-5heteroaryl rings, respectively, one of said at least one nitrogen is directly linked to the sulfonyl group of formula I, and said C^sheterocycloalkyl and C_2-5heteroaryl are optionally substituted with one or more groups selected from halogen, C_1-3alkoxy, C_1-3alkylamino, and C_2-5acylamino; R², R³ and R⁴ are independently selected from fiuoro and methyl.

6. A compound selected from

and pharmaceutically acceptable salts thereof.

7. A compound selected from:

N-(1-{[{2-fer^Butyl-1-[(4,4-difluorocyclohexyl)methyl]-li^:f-berizimidazol-5- yl}(methyl)amino]sulfonyl}piperidin-4-yl)acetamide;

N-[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5-yl]-N- methylisoxazolidine-2 -sulfonamide;

N-[2-tert-butyl-1-(tetrahydro-2/i-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-N- methylazetidine- 1 -sulfonamide; N-[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-N-- methylpyrrolidine- 1 -sulfonamide;

N-[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-N- methylmorpholine-4-sulfonamide; N-[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-N- methylpiperidine- 1 -sulfonamide; N-{2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl}-N- methylpiperidine- 1 -sulfonamide;

N-[2-( 1 , 1 -difluoroethyl)- 1 -(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]- N-methylisoxazolidine-2-sulfonamide; N-(I- {[[2-(1 , 1 -difluoroethyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-

5-yl](methyl)amino]sulfonyl}piperidin-4-yl)acetamide;

1 - { [[2-tert-butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}-N-cyclopropylpiperidine-4-carboxamide; 1 - {[[2-tert-butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}-N-isopropylpiperidine-4-carboxamide; 1-{[[2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}-N-cyclobutylpiperidine-4-carboxamide;

1- { [[2-tert-butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}-N-cyclopentylpiperidine-4-carboxamide;

1 - { [[2-tert-butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}-N-pyrrolidin-1-ylpiperidine-4-carboxamide;

1 - {[[2-tert-butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}-N-1H-pyrrol-1-ylpiperidine-4-carboxamide; 1 - { [[2-tert-butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}-N-etliylpiperidine-4-carboxamide;

N-(tert-butyl)- 1 - { [[2-tert-butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)-1H- benzimidazol-5-yl](methyl)amino]sulfonyl}piperidine-4-carboxamide;

1 - { [[2-tert-butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl}(methyl)aminojsulfonyl}-N,N-dimethylpiperidine-4-carboxamide; 1-{[[2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}-N,N-diethylpiperidine-4-carboxamide; 1-{[[2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}-N-methylpiperidine-4-carboxamide;

1 - { [[2-tert-butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)- lif-benzimidazol-5- yl](methyl)amino]sulfonyl}-N-propylpiperidine-4-carboxainide; N-butyl- 1 - { [[2-tert-butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl> 1H-benzimidazol-5- yl](methyl)amino]sulfonyl}piperidine-4-carboxamide; 1-{[[2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}-N-(2,2,2-trifluoroethyl)piperidme-4-carboxamide; N-allyl- 1 - { [[2-tert-butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)- 1H-benzimidazol-5- yl](methyl)amino]sulfonyl}piperidine-4-carboxamide; 1-{[[2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl] (methyl)amino] sulfonyl} -N-isobutylpiperidine-4-carboxamide; 1-{[[2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}-N-(2-hydroxy-1-methyletb.yl)piperidine-4-carboxamide; 1 - { [[2-tert-butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)- liZ-benzimidazol-5- yl](methyl)amino]sulfonyl}-N-(2-liydroxyetb.yl)piperidine-4-carboxamide;

Ethyl 1-{[[2-tert-butyl-1-(tetrahydro-2Η-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}piperidine-4-carboxylate;

N-( 1 - { [[2-tert-butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)- li7-benzimidazol-5- yl](methyl)amino]sulfonyl}azetidin-3-yl)cyclopropanecarboxamide; N-(I- {[[2-tert-butyl-l -(tetrahydro^H-pyran^-ylinetliyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl} azetidin-3-yl)-2-methylpropanamide; N-( 1 - { [[2-tert-butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)- 1H-benzimidazol-5- ylJ^ethyl)amino]sulfonyl}azetidin-3-yl)cyclobutanecarboxamide; N-(1-{[[2-ter^butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}azetidin-3-yl)butanamide;

N-(I- { [[2-tert-butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)- 1H-ben2;imidazol-5- yl](methyl)amino]sulfonyl}azetidin-3-yl)propanamide;

Methyl 1 - { [[2-tert-butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)- 1H-benzimidazol-5- yl](methyl)amino]sulfonyl} azetidine-3-carboxylate;

N-[2-(l,l-dime%lethyl)-1-[(tetrahydro-2H-pyran-4-yl)methyl]-1H-benziinidazol-5- yl]hexahydro-N-methyl-1H-azepine- 1 -sulfonamide; N-[I-(1 , 1 -dimethylethyl)- 1 -[(tetrahydro-2H-pyran-4-yl)methyl]- 1H-benzimidazol-5- yl]-N,4-dimethyl-1-piperidinesulfonamide;

N-[2-(l , 1 -dimethylethyl)- 1 -[(tetrahydro-2H-pyran-4-yl)methyl]- 1H-benzimidazol-5- yl]-3-(hydroxymethyl)-N-methyl-1-piperidinesulfonamide; N-[I-(I, \ -dimethylethyl)- 1 - [(tetrahydro-2H-pyran-4-yl)methyl]- 1H-benzimidazol-5- yl]-4-hydroxy~N-methyl-1-piperidmesulfonamide;

N-[2-(l,l-dimethylethyl)-1-[(tetrahydro-2H-pyran-4-yl)methyl]-1H-benzimidazol-5- yl]-4-methoxy-N-methyl- 1 -piperidinesulfonamide;

N-[2-(l,l-dimethylethyl)-1-[(tetrahydro-2H-pyran-4-yl)methyl]-1H-benzimidazol-5- yl]-3-hydroxy-N-methyl-1-piperidinesulfonamide;

N-[2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5-yl]-4,4- difluoro-N-methylpiperidine-1-sulfonamide; N-[2-tert-butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)- lH-benzimidazol-5-yl]-3 ,3 - difluoro-N-methylpyrrolidine- 1 -sulfonamide;

Methyl 1-{[[2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}piperidine-4-carboxylate;

N-[2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5-yl]-N- methylisoxazolidine-2-sulfonamide;

(4R)-N-[2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-4- hydroxy-N,4-dimethylisoxazolidine-2-sulfonamide;

N-(1-{[[2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}piperidin-4-yl)acetamide; N-(1-{[[2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5- yl](methyl)amino]sulfonyl}piperidin-4-yl)-2,2-dimethylpropanamide; tert-Butyl [ 1 -( {methyl[ 1 -(tetrahydro-2H-pyran-4-ylmethyl)-2-(trifluoromethyl)- IH- benzimidazol-5-yl]amino}sulfonyl)ρiperidin-4-yl]carbamate tert-Butyl 4-( {methyl[ 1 -(tetrahydro-2H-pyran-4-ylmethyl)-2-(trifluoromethyl)- IH- benzimidazol-5-yl]amino}sulfonyl)piperazine-1-carboxylate;

4- { [(Cy clopropylamino)carbony 1] amino} -N-methyl-N-t 1 -(tetrahy dro-2H-pyran-4- ylmethyl)-2-(trifiuoromethyl)-1H-benzimidazol-5-yl]piperidine- 1 -sulfonamide; N-cyclopropyl-4-({methyl[l-(tetrahydro-2H-pyran-4-ylmethyl)-2-(trifluoromethyl)- 1H-benzimidazol-5-yljaminolsulfony^piperazine-1-carboxamide;

4-{[(isopropylamino)carbonyl]amino}-N-methyl-N-[l-(tetraliydro-2H-pyran-4- ylmethyl)-2-(trifluoromethyl)-1H-beiizimidazol-5-yl]piperid.ine-1-sulfonaiiiide; N-isopropyl-4-({methyl[l-(teixahydro-2H-pyran-4-ylmethyl)-2-(triflxioromethyl)-1H- benzimidazol-5-yl]amino}sulfonyl)piperazine-1-carboxamide;

N-[I -( {methyl[l -(tetrahydro-2H-pyran-4-ylmethyl)-2-(trifluoromethyl)-1H- benzimidazol-5-yl]amino}sulfonyl)piperidin-4-yl]acetamide;

2,2-Dimethyl-N-[l-({me%l[l-(tetrahyώo-2H-pyran-4-ylmethyl)-2-(trifluoromethyl)- 1H^"-benzimidazol-5-yl]amino}sulfonyl)piperidm-4-yl]propanamide;

2-Methyl-N-[l-({methyl[l-(tetrahydro-2H-pyran-4-ylmethyl)-2-(trifluoromethyl)-1H- benzimidazol-5-yl]amino}sulfonyl)piperidin-4-yl]propanamide;

4-Acetyl-N-methyl-N-[l-(tetrahydro-2H-pyran-4-ylmethyl)-2-(trifluoromethyl)-1H- benzimidazol-5-yl]piperazine-1-sulfonamide; 4-(2,2-Dimethylpropanoyl)-N-methyl-N-[l-(tetrahydro-2H-pyran-4-ylmethyl)-2-

(trifluoromethyl)-1H-benzimidazol-5-yl]piperazine- 1 -sulfonamide;

N-(1-{[{2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5- yl} (methyl)amino] sulfonyl} piperidin-4-yl)acetamide ;

N-(1-{[{2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5- yl}(methyl)amino]sulfonyl}piperidin-4-yl)-2,2-dimethylpropanamide;

N- {2-tert-Butyl-l -[(4,4-difluorocyclohexyl)methyl]-li-^r-benzitnidazol-5-yl} -N- methylmorpholine-4-sulfonamide;

N-{2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl}-N- methylpyrrolidine- 1 -sulfonamide; N-{2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl}-3_:,3- difluoro-N-methylpyrrolidine- 1 -sulfonamide;

N- {2-tert-Butyl- 1 -[(4,4-difluorocyclohexyl)methyl] -1H-benzimidazol-5-yl} -N- methylisoxazolidine-2-sulfonamide;

N-{2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-lJ^c-^'-benzimidazol-5-yl}-4,4- difluoro-N-methylpiperidine-1-sulfonamide; tert-Butyl 4-{[{2-te^butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5- yl} (methyl)amino] sulfonyl } piperazine- 1 -carboxylate; 4-{[{2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5- yl}(methyl)amino]sulfonyl}-N-isopropylpiperazine-1-carboxamide;

4-{[{2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5- yl}(methyl)amino]sulfonyl}-N-methylpiperazine-1-carboxamide; 4-{[{2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5- yl}(methyl)amino]sulfonyl}-N-cyclopropylpiperazme-1-carboxamide;

4-{[{2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5- yl}(methyl)amino]sulfonyl}-N-cyclobutylpiperazine-1-carboxamide;

N-{2-tert-Butyl-1- [(4,4-difluorocyclohexyl)methyl] -1H-benzimidazol-5-yl} -N- methyl-4-{[(methylamino)carbonyl]amino}piperidine-1-sulfonamide;

N-[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-Ν- methylisoxazolidine-2-sulfonamide;

4-Acetyl-N-[2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-

N-methylpiperazine- 1 -sulfonamide ; N-[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-4-(2,2- dimethylpropanoyl)-N-methylpiperazine- 1 -sulfonamide;

4-B enzoyl-N- [2-tert-butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5 - yl]- N-methylpiperazine- 1 -sulfonamide;

N-[2-tert-Butyl-1-(tetraliydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-N- methyl-4-(3 -methylbutanoyl)piperazine- 1 -sulfonamide;

N-[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-4-

(cyclopropylcarbonyl)-N-methylpiperazine- 1 -sulfonamide;

N-[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]--Y- methyl-4-propionylpiperazine- 1 -sulfonamide; N-[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-4- isobutyryl-N-methylpiperazine- 1 -sulfonamide;

N-[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-4-

(cyclobutylcarbonyl)-N-methylpiperazine-1-sulfonamide;

N-[2-tert-Butyl-1-(teixahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-4- butyryl-N-methylpiperazine- 1 -sulfonamide;

4-{[[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl} -N,N-dimethylpiperazine- 1 -carboxamide; 4-{[[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}-N-isopropylpiperazine-1-carboxamide;

4-{[[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}-N-cyclopentylpiperazine-1-carboxamide; 4- { [[2-tert-Butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}-N-methylpiperazine-1-carboxaπiide;

4-{[[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl} -N-cyclopropylpiperazine- 1 -carboxamide;

4-{[[2-tert-Butyl-1-(tetrahydro-2N-pyran-4-ylmethyl)-1H-benzimidazol-5- yl] (methyl)amino] sulfonyl } -N-cyclobutylpiperazine- 1 -carboxamide; N-(tert-Butyl)-4-{[[2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H- benzimidazol-5-yl](methyl)amino]sulfonyl}piperazine-1-carboxamide;

N-butyl-4-{[[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}piperazine-1-carboxamide; N-Allyl-4- { [[2-tert-butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}piperazine-1-carboxamide;

4-{[[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}-N-ethylpiperazine-1-carboxamide;

4- {[[2-tert-Butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}-N-propylpiperazine-1-carboxamide;

4-{[[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}-N-(cyclopropylmethyl)piperazme-1-carboxamide; N-[2-tert-Butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-4-( 1H- imidazol-1 -ylcarbonyl)-N-methylpiperazine-l -sulfonamide; Isopropyl 4- { [[2-tert-butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}piperazine-1-carboxylate; N-(1-{[[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl] (methyl)amino]sulfony 1} pyrrolidin-3 -yl)acetamide ;

N-(1- { [[2-tert-Butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}pyrrolidin-3-yl)-2,2-dimethylpropanamide; N-(1-{[[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}azetidin-3-yl)acetamide; N-{2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl}-N- methyl- 1H-imidazole- 1 -sulfonamide;

N-{2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl}-N- methyl-1 H- 1 ,2,4-triazole- 1 -sulfonamide; N-{2-tert-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl}-N- methyl- IH- 1 ,2,3-triazole- 1 -sulfonamide; N-[2-tert-Butyl-1-(tetrahydro-2/i-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-4- formyl-N-methyl- 1H-pyrazole- 1 -sulfonamide; 1-{[[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl] (methyl) amino] sulfonyl} -N-cyclopropyl-1H-pyrazole-4-carboxamide;

1 - { [[2-tert-Butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}-N-ethyl-1H-pyrazole-4-carboxamide; N-Allyl- 1 - { [[2-tert-butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}-1H-pyrazole-4-carboxamide; 1 - { [[2-tert-Butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl] (methyl) amino] sulfonyl} -N-propyl-1H-pyrazole-4-carboxamide ; 1-{[[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}-N,N-dimethyl-1H-pyrazole-4-carboxamide; 1-{[[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}-N-methyl-1H-pyrazole-4-carboxamide;

N-(tert-Butyl)-1-{[[2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H- benzimidazol-5-yl](methyl)amino]sulfonyl}-1H-pyrazole-4-carboxamide;

N-(I- { [[2-tert-Butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}-1H-pyrazol-3-yl)acetamide; N-[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-4- formyl-N-methyl- 1H-imidazole- 1 -sulfonamide;

1 - { [[2-tert-Butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}-N-cyclopropyl-1H-imidazole-4-carboxamide;

1 - { [[2-tert-Butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl] (methyl)amino]sulfonyl} -N-cyclopropyl-1H-pyrazole-3 -carboxamide; 1-{[[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5- yl](methyl)amino]sulfonyl}-N-isopropyl-1H-pyrazole-3-carboxamide; 1 - { [[2-tert-Butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)- 1H-benzimidazol-5- yl] (methyl) amino] sulf onyl } -N-propyl- 1H-pyrazole-3 -carboxamide ;

N- Allyl- 1 - { [ [2-tert-butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)- 1 H-benzimidazol-5- yl] (methyl)amino]sulfbnyl } -1H-pyrazole-3-carboxamide; 1 - { [[2-tgrt-Butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)- 1H-benzimidazol-5- yl](methyl)amino]sulfonyl}-N-ethyl-1H-pyrazole-3-carboxamide; N-[2-tert-Butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-N- methyl-4-(morpholin-4-ylcarbonyl)piperazine- 1 -sulfonamide;

4- { [[2-tørt-Butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)- 1H-benzimidazol-5- yl] (methyl)amino] sulfonyl } -N-(2-hydroxyethyl)piperazine- 1 -carboxamide;

N-[2-tert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-N- methyl-4-( 1H-pyrazol- 1 -ylcarbonyl)piperazine- 1 -sulfonamide;

N-[2-fert-Butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-N- methyl-4-(pyrrolidm-1-ylcarbonyl)piperazine-1-sulfonamide; and pharmaceutically acceptable salts thereof.

8. A compound according to any one of claims 1-7 for use as a medicament.

9. The use of a compound according to any one of claims 1-7 in the manufacture of a medicament for the therapy of pain.

10. The use of a compound according to any one of claims 1-7 in the manufacture of a medicament for the treatment of anxiety disorders.

11. The use of a compound according to any one of claims 1-7 in the manufacture of a medicament for the treatment of cancer, multiple sclerosis, Parkinson's disease, Ηuntington's chorea, Alzheimer's disease, gastrointestinal disorders and cardiovascular disorders.

12. A pharmaceutical composition comprising a compound according to any one of claims 1-7 and a pharmaceutically acceptable carrier.

13. A method for the therapy of pain in a warm-blooded animal, comprising the step of administering to said animal in need of such therapy a therapeutically effective amount of a compound according to any one of claims 1-7.

14. A method for preparing a compound of Formula I, comprising the steps of:

I a) reacting a compound of Formula II with a compound of formula HI,

π. in b) treating reaction product of step a) with MeOTf; c) reacting reaction product of step b) with R¹H, wherein

G is selected from -O-, -CHF-, and -CF₂-; R¹ is a C_2-6heterocyclyl, wherein said C_2-6heterocyclyl includes at least one nitrogen on said d-_δheterocyclyl ring, one of said at least one nitrogen is directly linked to the sulfonyl group of formula I, and said C_2-6heterocyclyl is optionally substituted with one or more groups selected from halogen, hydroxy, R⁵-C(=O)-, R⁵- C(=O)-NH-, R⁵R⁶-NH-C(=O)-, R⁵R⁶-NH-C(=O)-NH-, R⁵-O-C(=O)-, R⁵-O-C(=O)- NH-, C_1-6alkoxy, and Ci-βalkylamino, wherein said R⁵, R⁶ are independently selected from -H, C_1-6alkyl, C_6-1oaryl, C₂-₆alkenyl, C_3-6cycloalkyl, C2-₆heterocyclyl, halogenated C_1-6alkyl, and hydroxy-d^alkyl; and

R², R³ and R⁴ are independently selected from fluoro and methyl.